

4 protein - protein search, using sw model	August 19, 2005, 23:18:33 ; Search time 160.135 Seconds (without alignments), 60.380 Million cell updates/sec	Article: US-10-603-002-18
perfect score: 122	Sequence: 1 MAISGVGVVLFITIAVMSAQESWA 25	Scoring table: BLOSUM62
gapext: 0.5	gapext: 10.0 , Gapext 0.5	gapext: 10.0 , Gapext 0.5
searched: 2105692 seqs, 386760381 residues	searched: 2105692 seqs, 386760381 residues	searched: 2105692 seqs, 386760381 residues

11 TRANSMISSION

Post-processing:	
Minimum Match	0%
Maximum Match	100%
Listing first	45 summaries
Database :	A_Geneseq_16Dec04:*
	1: GeneseqP1908:*
	2: GeneseqP1908:*
	3: GeneseqP20008:*
	4: GeneseqP20018:*
	5: GeneseqP20028:*
	6: GeneseqP2003ab:*
	7: GeneseqP2003bc:*
	8: GeneseqP20048:*

and is derived by analysis of the total score distribution. OS Homo sapiens. XX DD 50940171-11

SUMMARY

result	No.	Score	Query	Match	Length	DB	ID	Description
1	122	100.0		25	2	AAR19445	Aar19445	Immunomod
	122	100.0		25	2	AAR19587	Aar19587	Sequence
	122	100.0		25	2	ARM11864	Aar11864	MHC class
	122	100.0		25	2	AAY09341	Aay09341	Human pap
	122	100.0		25	3	AAY0694	Aay0694	Endoplasm
	122	100.0		25	3	AAB30292	Aab30292	CD4+ T-cell
	122	100.0		25	4	AAG67288	Aag67288	Amino aci
	122	100.0		25	4	AAB951956	Aab951956	HLA-DRB1P
	122	100.0		25	4	AAG64714	Aag64714	HPV immun
	122	100.0		25	4	AAB220205	Aab220205	HLA-DR1a1
	122	100.0		25	4	AAU01561	Aau01561	Hydrophob
	122	100.0		25	5	AAO17006	Aao17006	HLA-Dialy
	122	100.0		25	5	ABG68880	Abg68880	Endoplasm
	122	100.0		25	5	AAE19014	Aae19014	Hydrophob
	122	100.0		25	5	ABD09908	Abd09908	Radioacti
	122	100.0		25	5	ABB75927	Abb75927	Endoplasm
	122	100.0		25	5	ABB08107	Abb08107	MHC class
	122	100.0		25	6	ABU0975	Abu0975	Human exp
	122	100.0		25	6	AAC35568	Aac35568	Hydrophob
	122	100.0		25	6	AAO23269	Aao23269	Hydrophob
	122	100.0		25	6	ABU63379	Abu63379	Human tPA
	122	100.0		25	7	ABU0009	Abu0009	Human Leu
	122	100.0		25	7	ADP5571	Adp5571	Human big
	122	100.0		25	8	ADM13766	Adm13766	MHC class
	122	100.0		25	8	ADN59204	Adn59204	HLA-DR1p

XX	03-MAR-1994 .						
PD							
PF	11-AUG-1993 ;	93WO-US007545					
XX							
PR	11-AUG-1992 ;	92US-00925460					
PR	15-JUN-1993 ;	93US-00077255					
XX							
PA	(HARD ) HARVARD COLLEGE .						
XX							
PI	Urban RG, Chicz RM, Vignal						
PI	Strominger JL;						
XX							
WPI	1994-082825/10 .						
XX							
PT	Novel immunomodulatory Peptid						
PT	treatment of auto:immune dis						
PT	vaccination .						
XX							
PS	Claim 13; Page 94; 139pp; En						
PS							
XX	The sequences given in AAR95						
CC	fragments of naturally-occur						
CC	fragments are between 10-30						
CC	helicocompatibility complex (						
CC	used for therapy f autoimmu						
CC	rheumatoid arthritis and multi						
CC	rejection. They may also be						
CC	recombinant-mediated response wh						

CC both, depending on the length and character of the immunogenic peptides.  
 CC (Updated on 25-MAR-2003 to correct PN field.) (Updated on 25-MAR-2003 to  
 CC correct PR field.)

SQ Sequence 25 AA;  
 Query Match 100.0%; Score 122; DB 2; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservate 0; Mismatches 0; Indels 0; Gaps 0;  
 OS Synthetic.

Qy 1 MAISGYPVVLGPFPPIAVLMSAQESWA 25  
 Db 1 MAISGYPVVLGPFPPIAVLMSAQESWA 25

RESULT 2  
 AAR49587  
 ID AAR49587 standard; peptide; 25 AA.

XX AC AAR49587;  
 XX DT 25-MAR-2003 (revised)  
 DT 15-SEP-1994 (first entry)

DE Sequence of MHC class II alpha signal peptide.

XX KW Trafficking sequence; signal peptide; major histocompatibility complex.  
 XX OS Synthetic.

XX PN WO9404557-A1.  
 XX PD 03-MAR-1994.

XX PF 11-AUG-1992; 92WO-US006692.  
 PR 11-AUG-1992; 92WO-US006692.

XX PA (HARD ) HARVARD COLLEGE.  
 XX Urban RG, Chiccz RM, Vignal DAA, Hedley MI, Stern LJ;  
 PI Strominger JL;  
 XX WPI; 1994-083102/10.

XX New peptide binding to MHC class II allotype - useful for treating auto-  
 immune diseases, transplant rejection and for immunisation.  
 PS Claim 20; Page 49; 60pp; English.

XX A trafficking sequence is an AA sequence which functions to control  
 CC intracellular trafficking (directed movement from organelle to organelle  
 CC or to the cell surface) of a polypeptide to which it is attached. Such  
 CC trafficking sequences might traffic the polypeptide to ER, lysosome, or  
 CC an endosome, and include signal peptides, ER retention peptides such as  
 CC AAR49584; and lysosome-targeting peptides such as AAR49585 and AAR49586.  
 CC An example of a signal peptide with such a function is the signal peptide  
 CC of MHC class II alpha (AAR49587). (Updated on 25-MAR-2003 to correct PN  
 XX field.)

SQ Sequence 25 AA;  
 Query Match 100.0%; Score 122; DB 2; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservate 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGYPVVLGPFPPIAVLMSAQESWA 25  
 Db 1 MAISGYPVVLGPFPPIAVLMSAQESWA 25

RESULT 3  
 AAW31864  
 ID AAW31864;  
 XX AC AAW31864;  
 XX DT 06-MAY-1998 (first entry)  
 DE MHC class II alpha signal peptide.  
 XX RNA-loaded antigen presenting cell; trafficking sequence; APC production;  
 KW tumour formation; Pathogen infection; antigenic epitope; immune response;  
 KW T cell proliferation; cytotoxic T lymphocyte; adoptive immunotherapy;  
 KW therapy; TAE; CTL; PAE; MHC class II alpha signal peptide.  
 XX OS Synthetic.

XX PN WO9741210-A1.  
 XX PD 06-NOV-1997.  
 XX PR 30-APR-1997; 97WO-US007317.

XX PA (UVDU-) UNIV DUKE.  
 XX PI Nair SK, Boczkowski DJ, Gilboa E;  
 XX DR WPI; 1997-549715/50.

XX PS Claim 49; Page 38; 47pp; English.  
 XX CC This sequence represents a MHC class II alpha signal peptide, and can be  
 CC used in the method of the invention. The method is for producing an RNA-  
 CC loaded antigen presenting cell (APC) that presents on its surface a  
 CC tumour or pathogen antigenic epitope (TAE or PAE respectively) that  
 CC induces T cell proliferation and an immune response against the tumour or  
 CC pathogen, and comprises introducing into an APC in vitro, RNA that  
 CC encodes the antigen. The RNA-loaded APCs can be used to stimulate  
 CC cytotoxic T lymphocyte (CTL) proliferation ex vivo or in vivo. The ex  
 CC vivo expanded CTL can be administered to a patient in a method of  
 CC adoptive immunotherapy. The methods can be used for treating or  
 CC preventing tumour formation or pathogen infection caused by e.g. HIV,  
 CC hepatitis, influenza, poliomyelitis, measles, herpes, mumps or rubella  
 CC viruses, Salmonella, Shigella or Enterobacter. The method circumvents the  
 CC need to purify RNA or isolate and identify a TAE or PAE

XX SQ Sequence 25 AA;  
 XX PS Claim 49; Page 38; 47pp; English.  
 XX CC This sequence represents a MHC class II alpha signal peptide, and can be  
 CC used in the method of the invention. The method is for producing an RNA-  
 CC loaded antigen presenting cell (APC) that presents on its surface a  
 CC tumour or pathogen antigenic epitope (TAE or PAE respectively) that  
 CC induces T cell proliferation and an immune response against the tumour or  
 CC pathogen, and comprises introducing into an APC in vitro, RNA that  
 CC encodes the antigen. The RNA-loaded APCs can be used to stimulate  
 CC cytotoxic T lymphocyte (CTL) proliferation ex vivo or in vivo. The ex  
 CC vivo expanded CTL can be administered to a patient in a method of  
 CC adoptive immunotherapy. The methods can be used for treating or  
 CC preventing tumour formation or pathogen infection caused by e.g. HIV,  
 CC hepatitis, influenza, poliomyelitis, measles, herpes, mumps or rubella  
 CC viruses, Salmonella, Shigella or Enterobacter. The method circumvents the  
 CC need to purify RNA or isolate and identify a TAE or PAE

RESULT 4  
 AAY09341  
 ID AAY09341 standard; peptide; 25 AA.  
 XX AC AAY09341;  
 XX DT 08-JUL-1999 (first entry)  
 DE Human papillomavirus E7 protein immunogenic peptide #10.  
 XX KW Human papillomavirus; HPV; E7 protein; immunogenic; immune response;  
 KW infection; exophytic coneyloma; cervical cancer; respiratory papilloma;

RESULT 3  
 AAW31864

KW	conjunctival papilloma; genital tract infection.	XX	Duke-Cohan JS, Schlossman SF;
XX	Human papillomavirus.	PI	XX
OS	Synthetic.	XX	WPI; 2000-271373/23.
XX	W09918995-A1.	DR	
XX	22-APR-1995.	XX	Isolated nucleic acids encoding human attractin polypeptides useful for enhancing immune responses.
PD	22-APR-1995.	XX	Disclosure; Page 30; 120pp; English.
XX	PP 09-OCT-1998; 98WO-US021456.	XX	The patent discloses four forms of human attractin polypeptides which enhance immune response by promoting macrophage and monocyte spreading in the presence of T cells. These include soluble attractin-1 and -2 and membrane attractin-1 and -2. These various forms of attractin are encoded by alternatively spliced mRNA molecule transcribed from a single gene.
XX	PR 09-OCT-1997; 97US-00948378.	CC	The present sequence is a hydrophobic signal peptide which can be used to direct attractin to endoplasmic reticulum (ER). Attractin can be used to enhance immune response in immunosuppressed patients such as those undergoing chemo- and radio-therapy treatment for cancer or those suffering from common variable immunodeficiency syndrome. The protein may also be used to screen modulators (agonists and antagonists) of immune responses which may also be used to regulate immune reactions. Attractin antibodies can be used to inhibit immune response in transplant recipients or patients afflicted with autoimmune disease.
XX	(PANG-) PANGAEA PHARM INC.	CC	
PA	Urban RG, Chicz RM, Collins BJ, Hedley ML;	CC	
PI	DR; 1999-277445/23.	CC	
XX	WPI; 1999-277445/23.	CC	
PT	New human papilloma virus peptides - used for preventing or treating e.g. exophytic condyloma, cervical cancer, respiratory papilloma, conjunctival papilloma or genital tract infection.	CC	
PT	Claim 13; Page 25; 40pp; English.	CC	
PS	Sequence 25 AA;	CC	
XX	The present invention describes human papillomavirus peptides which are used for preventing or treating e.g. exophytic condyloma, cervical cancer, respiratory papilloma, conjunctival papilloma or genital tract infection. The peptides correspond to human papilloma virus (HPV) E7 sequences. The peptides and DNA encoding them can be used for inducing an immune response to HPV in a mammal. They can be used for treating a human who suffers from or is at risk of conditions such as exophytic condyloma, flat condyloma, cervical cancer, respiratory papilloma, conjunctival papilloma, genital tract HPV infection and cervical dysplasia. They can also be used for treating or preventing e.g. bowenoid papulosis, anal dysplasia, vulval cancer, or prostate cancer	CC	
XX	Sequence 25 AA;	CC	
SQ	Query Match 100.0%; Score 122; DB 2; Length 25; Best Local Similarity 100.0%; Pred. No. 3.9e-13; Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0; Gaps 0;	XX	Query Match 100.0%; Score 122; DB 3; Length 25; Best Local Similarity 100.0%; Pred. No. 3.9e-13; Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0; Gaps 0;
Qy	1 MAISGVPLGFPIIAVLMQAQESWA 25	XX	Qy 1 MAISGVPLGFPIIAVLMQAQESWA 25
Db	1 MAISGVPLGFPIIAVLMQAQESWA 25	XX	Db 1 MAISGVPLGFPIIAVLMQAQESWA 25
RESULT 6			
AA	AAB30292 standard; peptide; 25 AA.	XX	AAB30292 standard; peptide; 25 AA.
ID	AAB30292;	XX	AAB30292;
AC		XX	
DT	12-FEB-2001 (first entry)	XX	12-FEB-2001 (first entry)
DB	CD4+ T-cell activation methods peptide ligand #54.	XX	CD4+ T-cell activation methods peptide ligand #54.
XX	CD4+ T-cell activation; peptide epitope; autoimmune disease; infectious disease; cancer; immunological mass fingerprinting.	XX	CD4+ T-cell activation; peptide epitope; autoimmune disease; infectious disease; cancer; immunological mass fingerprinting.
XX	Synthetic.	XX	Synthetic.
OS		XX	
XX	WO200063702-A1.	XX	WO200063702-A1.
AC		XX	
XX	26-OCT-2000.	XX	26-OCT-2000.
DT	20-APR-2000; 2000WO-US010888.	XX	20-APR-2000; 2000WO-US010888.
XX	PR 21-APR-1999; 99US-00235868.	XX	PR 21-APR-1999; 99US-00235868.
DE	PR 21-APR-1999; 99US-0130355P.	XX	PR 21-APR-1999; 99US-0130355P.
XX	(ZYCO-) ZYCOS INC.	XX	(ZYCO-) ZYCOS INC.
XX	(UNLO ) KINGS COLLEGE LONDON.	XX	(UNLO ) KINGS COLLEGE LONDON.
OS	Peakman M, Chicz RM;	XX	Peakman M, Chicz RM;
XX	PN WO200015651-A1.	XX	PN WO200015651-A1.
XX	PR 23-MAR-2000.	XX	PR 23-MAR-2000.
PD	PR 14-SEP-1999; 99WO-US020948.	XX	PR 14-SEP-1999; 99WO-US020948.
XX	PR 14-SEP-1998; 98US-0100137P.	XX	PR 14-SEP-1998; 98US-0100137P.
PA	(DAND ) DANA FARBER CANCER INST INC.	XX	(DAND ) DANA FARBER CANCER INST INC.
PS	Disclosure; Page 63; 118pp; English.	XX	Disclosure; Page 63; 118pp; English.

XX The present invention is concerned with a method, designated  
 CC immunological mass fingerprinting, which enables the identification of  
 CC peptide epitopes that activate CD4+ T-cells. Peptides of this kind are  
 CC also given. CD4+ cells are involved in the pathogenesis of disease, and  
 CC the peptides can be used in the prevention and treatment of autoimmune  
 CC diseases such as diabetes, multiple sclerosis, rheumatoid arthritis,  
 CC myasthenia gravis, systemic lupus erythematosus, autoimmune premature  
 CC ovarian failure, Graves' thyroiditis, Hashimoto's thyroiditis, primary  
 CC hypothyroidism, coeliac disease, primary biliary cirrhosis, autoimmune  
 CC hepatitis, Addison's disease, vitiligo, systemic sclerosis and anti-  
 CC glomerular basement membrane disease, infectious diseases including  
 CC leprosy, measles, hepatitis C, HIV and parasitic diseases, and cancer  
 XX Sequence 25 AA;

Query Match 100.0%; Score 122; DB 3; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 MAISGYPVVLGFETTIAVLMQAESWA 25  
 Db 1 MAISGYPVVLGFETTIAVLMQAESWA 25

RESULT 7  
 AAG67288 ID AAG67288 standard; peptide; 25 AA.  
 XX AC AAG67288;  
 XX DT 13-NOV-2001 (first entry)  
 XX Amino acid sequence of a hydrophobic signal peptide.  
 XX hB7-H2; T cell stimulator; immunosuppression; cancer; AIDS;  
 KW congenital immune deficiency; cellular immune response;  
 KW autoimmune condition; autoimmune disease; rheumatoid arthritis;  
 KW multiple sclerosis; insulin-dependent diabetes mellitus.  
 XX Unidentified.  
 XX PN WO200164704-A1.  
 XX PD 07-SEP-2001.  
 XX PP 02-MAR-2001; 2001WO-US006769.  
 XX PR 02-MAR-2000; 2000US-0186519P.  
 PA (MAYO-) MAYO FOUND MEDICAL EDUCATION & RES.  
 XX PI Chen L;  
 XX WPI; 2001-514837/56.  
 XX DR 2001-26596/27.

PT An isolated DNA encoding a hB7-H2 polypeptide, useful for treating  
 PT cancer, AIDS, or autoimmune diseases (e.g. rheumatoid arthritis, multiple  
 PT sclerosis or insulin-dependent diabetes mellitus).  
 PS Disclosure; Page 20; 50pp; English.  
 CC The specification describes polypeptide, designated hB7-H2. The hB7-H2  
 CC polypeptide co-stimulates T cells. The hB7-H2 proteins and its variants  
 CC are generally useful as immune response-stimulating therapeutics. For  
 CC example, the polypeptides can be used for treatment of disease conditions  
 CC characterized by immunosuppression, e.g., cancer, AIDS or AIDS-related  
 CC complex, other virally or environmentally-induced conditions, and certain  
 CC congenital immune deficiencies. They may also be employed to increase  
 CC immune function that has been impaired by the use of radiotherapy or  
 CC immunosuppressive drugs such as certain chemotherapeutic agents, and  
 CC therefore are particularly useful when given in conjunction with such  
 CC drugs or radiotherapy. The hB7-H2 nucleic acid and polypeptide can be

XX used to treat conditions involving cellular immune responses, e.g.,  
 CC inflammatory conditions (such as, for example, those induced by  
 CC infectious agents including Mycobacterium tuberculosis or M. leprae), or  
 CC other pathologic cell-mediated responses such as those involved in  
 CC autoimmune diseases (e.g. rheumatoid arthritis), multiple sclerosis, or  
 CC insulin-dependent diabetes mellitus). AAG67288-91 can be used to direct  
 CC hB7-H2 to specific intracellular compartments  
 XX Sequence 25 AA;  
 Query Match 100.0%; Score 122; DB 4; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 MAISGYPVVLGFETTIAVLMQAESWA 25  
 DB 1 MAISGYPVVLGFETTIAVLMQAESWA 25  
 RESULT 8  
 AAB95956 ID AAB95956 standard; peptide; 25 AA.  
 XX AC AAB95956;  
 XX DT 25-JUN-2001 (first entry)  
 XX DE HLA-DRalpha signal sequence SEQ ID 63.  
 XX KW Epitope; tumour antigen; antiviral; immunostimulatory; cervical cancer;  
 KW human papillomavirus-associated disease; condyloma; cervical dysplasia;  
 KW cervical dysplasia; major histocompatibility complex; MHC I.  
 XX OS Homo sapiens.  
 XX PN WO200119408-A1.  
 XX PD 22-MAR-2001.  
 XX PF 18-SEP-2000; 2000WO-US025559.  
 XX PR 16-SEP-1999; 99US-00398534.  
 XX PR 16-SEP-1999; 99US-0154665P.  
 XX PR 09-DEC-1999; 99US-00458173.  
 XX PR 09-DEC-1999; 99US-0169846P.  
 XX PA (ZYCO-) ZYCOS INC.  
 XX PI Hedley ML, Urban RC, Chicz RM;  
 XX DR WPI; 2001-26596/27.  
 XX PS Disclosure; Page 8; 64pp; English.  
 PT Novel nucleic acids encoding polypeptide polypeptides containing multiple  
 PT epitopes from one or more proteins, useful for treating tumors and as  
 PT vaccines against pathogenic agents.  
 XX  
 CC This invention relates to polynucleotides encoding a hybrid polypeptide  
 CC comprising a signal sequence and three segments that are either  
 CC contiguous or separated by a spacer amino acid or spacer peptide. The  
 CC invention specifically details polynucleotides encoding a polypeptide  
 CC peptide where the peptide segments are tumour antigens or a naturally  
 CC occurring protein of a pathogenic agent. The polypeptide peptides exhibit  
 CC antiviral and immunostimulatory activity. The polynucleotide and  
 CC peptide co-polynucleotide peptides are useful for eliciting an immune response in a  
 CC mammal. The polynucleotide and protein are useful as vaccines for  
 CC treating tumours and pathogenic infections. The polynucleotide is also  
 CC useful for preventing or treating human papillomavirus (HPV)-associated  
 CC diseases, particularly exophytic condyloma, flat condyloma, cervical  
 CC cancer, respiratory papilloma, conjunctival papilloma, genital-tract HPV  
 CC infection, cervical dysplasia, high grade squamous intraepithelial  
 CC lesions, and anal HPV infection. The polynucleotide and polypeptide are

CC useful for generating or enhancing prophylactic or therapeutic immune response against pathogens, tumours or autoimmune diseases in a population of individuals having diverse MHC allotypes, as positive controls in T cell stimulation assays in vitro, and as tools to understand processing of epitopes within cells. Peptides AAB95894 - AAB96037 and AAB96044 AAB96048 represent major histocompatibility complex I (MHC I) associated tumour and pathogen antigens. The peptides can be used as part of the polypeptide proteins of the invention. Also included are examples of the polypeptide proteins represented by AAB96050 - AAB96052, and localisation signal peptides AAB96038 - AAB96043 and AAB96049 which can be used in the construction of the polypeptide peptides

XX Sequence 25 AA;

SQ Query Match 100.0%; Score 122; DB 4; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13; Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy

1 MAISGVPLGFFIAVLMQAESWA 25

Db

1 MAISGVPLGFFIAVLMQAESWA 25

RESUL 9

ID AAG64714 Standard; peptide; 25 AA.

XX

AC AAG64714;

XX

DT 24-SEP-2001 (first entry)

XX

DB HPV immunogenic peptide SEQ ID 18.

XX

XX Immunogenic peptide; HPV; class I restricted T cell epitope; cytostatic;

XX antiviral; exophytic condyloma; flat condyloma; cervical cancer;

XX respiratory papilloma; conjunctival papilloma; genital-tract HPV;

XX cervical dysplasia.

OS Human papillomavirus.

XX

PN US2001006639-A1.

XX

PD 05-JUL-2001.

XX

PP 12-JAN-2001; 2001US-0075980.

XX

PR 09-OCT-1997; 97US-0061657P.

PR 09-OCT-1998; 98US-00169425.

XX

PA (ZYCO-) ZYCOS INC.

PA

Urban RG, Chiez RM, Collins EJ, Hedley ML;

XX

WPI; 2001-407585/43.

XX

Immunogenic peptides from human papilloma virus type 16 E7 protein that

PR comprise overlapping class I restricted T cell epitopes, useful in

PR vaccines for treating or preventing as exophytic condyloma, flat

PR condyloma and cervical cancer.

XX

PS Claim 13; Page 7; 12pp; English.

XX

This invention relates to immunogenic peptides from human papillomavirus (HPV) type 16 E7 protein. The peptides are overlapping class I restricted T cell epitopes. The invention includes a therapeutic composition and vaccine containing the immunogenic peptides. Use of the composition results in cytostatic and/or antiviral activity. The peptides and nucleic acids encoding them can be used as vaccines to treat or prevent disease conditions such as exophytic condyloma, flat condyloma, cervical cancer, respiratory papilloma, conjunctival papilloma, genital-tract HPV infection, and cervical dysplasia. The present sequence represents a peptide of the invention

XX Sequence 25 AA;

SQ Query Match 100.0%; Score 122; DB 4; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy

1 MAISGVPLGFFIAVLMQAESWA 25

Db

1 MAISGVPLGFFIAVLMQAESWA 25

CC

RESULT 10

ID AAB20205 standard; peptide; 25 AA.

XX

AC AAB20205;

XX

DT 14-MAY-2001 (first entry)

XX

DB HLA-DR-alpha signal peptide.

XX

XX Human leukocyte antigen; HLA-DR-alpha; signal peptide;

XX HPV; immunogen; E7 protein; vaccine; infection;

XX gene therapy; exophytic condyloma; flat condyloma; cervical papilloma; cervical dysplasia.

XX Human.

XX OS

XX PN

XX US6183746-B1.

XX XX

XX PD

XX 06-FEB-2001.

XX XX

XX PP

XX 09-OCT-1998; 98US-00169425.

XX XX

XX PR

XX 09-OCT-1997; 97US-0061657P.

XX XX

XX PA (ZYCO-) ZYCOS INC.

XX XX

XX PI

XX Urban RG, Chiez RM, Collins EJ, Hedley ML;

XX XX

XX DR

XX WPI; 2001-190339/19.

XX XX

PT Inducing an immune response in a mammal for prophylaxis and treatment of human papilloma virus infections such as cervical cancer, comprises administering immunogenic peptides from the papilloma virus type 16 E7 protein.

PT XX

PT Claim 25; Col 32; 23pp; English.

PT XX

PT CC The present sequence is that of the non-polymorphic HLA-DR-alpha chain gene leader sequence. Claimed methods of the invention involve the administration to a mammal, such as a human, of a nucleic acid encoding a polypeptide comprising a first peptide, which controls intracellular trafficking, e.g. the present sequence, and a second peptide, which is derived from human papilloma virus type 16 E7 protein and which contains multiple overlapping class I HLA-binding T-cell epitopes. The immunogenic peptides and nucleic acids of the invention are used as vaccines prophylactically or therapeutically in subjects having, suspected of having, or at risk of exophytic condyloma, flat condyloma, cervical cancer, respiratory papilloma, conjunctival papilloma, genital-tract HPV infection and cervical dysplasia (claimed)

CC XX

CC SQ Sequence 25 AA;

CC



XX CYP1B1; major histocompatibility complex; cancer; endoplasmic reticulum;  
 KW double PEP-Padre protein; rodent; cytosstatic; MHC; nuclear localisation;  
 KW double PEP-Padre protein; ER; lysosome; secretion targeting.  
 OS Unidentified.  
 XX WO200242325-A2.  
 XX PD 30-MAY-2002.  
 XX PP 31-OCT-2001; 2001WO-US045170.  
 XX PR 31-OCT-2000; 2000US-0244501P.  
 PR 12-JAN-2001; 2001US-0261719P.  
 PR 15-JUN-2001; 2001US-0298428P.  
 XX PA (ZYCO-) ZYCO INC.  
 XX PI Aziz N, Hedley ML, Urban RG, Tomlinson AJ, Cole G;  
 XX WPI; 2002-557504/59.  
 XX PT CYP1B1 polynucleotide for inducing immune response against cancer, has  
 transcriptional units encoding polypeptides, and lack sequences found in  
 untranslated region of naturally occurring forms of transcript.  
 XX Disclosure: Page 4; 73pp; English.  
 XX The invention relates to a polynucleotide comprising a transcriptional  
 unit (TU) encoding CYP1B1, or protein comprising a peptide that binds to  
 a major histocompatibility complex class I or II molecule, where TU does  
 not contain a translational repressor element. The sequences are useful  
 for inducing an immune response especially T or B cell response, in a  
 mammal suffering from, or at risk of, cancer, where the method preferably  
 comprises detecting expression of CYP1B1 in a tumour of a mammal, and  
 administering CYP1B1 DNA, where the mammal belongs to a species,  
 especially human, and CYP1B1 polypeptide of a different species which is  
 a naturally occurring CYP1B1 polypeptide of a different species which is  
 a rodent, preferably a rat or mouse. The sequences of the invention are  
 further useful for reducing tumour growth or tumour activity in a mammal  
 by identifying a mammal having a tumour, administering CYP1B1 DNA, and  
 detecting a reduction in the size or activity of the tumour. This  
 sequence represents a peptide of the invention  
 XX SQ Sequence 25 AA;

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25  
 Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

RESULT 15

ABB0908 standard; peptide; 25 AA.  
 ID ABB0908  
 XX AC ABB0908;  
 XX DT 10-JUN-2002 (first entry)

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

RESULT 14  
 AAE19014  
 ID AAE19014 standard; peptide; 25 AA.  
 XX AC AAE19014;  
 XX DT 21-MAY-2002 (first entry)

DB Hydrophobic signal peptide.  
 XX KW B7-H3; B7-H4; T cell; immunodeficiency disease; immune response;  
 KW augmenter; cancer; acquired immune deficiency syndrome; AIDS; viricide;  
 KW AIDS-related complex disease; virally-induced condition; immunotherapy;  
 KW environmentally-induced condition; immune mechanism; immunostimulator;  
 KW cytosstatic; anti-HIV; congenital immune deficiency; signal peptide.  
 XX OS Unidentified.

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPTLGFFIIVLMSAQESWA 25

Db 1 MAISGVPTLGFFIIVLMSAQESWA 25

Query Match 100.0%; Score 122; DB 5; Length 25;

PR 20-JUL-2000; 2000US-0219759P.  
 XX (MINN ) UNIV MINNESOTA.  
 PA (UABR-) UAB RES FOUND.

XX P1 Vallera DA, Buchsbaum DJ;

XX DR WPI; 2002-241556/29.

XX PT Radiolabeled immunotoxins, useful for treating pathological conditions by  
 PT killing pathogenic cells e.g. cancer, comprises toxic domain, targeting  
 domain and at least one radionuclide atom.

XX PS Disclosure; Page 18; 53PP; English.

XX The sequence represents a possible signal peptide for a radiolabelled  
 CC immunotoxin of the invention. The invention relates to a novel  
 CC radiolabelled immunotoxin (RIT) comprising a toxic domain, a targeting  
 CC domain, and at least one radionuclide atom. The RIT has cytotoxic,  
 CC immunosuppressive, antibacterial, virucide, haemostatic, antirheumatic,  
 CC antiarthritic, antidiabetic, neuroprotective, muscular-active,  
 CC dermatological, antiinflammatory, tuberculostatic, anti-HIV, nootropic,  
 CC and hepatotropic activity. The radiolabelled immunotoxin proteins (RIT and  
 CC RMIT) are administered as therapeutic agents to a subject to treat  
 CC pathological conditions such as cancer, graft-versus-host disease (GVHD),  
 CC autoimmune disease or infectious diseases. The method is effective  
 CC against pathogenic cells and involves killing target cells in the subject

XX Sequence 25 AA;

Query Match 100.0%; Score 122; DB 5; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 3 9e-13;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 MAISGVPVLGFFITAVLMSAQESWA 25  
 Db 1 MAISGVPVLGFFITAVLMSAQESWA 25

Search completed: August 19, 2005, 23:29:46  
 Job time : 162.135 sec<sub>8</sub>

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model  
Run on: August 19, 2005, 23:21:28 ; Search time 74.2703 Seconds  
(without alignments)  
82.738 Million cell updates/sec

Title: US-10-603-062-16  
Perfect Score: 67  
Sequence: 1 LMGTGIVCPIC 12

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing First 45 summaries

Database : UniProt\_03:  
1: uniprot\_sprot:  
2: uniprot\_trembl:  
\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Query	Score	Match	Length	DB	ID	Description
1		67	100.0	26	2	Q84267	Q84267 human papill
2		67	100.0	94	2	Q885P6	Q885P6 human papill
3		67	100.0	98	2	VE7 HPV16	VE7 HPV16
4		67	100.0	98	2	011650	011650 human papill
5		67	100.0	98	2	012337	012337 human papill
6		67	100.0	98	2	012338	012338 human papill
7		67	100.0	98	2	Q8QRD2	Q8QRD2 human papill
8		67	100.0	98	2	Q8QRD3	Q8QRD3 human papill
9		67	100.0	98	2	Q8QRD4	Q8QRD4 human papill
10		67	100.0	98	2	Q8VJ10	Q8VJ10 human papill
11		67	100.0	98	2	Q778H3	Q778H3 human papill
12		67	100.0	98	2	Q778H5	Q778H5 human papill
13		60	89.6	97	2	Q82006	Q82006 human papill
14		58	86.6	93	2	Q9QDH4	Q9QDH4 human papill
15		58	86.6	93	2	Q9QDH4	Q9QDH4 human papill
16		58	86.6	93	2	Q9QDH6	Q9QDH6 human papill
17		58	86.6	93	2	Q9QDH8	Q9QDH8 human papill
18		58	86.6	98	1	VE7 HPV11	VE7 HPV11
19		58	86.6	98	1	VE7 HPV6B	VE7 HPV6B
20		58	86.6	98	1	Q9Q1P4	Q9Q1P4 human papill
21		57	85.1	98	1	VE7 HPV6A	VE7 HPV6A
22		56	83.6	94	2	Q6E5Q1	Q6E5Q1 human papill
23		56	83.6	94	2	Q6E5Q8	Q6E5Q8 human papill
24		56	83.6	99	2	090724	090724 human papill
25		56	83.6	101	1	VE7 HPV13	VE7 HPV13
26		55	82.1	93	1	VE7 HPV35	VE7 HPV35
27		55	82.1	93	1	VE7 HPV35	VE7 HPV35
28		55	82.1	99	2	Q76WP2	Q76WP2 human papill
29		55	82.1	104	1	VE7 HPV40	VE7 HPV40
30		54	80.6	95	2	Q9b5W9	Q9b5W9 human papill
31		54	80.6	96	2	Q98005	Q98005 human papill

ALIGNMENTS							
Scoring table: BLOSUM62	Gapop 10.0 , Gapext 0.5						
Searched: 1612378 seqs, 512079187 residues							
Total number of hits satisfying chosen parameters: 1612378							
Minimum DB seq length: 0							
Maximum DB seq length: 2000000000							
Post-processing: Minimum Match 0%							
Maximum Match 100%							
Listing First 45 summaries							
Database : UniProt_03: 1: uniprot_sprot: 2: uniprot_trembl: *							
RESULT 1							
Q84267							
ID 084267 , PRELIMINARY;							
AC Q84267;							
DT 01-NOV-1996 (TREMBLrel. 01, Created)							
DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)							
DT 01-DEC-2001 (TREMBLrel. 19, Last annotation update)							
DE E7 ORF (Fragment).							
OS Human papillomavirus.							
OC Viruses; dsDNA viruses, no RNA stage; Papillomaviridae;							
NCBI_TaxID=10566;							
RN [1]							
RP SEQUENCE FROM N.A.							
RX MEDLINE=89095007; PubMed=2536104;							
RA Choo K.-B., Cheung W.-F., Lieu L.-N., Lee H.-H., Han S.-H.; "Presence of Caenated Human Papillomavirus Type 16 Episomes in a Cervical Carcinoma Cell Line."; J. Virol. 63:782-789 (1989).							
FT EMBL; M2415; AAA46344.; -;							
DR IntertPro; IPR000148; Papvi_E7.							
DR Pfam; PF00527; E7; 1.							
FT NON_TBR 1 1 1 1 MW; 91C16F1D34D18B34 CRC64;							
SQ SEQUENCE 26 AA; 2799 MW; 91C16F1D34D18B34 CRC64;							
Query Match 100.0%; Score 67; DB 2; Length 26;							
Best Local Similarity 100.0%; Pred. No. 0.00081;							
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;							
QY 1 LMGTGIVCPIC 12							
Db 11 LMGTGIVCPIC 22							
RESULT 2							
Q8B5P6							
ID Q8B5P6 , PRELIMINARY;							
AC Q8B5P6;							
DT 01-MAR-2003 (TREMBLrel. 23, Created)							
DT 01-MAR-2003 (TREMBLrel. 23, Last sequence update)							
DT 01-JUN-2003 (TREMBLrel. 24, Last annotation update)							
DE E7 oncoprotein (Fragment).							
OS Human papillomavirus type 16.							
OC Viruses; dsDNA viruses, no RNA stage; Papillomaviridae;							
NCBI_TaxID=10581;							
RN [1]							
RP SEQUENCE FROM N.A.							
RA Ponglikitmongkol, M.; Vaiteewoottacharn, K.; Submitted (JAN-2002) to the ENBL/GenBank/DBJ databases.							
RL EMBL; AF46197; AAO15692; 1;							
DR IntertPro; IPR000148; Papvi_E7.							
DR Pfam; PF00527; E7; 1.							
FT NON_TER 94 94							

SQ	SEQUENCE	94 AA;	10555 MW;	7CC3281BB2AE2C8A CRC64;	DR EMBL; AF003026; AAB70743.1; -.
	Query Match	100. 0%;	Score 67;	DB 2;	DR PIR; A03688; W7WLHS.
	Best Local Similarity	100. 0%;	Pred. No. 0. 0024;	Length 94;	DR PROTEIN; IPK00148; Papvi_E7.
	Matches 12;	Conservative 0;	Mismatches 0;	Indels 0;	DR PFAM; PR00527; E7.1.
Qy	1 LMGTIGIVCPIC 12				KW DNA-binding; Early protein; Oncogene; Trans-acting factor;
Db	83 LMGTIGIVCPIC 94				KW Transcription regulation.
					FT SITE 58 61 C-XX-C motif-1.
					FT SITE 91 94 C-XX-C motif-2.
					SQ SEQUENCE 98 AA; 11022 MW; 95D61234CDC9EB CRC64;
	RESULT 3				Query Match 100.0%;
VE7 HPV16	ID HPV16	STANDARD;	PRT;	98 AA.	Best Local Similarity 100.0%;
AC P03159;	DT 21-JUL-1986 (Rel. 01, Created)				Pred. No. 0.025;
OX NCBI_TAXID=10581;	DT 21-JUL-1986 (Rel. 01, Last sequence update)				Mismatches 0;
RN [1]	RP SEQUENCE FROM N.A.				Indels 0;
PMID=81246220;	PubMed:2990099;				Gaps 0;
RA Seedorf K., Krammer G., Durst M., Suhai S., Rowekamp W.G.;	RA "Human papillomavirus type 16 DNA sequence.";				
RT Virology 145:181-185(1985).	RT Viruses: dsDNA viruses, no RNA stage; Papillomaviridae;				
RN [2]	RP SEQUENCE FROM N.A.				
PMID=90218027;	PubMed:2157796;				
RA Schnsider-Maunoury S., Pehau-Arnaudet G., Breithurd P., Orth G.;	RA "Expression of the human papillomavirus type 16 genome in SK-v cells, a line derived from vulvar intraepithelial neoplasia.";				
RT J. Gen. Virol. 71:809-817(1990).	RT Gen. variants in E7 gene of human papillomavirus type 16 from cervical cancerous and noncancerous lesions of Korean women.";				
RN [3]	RP SEQUENCE FROM N.A.				
PMID=9218027;	PubMed:2157796;				
RA Song Y.-S., Kee S.H., Kim J.W., Park N.-H., Kang S.-B., Chang W.-H.,	RA "Major sequence variants in E7 gene of human papillomavirus type 16 from cervical neoplasia in southern China.";				
RL Submitted (NOV-1996) to the EMBL/GenBank/DBJ databases.	RL Submitted (OCT-1996) to the EMBL/GenBank/DBJ databases.				
RN [4]	RP SEQUENCE FROM N.A.				
PMID=80223347;	PubMed:2836062;				
RA Phelps W.C., Yee C.L., Munger K., Howley P.M.;	RA "The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A.";				
RT Cell 53:539-547(1998).	RT Human papillomavirus type 16 intratypic variant infection and risk				
CC -!- FUNCTION: E7 protein has both transforming and trans-activating	CC for cervical neoplasia in southern China.";				
CC activities.	CC J. Infect. Dis. 186:696-700(2002).				
CC	CC This SWISS-PROT entry is copyright. It is produced through a collaboration				
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -	CC the European Bioinformatics Institute. There are no restrictions on its				
CC use by non-profit institutions as long as its content is in no way	CC modified and this statement is not removed. Usage by and for commercial				
CC entities requires a license agreement (see <a href="http://www.isb-sib.ch/announce/">http://www.isb-sib.ch/announce/</a>	CC or send an email to licensee@isb-sib.ch).				
CC	CC				
DR EMBL; K02718; AAA46340.1; -.	DR EMBL; K02718; AAA46340.1; -.				
DR EMBL; D00735; BAA06333.1; -.	DR EMBL; D00735; BAA06333.1; -.				
DR EMBL; U76411; AAB1886.1; -.	DR EMBL; U76411; AAB1886.1; -.				
DR EMBL; U76412; AAB18863.1; -.	DR EMBL; U76412; AAB18863.1; -.				
DR EMBL; U76413; AAB18864.1; -.	DR EMBL; U76413; AAB18864.1; -.				
DR EMBL; A003020; AAB7073.1; -.	DR EMBL; A003020; AAB7073.1; -.				
DR EMBL; A003023; AAB70740.1; -.	DR EMBL; A003023; AAB70740.1; -.				
DR EMBL; A003024; AAB70741.1; -.	DR EMBL; A003024; AAB70741.1; -.				
DR EMBL; A003025; AAB70742.1; -.	DR EMBL; A003025; AAB70742.1; -.				

RESULT 5

Query Match 100.0%; Score 67; DB 2; Length 98;  
Best Local Similarity 100.0%; Pred. No. 0.0025;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 LMGTGIVCPIC 12  
Db 83 LMGTGIVCPIC 94

DR EMBL; AF003022; AAB70739.1; -;  
DR EMBL; AF77385; AAM0305.1; -;  
DR InterPro; IPR00148; Papvi\_E7.  
DR Pfam; PF00527; E7; 1.  
SEQUENCE 98 AA; 10995 MW; 81E53B534CC3281B CRC64;

Query Match 100.0%; Score 67; DB 2; Length 98;  
Best Local Similarity 100.0%; Pred. No. 0.0025;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 LMGTGIVCPIC 12  
Db 83 LMGTGIVCPIC 94

RESULT 6

Query Match 100.0%; Score 67; DB 2; Length 98;  
Best Local Similarity 100.0%; Pred. No. 0.0025;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 LMGTGIVCPIC 12  
Db 83 LMGTGIVCPIC 94

DR EMBL; AF003022; AAB70739.1; -;  
DR EMBL; AF77385; AAM0305.1; -;  
DR InterPro; IPR00148; Papvi\_E7.  
DR Pfam; PF00527; E7; 1.  
SEQUENCE 98 AA; 10960 MW; 9BD612534CCEA59B CRC64;

Query Match 100.0%; Score 67; DB 2; Length 98;  
Best Local Similarity 100.0%; Pred. No. 0.0025;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 LMGTGIVCPIC 12  
Db 83 LMGTGIVCPIC 94

RESULT 7

Query Match 100.0%; Score 67; DB 2; Length 98;  
Best Local Similarity 100.0%; Pred. No. 0.0025;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 LMGTGIVCPIC 12  
Db 83 LMGTGIVCPIC 94

DR EMBL; AF003022; AAB70739.1; -;  
DR EMBL; AF77385; AAM0305.1; -;  
DR InterPro; IPR00148; Papvi\_E7.  
DR Pfam; PF00527; E7; 1.  
SEQUENCE 98 AA; 10960 MW; 9BD612534CCEA59B CRC64;

SEQUENCE FROM N.A.  
MEDLINE=22182962; PubMed=12195358;  
RX Chan P.K.S., Lam C.W., Cheung T.H., Li W.W.H., Lo K.W.K., Chan M.Y.M.,  
RA RA Cheung J.L.K., Xu L.Y., Cheng A.F.;  
RA RA "Human papillomavirus type 16 intratypic variant infection and risk  
RT for cervical neoplasia in southern China.";  
RT J. Infect. Dis. 186:696-700(2002).  
RL DR EMBL; AF46345; AAL96650.1; -;  
DR DR InterPro; IPR000148; Papvi\_E7.  
DR DR Pfam; PF00527; E7; 1.  
SQ SEQUENCE 98 AA; 11045 MW; 9C48C534CD7664B CRC64;

SEQUENCE FROM N.A.  
MEDLINE=97437474; PubMed=9292007;  
RX Chan P.K.S., Lam C.W., Cheung T.H., Li W.W.H., Lo K.W.K., Chan M.Y.M.,  
RA RA Cheung J.L.K., Xu L.Y., Cheng A.F.;  
RA RA "Sequence variations and viral genomic state of human papillomavirus  
RT type 16 in penile carcinomas from Ugandan patients.";  
RT J. Gen. Virol. 78:2199-2208(1997).  
RL DR EMBL; AF003021; AAB70738.1; -;  
DR DR InterPro; IPR00148; Papvi\_E7.  
DR DR Pfam; PF00527; E7; 1.  
SQ SEQUENCE 98 AA; 11056 MW; 19DEBBF14CD2C705 CRC64;

SEQUENCE FROM N.A.  
MEDLINE=97437474; PubMed=9292007;  
RX Chan P.K.S., Lam C.W., Cheung T.H., Li W.W.H., Lo K.W.K., Chan M.Y.M.,  
RA RA Cheung J.L.K., Xu L.Y., Cheng A.F.;  
RA RA "Sequence variations and viral genomic state of human papillomavirus  
RT type 16 in penile carcinomas from Ugandan patients.";  
RT J. Gen. Virol. 78:2199-2208(1997).  
RL DR EMBL; AF46345; AAL96650.1; -;  
DR DR InterPro; IPR000148; Papvi\_E7.  
DR DR Pfam; PF00527; E7; 1.  
SQ SEQUENCE 98 AA; 11045 MW; 9C48C534CD7664B CRC64;

SEQUENCE FROM N.A.  
MEDLINE=22182962; PubMed=12195358;  
RX Chan P.K.S., Lam C.W., Cheung T.H., Li W.W.H., Lo K.W.K., Chan M.Y.M.,  
RA RA Cheung J.L.K., Xu L.Y., Cheng A.F.;  
RA RA "Human papillomavirus type 16 intratypic variant infection and risk  
RT for cervical neoplasia in southern China.";  
RT J. Infect. Dis. 186:696-700(2002).  
RL DR EMBL; AF46345; AAL96650.1; -;  
DR DR InterPro; IPR000148; Papvi\_E7.  
DR DR Pfam; PF00527; E7; 1.  
SQ SEQUENCE 98 AA; 11021 MW; 9BD6125946D2C3E1 CRC64;

Query Match	100.0%	Score 67; DB 2; Length 98;	PRT;	98 AA.
Best Local Similarity	100.0%	Pred. No. 0.0025;	Indels	0; Gaps 0;
Matches	12;	Conservative 0; Mismatches 0;	Indels	0; Gaps 0;
Qy	1 LMGTGIVCPIC 12			
Db	83 LMGTGIVCPIC 94			
RESULT 9				
Q8QRD4	PRELIMINARY;	PRT;	98 AA.	
AC Q8QRD4;				
DT 01-JUN-2002 (TREMBLrel. 21, Created)				
DT 01-JUN-2002 (TREMBLrel. 21, Last sequence update)				
DT 01-OCT-2002 (TREMBLrel. 22, Last annotation update)				
DB E7 protein.				
OS Human papillomavirus type 16.				
OC Viruses; dsDNA viruses, no RNA stage; Papillomaviridae;				
OC Papillomavirus.				
OX NCBI_TaxID=10581;				
RN [1]				
SEQUENCE FROM N.A.				
RA MEDLINE=22182962; PubMed=12195358;				
RA Chan P.K.S., Lam C.W., Cheung T.H., Li W.W.H., Lo K.W.K., Chan M.Y.M.,				
RA Cheung T.J.K., Xu L.Y., Cheng A.F.;				
RT "Human papillomavirus type 16 intratypic variant infection and risk				
RT for cervical neoplasia in southern China. ";				
RL J. Infect. Dis. 186:696-700(2002).				
DR EMBL; AF486329; AU96634.1; -.				
DR InterPro; IPR000148; Papvi_E7.				
DR PF00527; E7. 1.				
DR SEQID 98 AA; 11025 MW; 86E24B234CC3281B CRC64;				
SQ				
Query Match	100.0%	Score 67; DB 2; Length 98;	PRT;	98 AA.
Best Local Similarity	100.0%	Pred. No. 0.0025;	Indels	0; Gaps 0;
Matches	12;	Conservative 0; Mismatches 0;	Indels	0; Gaps 0;
Qy	1 LMGTGIVCPIC 12			
Db	83 LMGTGIVCPIC 94			
RESULT 10				
Q8V1J0	PRELIMINARY;	PRT;	98 AA.	
AC Q8V1J0;				
DT 01-MAR-2002 (TREMBLrel. 20, Created)				
DT 01-MAR-2002 (TREMBLrel. 20, Last sequence update)				
DT 01-JUN-2002 (TREMBLrel. 21, Last annotation update)				
DB E7 protein.				
OS Human papillomavirus type 16.				
OC Viruses; dsDNA viruses, no RNA stage; Papillomaviridae;				
OC Papillomavirus.				
OX NCBI_TaxID=10581;				
RN [1]				
SEQUENCE FROM N.A.				
RA Jinhu X., Xinxing W., Yun T. i				
RA Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.				
DR EMBL; AF461264; AU66736.1; -.				
DR PF00527; E7. 1.				
DR SEQID 98 AA; 10997 MW; 9BD610834CCBA59B CRC64;				
SQ				
Query Match	100.0%	Score 67; DB 2; Length 98;	PRT;	98 AA.
Best Local Similarity	100.0%	Pred. No. 0.0025;	Indels	0; Gaps 0;
Matches	12;	Conservative 0; Mismatches 0;	Indels	0; Gaps 0;
Qy	1 LMGTGIVCPIC 12			
Db*	83 LMGTGIVCPIC 94			
RESULT 11				
Q778H3	PRELIMINARY;	PRT;	98 AA.	
AC Q778H3;				
DT 05-JUL-2004 (TREMBLrel. 27, Created)				
DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)				
DT 05-JUL-2004 (TREMBLrel. 27, Last annotation update)				
DB E7 protein (Fragment).				
OS Human papillomavirus type 16.				
OC Viruses; dsDNA viruses, no RNA stage; Papillomaviridae;				
OC Papillomavirus.				
OX NCBI_TaxID=10581;				
RN [1]				
SEQUENCE FROM N.A.				
RA MEDLINE=20112892; PubMed=10644829;				
RA van Duin M., Snijders P.J., Vossen, M.T., Klaassen E., Voorhorst F.,				
RA Verheijen R.H., Helmerhorst T.J., Meijer C.J., Walboomers J.M.;				
RT "Analysis of human papillomavirus type 16 E6 variants in relation to				
RT p53 codon 72 polymorphism genotypes in cervical carcinogenesis.";				
RT J. Gen. Virol. 81:317-325 (2000).				
RL EMBL; AU388063; CAB45119.1; -.				
DR InterPro; IPR000148; Papvi_E7.				
DR Pfam; PF00527; E7. 1.				
FT NON_TER 98 AA; 10995 MW; 81E53B534CC3281B CRC64;				
SQ				
Query Match	100.0%	Score 67; DB 2; Length 98;	PRT;	98 AA.
Best Local Similarity	100.0%	Pred. No. 0.0025;	Indels	0; Mismatches 0;
Matches	12;	Conservative 0; Mismatches 0;	Indels	0; Gaps 0;
Qy	1 LMGTGIVCPIC 12			
Db	83 LMGTGIVCPIC 94			
RESULT 12				
Q778H5	PRELIMINARY;	PRT;	98 AA.	
AC Q778H5;				
DT 05-JUL-2004 (TREMBLrel. 27, Created)				
DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)				
DB E7 protein (Fragment).				
OS Human papillomavirus type 16.				
OC Viruses; dsDNA viruses, no RNA stage; Papillomaviridae;				
OC Papillomavirus.				
OX NCBI_TaxID=10581;				
RN [1]				
SEQUENCE FROM N.A.				
RA MEDLINE=20112892; PubMed=10644829;				
RA van Duin M., Snijders P.J., Vossen, M.T., Klaassen E., Voorhorst F.,				
RA Verheijen R.H., Helmerhorst T.J., Meijer C.J., Walboomers J.M.;				
RT "Analysis of human papillomavirus type 16 E6 variants in relation to				
RT p53 codon 72 polymorphism genotypes in cervical carcinogenesis.";				
RT J. Gen. Virol. 81:317-325 (2000).				
RL EMBL; AU388062; CAB45117.1; -.				
DR InterPro; IPR000148; Papvi_E7.				
DR Pfam; PF00527; E7. 1.				
FT NON_TER 98 AA; 10995 MW; 81E53B534CC3281B CRC64;				
SQ				
Query Match	100.0%	Score 67; DB 2; Length 98;	PRT;	98 AA.
Best Local Similarity	100.0%	Pred. No. 0.0025;	Indels	0; Mismatches 0;
Matches	12;	Conservative 0; Mismatches 0;	Indels	0; Gaps 0;
Qy	1 LMGTGIVCPIC 12			
Db	83 LMGTGIVCPIC 94			
RESULT 13				
Q82006	PRELIMINARY;	PRT;	97 AA.	
ID Q82006				

AC Q82006; (TrEMBLrel. 01, Created)  
 DT 01-NOV-1995 (TrEMBLrel. 01, Last sequence update)  
 DT 01-NOV-1995 (TrEMBLrel. 19, Last annotation update)  
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
 DB protein.  
 OS Human papillomavirus type 73.  
 OC Viruses; dsDNA viruses, no RNA stage; Papillomaviridae;  
 OC Papillomavirus  
 OC NCBI\_TaxID=51033;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=96213793; PubMed=8635859;  
 RA Voelter C., He Y., Delius H., Roy-Burman A., Greenspan J.S.,  
 RA Greenspan D., de Villiers E.M.;  
 RT "Novel HPV types present in oral papillomatous lesions from patients  
 with HIV infection.";  
 RL Int. J. Cancer 66:433-456 (1996).  
 DR EMBL; X94165; CAA63983.1; -.  
 DR InterPro; IPR000148; Papv1\_B7.  
 DR Pfam; PF00527; E7; 1.  
 SQ SEQUENCE 97 AA; 10970 MW; 651D0345D048F022 CRC64;  
 Query Match 89.6%; Score 60; DB 2; Length 97;  
 Best Local Similarity 91.7%; Pred. No. 0.036;  
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Qy 1 LMGTIGIVCPIC 12  
 Db 82 LMGTIGIVCPNC 93

RESULT 14  
 Q9QDH2 PRELIMINARY; PRT; 93 AA.  
 ID Q9QDH2;  
 AC Q9QDH2;  
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DB E7 protein (Fragment)  
 OS Human papillomavirus type 16.  
 OC Viruses; dsDNA viruses, no RNA stage; Papillomaviridae;  
 OC Papillomavirus  
 OC NCBI\_TaxID=10581;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Lee H.P., Song Y.S., Kim J.W., Roh J.W., Park N.H., Kang S.B.;  
 RL Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.  
 DR EMBL; AP187869; AAFL13399.1; -.  
 DR InterPro; IPR000148; Papv1\_B7.  
 DR Pfam; PF00527; E7; 1.  
 FT NON\_TER 93  
 SQ SEQUENCE 93 AA; 10452 MW; 83281BB2AE2C8A1F CRC54;

Query Match 86.6%; Score 58; DB 2; Length 93;  
 Best Local Similarity 100.0%; Pred. No. 0.074;  
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LMGTIGIVCP1 11  
 Db 83 LMGTIGIVCP1 93

RESULT 15  
 Q9QDH4 PRELIMINARY; PRT; 93 AA.  
 ID Q9QDH4;  
 AC Q9QDH4;  
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
 DB E7 protein (Fragment).  
 OS Human papillomavirus type 16.  
 OC Viruses; dsDNA viruses, no RNA stage; Papillomaviridae;  
 OC Papillomavirus.

This Page Blank (uspto)

GenCore version 5.1.6  
Copyright (C) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: August 19, 2005, 23:21:28 ; Search time 154.73 Seconds  
(without alignments)  
82.738 Million cell updates/sec

Title: US-10-603-062-18  
Perfect score: 122  
Sequence: 1 MAISGPVTLGFFIIAVLMSAQESWA 25

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters:

1612378

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing First 45 summaries

Database :

UniProt 03:  
1: uniprot\_sprot:  
2: uniprot\_trembl:  
\*  
\*  
\*  
\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Query	Score	Match	Length	DB	ID	Description
1	122	100.0	27	2	019670		019670 homo sapien
2	122	100.0	50	2	019720		019720 homo sapien
3	122	100.0	229	2	030118		030118 homo sapien
4	122	100.0	254	1	2DRA_HUMAN		019903 homo sapien
5	122	100.0	254	2	Q6EWK6		Q6EWK6 macaca mulu
6	122	100.0	254	2	Q6EWL5		Q6EWL5 macaca mulu
7	122	100.0	254	2	Q9TP70		Q9TP70 homo sapien
8	118	96.7	254	2	Q6EWK9		Q6EWK9 macaca mulu
9	115	94.3	254	1	2DRA_MACMU		030631 macaca mulu
10	115	94.3	254	2	Q6EWK7		Q6EWK7 macaca mulu
11	105	83.2	254	2	Q30847		Q30847 orcto <sup>l</sup> agus
12	101	82.8	254	2	Q30437		Q30437 canis famil
13	83	68.0	251	2	Q31296		Q31296 sciurus abe
14	83	68.0	254	2	Q31297		Q31297 sciurus abe
15	83	68.0	254	2	Q31626		Q31626 sciurus abe
16	78	63.9	255	1	HA21_MOUSE		021904 mus musculus
17	78	63.9	255	1	HA22_MOUSE		024224 mus musculus
18	77.5	63.5	253	2	Q30828		Q30828 ovis aries
19	77	63.1	252	2	Q31295		Q31295 sciurus abe
20	76.5	63.1	254	2	Q19432		Q19432 felis silv
21	76.5	62.7	243	2	Q30846		Q30846 ovis aries
22	75	61.5	255	2	Q31092		Q31092 mus musculus
23	72.5	59.4	256	2	Q8MG88		Q8MG88 bos taurus
24	72.5	59.4	253	2	Q95111		Q95111 bos taurus
25	72.5	59.4	253	2	Q30309		Q30309 bos taurus
26	70.5	57.8	253	2	Q19810		Q19810 capra hircus
27	70	57.4	253	2	Q31294		Q31294 sciurus abe
28	70	57.4	254	2	Q19434		Q19434 felis silv
29	68	55.7	255	2	Q31281		Q31281 rattus norvegicus
30	68	55.7	255	2	Q6TP46		Q6TP46 rattus norvegicus
31	68	55.7	255	2	Q70RH7		Q70RH7 rattus norvegicus

#### ALIGNMENTS

RESULT 1									
ID	019670	PRELIMINARY	PRT;	PRT;	PRT;	PRT;	PRT;	PRT;	PRT;
AC	019670;								
DT	01-JAN-1998	(TREMBLrel.	05, Created)						
DT	01-JAN-1998	(TREMBLrel.	05, Last sequence update)						
DT	01-DEC-2001	(TREMBLrel.	19, Last annotation update)						
DB		Histocompatibility antigen HLA-DR alpha (Fragment).							
RA		Homo sapiens							
RA		Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Cetarrhini; Hominidae; Homo.							
RA		NCBI_TaxID=9606;							
RN		[1]							
RP		SEQUENCE FROM N.A.							
RX		MEDLINE=83169718; PubMed=6403940;							
RA		Das H.K., Biro P.A., Cohen S.N., Erlich H.A., von Gabain A., Schulz M.F., Lawrence S.K., Lemaux P.G., McDevitt H.O., Peterlin B.M., Soddy A.K., Weissman S.M.							
RA		"Use of synthetic oligonucleotide probes complementary to genes for human HLA-DR alpha and beta as extension primers for the isolation of 5' specific clones";							
RT		Proc. Natl. Acad. Sci. U.S.A. 80:1531-1535 (1983).							
RL		DR EMBL; V00524; CAA2783.1; -.							
DR		HSSP: P01897; 1LDP.							
FT		NON_TER	1						
SQ		SEQUENCE	27 AA;	2879 MW;	3A561D2DBDC0B233	CRC64;			
Query Match		100.0%	Score 122;	DB 2;	Length 27;				
Best Local Similarity		100.0%	Pred. No. 1..5e-10;						
Matches	25;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
Qy		1 MAISGPVVLGFFIIAVLMSAQESWA 25							
Db		1 MAISGPVVLGFFIIAVLMSAQESWA 25							
RESULT 2									
ID	019720	PRELIMINARY	PRT;	PRT;	PRT;	PRT;	PRT;	PRT;	PRT;
AC	019720;								
DT	01-JAN-1998	(TREMBLrel.	05, Created)						
DT	01-JAN-1998	(TREMBLrel.	05, Last sequence update)						
DT	01-JUN-2003	(TREMBLrel.	24, Last annotation update)						
DB		MHC class II HLA-DR-alpha chain precursor (Fragment).							
RA		Homo sapiens							
RA		Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Cetarrhini; Hominidae; Homo.							
RA		NCBI_TaxID=9606;							
RN		[1]							
RP		SEQUENCE FROM N.A.							
RX		MEDLINE=83146572; PubMed=6422242;							
RA		Gustafsson K., Wiman K., Larhammar D.G., Rask L., Peterson P.A.							
RT		"Signal sequences distinguishing class II histocompatibility antigen beta chains of different loci."							

RL	Scand. J. Immunol. 19:91-97 (1984).	
DR	EMBL; M35979; AAA36283.1; -.	
DR	GO; GO:0016020; C:membrane; IEA.	
DR	GO; GO:006955; P:immune response; IEA.	
DR	InterPro; IPR0103; MHC_II_alpha.	
PFam	PF00993; MHC_II_alpha; 1.	
KW	Signal; SIGNAL	1 25 Potential.
FT	CHAIN	26 >50 Potential.
FT	NON_TER	50 50
SQ	SEQUENCE	50 AA; 5620 MW; 8BFFF88265F8875D CRC64;
Query Match	Best Local Similarity	100.0%
	Matches	25; Conservative
Qy	1 MAISGVGVLFVLFIIAVLMSAQESWA 25	Score 122; DB 2; Length 50;
Db	1 MAISGVGVLFVLFIIAVLMSAQESWA 25	Pred. No. 2.4e-10; Mismatches 0; Indels 0; Gaps 0;
RESULT 3		
Q30118		PRELIMINARY; PRT; 229 AA.
ID	Q30118	
AC	Q30118; (TrEMBLrel. 01, Created)	
DT	01-NOV-1995 (TrEMBLrel. 01, Last sequence update)	
DT	01-MAR-2004 (TrEMBLrel. 26, Last annotation update)	
DE	MHC cell surface glycoprotein precursor.	
GN		
OS	Homo sapiens (Human)	
Name=HLA-DRA;		
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
NCBI_TaxID=9606;		
RN	SEQUENCE FROM N.A. MEDLINE=9101075; PubMed=2212658;	
RP	Koppeleman B., Cresswell P.	
RT	"Rapid nonlysosomal degradation of assembled HLA class II glycoproteins incorporating a mutant DR alpha-chain.";	
RT	J. Immunol. 145:2730-2736 (1990).	
RL	EMBL; M6033; AAA59987.1; -.	
DR	HSSP; P0103; 1-SEB.	
GO	GO:0016020; C:membrane; IEA.	
DR	GO; GO:006955; P:immune response; IEA.	
DR	InterPro; IPR007110; 1g-like.	
DR	InterPro; IPR003597; Ig_C1.	
DR	InterPro; IPR003006; Ig_MHC.	
DR	EMBL; M6033; AAA59987.1; -.	
DR	SMART; SM00993; MHC_II_alpha; 1.	
DR	SMART; SM00407; IgC1; 1.	
DR	PROSITE; PS00250; Ig_MHC; UNKNOWN_1.	
KW	Signal; SIGNAL	1 25 Potential.
FT	CHAIN	26 229 MHC cell surface glycoprotein.
SQ	SEQUENCE	229 AA; 25859 MW; 1RFD7B101R65335C CRC64;
Query Match	Best Local Similarity	100.0%
	Matches	25; Conservative
Qy	1 MAISGVGVLFVLFIIAVLMSAQESWA 25	Score 122; DB 2; Length 229;
Db	1 MAISGVGVLFVLFIIAVLMSAQESWA 25	Pred. No. 8.7e-10; Mismatches 0; Indels 0; Gaps 0;
RESULT 4		
2DRA_HUMAN	STANDARD;	
ID	2DRA_HUMAN	
AC	Q86160; Q86112;	
DT	21-JUL-1986 (Rel. 01, Created)	
DT	21-JUL-1986 (Rel. 01, Last sequence update)	
RP	SEQUENCE FROM N.A. MEDLINE=9101075; PubMed=2212658;	
RP	Koppeleman B., Cresswell P.	
RT	"Rapid nonlysosomal degradation of assembled HLA class II glycoproteins incorporating a mutant DR alpha-chain.";	
RT	Proc. Natl. Acad. Sci. U.S.A. 79:6013-6017 (1982).	
RN	SEQUENCE FROM N.A. MEDLINE=83221632; PubMed=6304715;	
RN	Das H.K., Lawrence S.K., Weissman S.M.;	
RT	"Structure and nucleotide sequence of the heavy chain gene of HLA-DR.";	
RT	Proc. Natl. Acad. Sci. U.S.A. 80:3543-3547 (1983).	
RN	SEQUENCE OF 26-204; MEDLINE=12263347; PubMed=6955253;	
RX	Yang C.-Y., Kratzin H., Gotz H., Thinnnes F.P., Kruse T., Egert G., Pauly E., Kolbel S., Werner P., Hilschmann N.;	
RA	"Primary structure of class II human histocompatibility antigens. 2nd Communication. Amino acid sequence of the N-terminal 179 residues of the alpha-chain of an HLA-DR2 allotype.";	
RT	Hope-Seyler S. Z. Physiol. Chem. 363:671-676 (1982).	
RL	SEQUENCE OF 26-60, AND SEQUENCE OF 32-202 AND 204-254 FROM N.A. MEDLINE=13025073; PubMed=6812963; DOI=10.1016/0092-8674(82)90021-6;	
RN	Larhammar D., Gustafsson K., Claesson L., Bill P., Wiman K., Schenning L., Sundelin J., Widmark E., Petersson P.A., Rask L., RT "Alpha chain of HLA-DR transplantation antigens is a member of the same protein superfamily as the immunoglobulins.";	
RT	Cell 30:153-161 (1982).	
RN	SEQUENCE FROM N.A. (DR*0101) MEDLINE=84057142; PubMed=6416803;	
RX	Kajimura Y., Toyoda H., Sato M., Miyakoshi S., Kaplan S.A., Ike Y., Goyer S.M., Silver J., Hawke D., Shively J.E., Suggs S.V., Wallace R.B., Itakura K.;	
RA	"Cloning the heavy chain of human HLA-DR antigen using synthetic oligodeoxyribonucleotides as hybridization probes.";	
RL	Nucleic Acids Res. 11:8663-8675 (1983).	
RN	SEQUENCE FROM N.A. (DR*0101) MEDLINE=84165507; PubMed=6324094;	
RX	Schamboeck A., Korman A.J., Kamb A., Strominger J.L.;	
RA	"Organization of the transcriptional unit of a human class II histocompatibility antigen: HLA-DR heavy chain.";	
RT	Nucleic Acids Res. 11:8663-8675 (1983).	
RN	SEQUENCE FROM N.A. (DR*0101) MEDLINE=8301300; PubMed=6811954;	
RX	Lee J.-S., Trowbridge J., Travers P.J., Carey J., Grosfeld F., Jenkins J., Bodmer W.P.;	
RA	"Sequence of an HLA-DR alpha-chain cDNA, clone and intron-exon organization of the corresponding gene.";	
RT	Nature 299:750-752 (1982).	
RN	SEQUENCE OF 29-254 FROM N.A. (DR*0102) MEDLINE=83229916; PubMed=6321129;	
RX	Korman A.J., Auffray C., Schamboeck A., Strominger J.L.;	
RA	"The amino acid sequence and gene organization of the heavy chain of the HLA-DR antigen: homology to immunoglobulins.";	
RT	Proc. Natl. Acad. Sci. U.S.A. 79:6013-6017 (1982).	
RN	SEQUENCE FROM N.A. (DR*0102) MEDLINE=91010755; PubMed=2212658;	
RX	Koppeleman B., Cresswell P.;	
RA	"Rapid nonlysosomal degradation of assembled HLA class II glycoproteins incorporating a mutant DR alpha-chain.";	
RT	Proc. Natl. Acad. Sci. U.S.A. 79:6013-6017 (1982).	

RL	J. Immunol. 145:2730-2736 (1990).	DR	EMBL; X00274; CAA25076_1; ALT_INIT.
RN	SEQUENCE OF 205-254 FROM N.A. (DRA*0102).	DR	EMBL; K01171; AAA59785_1; -.
RP	TISSUE=Blood;	DR	EMBL; J00194; AAA36225_1; -.
RC	MEDLINE=22337945;	DR	EMBL; J00201; AAA36301_1; -.
RX	PubMed=12445311;	DR	EMBL; M60334; AAA59783_1; -.
RX	RAKRALOVICOVAY J., MARSH S.G., Waller M.J., HammarskjöL L.,	DR	EMBL; AF481359; AAO23887_1; -.
RA	VORECHOVSKY I.;	PIR; A93952; HLTUDA.	
RA	"The HLA-DRA*01:02 allele: correct nucleotide sequence and associated HLA haplotypes.,"	DR	PDB; 1A8A; X-ray; A=30-205.
RT	Tissue Antigens 60:266-267 (2002).	DR	PDB; 1AQD; X-ray; A/D/G/J=26-217.
RL	X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 28-207.	DR	PDB; 1BQ2; X-ray; A/D=27-206.
RP	MEDLINE=94195388; PubMed=8145819; DOI=10.1038/3680215a0;	DR	PDB; 1B5M; X-ray; A=26-206.
RX	Stern L.J., Brown J.H., Jardetzky T.J., Gorga J.C., Urban R.G.,	DR	PDB; 1DXK; X-ray; A=26-206.
RA	Strominger J.L., Wiley D.C.;	DR	PDB; 1D5Z; X-ray; A=26-206.
RA	"Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide.,"	DR	PDB; 1D5B; X-ray; A=26-206.
RT	Nature 368:215-221(1994).	DR	PDB; 1D4H; X-ray; A/D=28-207.
RL	X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 28-207.	DR	PDB; 1FV1; X-ray; A/D=26-206.
RN	MEDLINE=93302847; PubMed=8316295; DOI=10.1038/364033a0;	DR	PDB; 1FPT; X-ray; A/D=26-207.
RP	Brown J.H., Jardetzky T.S., Gorga J.C., Stern L.J., Urban R.G.,	DR	PDB; 1H15; X-ray; A/D=26-207.
RX	Jardetzky T.S., Brown J.H., Gorga J.C., Stern L.J., Urban R.G.,	DR	PDB; 1H4Y; X-ray; A=26-207.
RA	Strominger J.L., Wiley D.C.;	DR	PDB; 1J0H; X-ray; A=26-206.
RA	"Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1.,"	DR	PDB; 1J0M; X-ray; A=26-206.
RT	Nature 364:33-39 (1993).	DR	PDB; 1J0N; X-ray; A=26-207.
RN	X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF COMPLEX WITH SEB.	DR	PDB; 1J0S; X-ray; A=26-207.
RP	MEDLINE=941203282; PubMed=8152483; DOI=10.1038/368111a0;	DR	PDB; 1J0V; X-ray; A=26-207.
RX	Jardetzky T.S., Brown J.H., Gorga J.C., Stern L.J., Urban R.G.,	DR	PDB; 1J0W; X-ray; A=26-207.
RA	Chi Y.I., Stauffacher C., Strominger J.L., Wiley D.C.;	DR	PDB; 1K50; X-ray; A=28-207.
RA	"Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen.,"	DR	PDB; 1KLG; X-ray; A=29-205.
RT	Nature 368:711-718 (1994).	DR	PDB; 1KLJ; X-ray; A=29-207.
RL	X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF COMPLEX WITH SEB.	DR	GO; GO:0005887; C: integral to plasma membrane; NAS.
RP	MEDLINE=941203283; PubMed=8152483; DOI=10.1038/378457a0;	DR	GO; GO:0045012; P: MHC class II receptor activity; NAS.
RX	Ghosh P., Amaya M., Mellins E., Wiley D.C.;	DR	GO; GO:0006955; P: immune response; NAS.
RA	"The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.,"	DR	InterPro; IPR007110; Ig-like.
RT	Nature 378:457-462 (1995).	DR	InterPro; IPR03597; Ig-cl.
RT	X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF COMPLEX WITH PEPTIDE FROM COLLAGEN.	DR	InterPro; IPR03006; Ig_MHC.
RP	MEDLINE=98014591; PubMed=9354468; DOI=10.1016/S1074-7613(00)80369-6;	DR	InterPro; IPR01003; MHC_II_alpha.
RX	Dessen A., Lawrence C.M., Cupo S., Zajdel D.M., Wiley D.C.;	DR	Pfam; PF0047; ig_1.
RA	"X-ray crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human collagen II.,"	DR	Pfam; PF00993; MHC_II_alpha; 1.
RT	RT	DR	SMART; SM00404; IgG1; IgG1; 1.
RT	RT	DR	PROSITE; PS50035; Ig_LIKE; 1.
RT	RT	DR	3D-structure; Direct_protein_sequencing; Glycoprotein; MHC II;
RT	RT	DR	KW Polymorphism; Signal; Transmembrane.
RT	RT	FT	SIGNAL 1 25 HLA class II histocompatibility antigen.
RT	RT	FT	CHAIN 26 254 DR alpha chain.
RL	X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF COMPLEX WITH PEPTIDE FROM MYELIN BASIC PROTEIN.	FT	Query Match 100.0%; Score 122; DB 1; Length 254;
RP	MEDLINE=9900672; PubMed=9782128;	FT	Best Local Similarity 100.0%; Pred. No. 9_4e-10;
RX	Smith K.J., Pyrdol J., Gauthier L., Wiley D.C., Wucherpfennig K.W.;	FT	Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
RA	"Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein.,"	FT	Qy 1 MAISGVPVGLGFFIAVMSAQESWA 25
RA	J. Exp. Med. 189:1511-1520(1998).	FT	Db 1 MAISGVPVGLGFFIAVMSAQESWA 25
RL	-I- SUBUNIT: Heterodimer of an alpha chain and a beta chain.	FT	RESULT 5
CC	-I- POLYMORPHISM: LOCATION: Type I membrane protein.	Q6EWK6	Q6EWK6 PRELIMINARY PRT; 254 AA.
CC	-I- POLYMORPHISM: LOCATION: Type I membrane protein.	ID	Q6EWK6 AC Q6EWK6
CC	DRA*0102. The sequence shown is that of DRA*0101.	DT	DT 25-OCT-2004 (TREMBurel. 28, Created)
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see <a href="http://www.isb-sib.ch/announce/">http://www.isb-sib.ch/announce/</a> or send an email to license@isb-sib.ch).	DT	DT 25-OCT-2004 (TREMBurel. 28, Last sequence update)
CC	CC	DT	DT 25-OCT-2004 (TREMBurel. 28, Last annotation update)
CC	CC	DB	DB MHC class II antigen.
CC	CC	GN	GN Name=DRA; Name=DRA;
CC	CC	OS	OS Macaca mulatta (Rhesus Macaque).
CC	CC	OC	OC Macrouridae; Meizozoa; Chordata; Craniata; Vertebrata; Euteleostomi;
CC	CC	OC	OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea.
CC	CC	OC	OC Cercopithecinae; Macaca.

OX	NCBI_TaxID=9544;	DR	PROSITE; PS50835; Ig_LIKE; 1.
RN	[1] SEQUENCE FROM N.A.	DR	PROSITE; PS00290; Ig_MHC; UNKNOWN 1.
RX	PubMed:15128802;	RW	Glycoprotein; MHC II; Transmembrane.
RA	de Groot N., de Groot N.G., Otting N., Heijmans C., Rouweler A.J.M.,	SEQUENCE	254 AA; EF4799D1A04440 CRC64;
RA	Doxiadis G.G., Bontrop R.E.;	Best Local Similarity	100.0%; Score 122; DB 2; Length 254;
RT	"Genetic make-up of the DR region in rhesus macaques: gene content, transcripts and pseudogenes".	Matches	25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
RT	J. Immunol. 172:6152-6157 (2004).	Query Match	100.0%; Score 122; DB 2; Length 254;
RL	DR EMBL; AJ566884; CAE22545..1; -.	Best Local Similarity	100.0%; Score 122; DB 2; Length 254;
PFam	PF00047; Ig-1.	Matches	25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
DR	GO; GO:0016020; C:membrane; IEA.	Qy	1 MAISGVPVIGFFITAVLMSAQSWSA 25
DR	GO; GO:006555; P:immune response; IEA.	Db	1 MAISGVPVIGFFITAVLMSAQSWSA 25
InterPro	IPR007110; Ig-like.	RESULT	7
DR	InterPro; IPR003597; Ig_C1.	ID	Q9T70
DR	InterPro; IPR003006; Ig_MHC.	PRELIMINARY	
DR	InterPro; IPR001003; MHC_II_alpha.	PRT	254 AA.
PFam	PF07654; C1-set; 1.	AC	Q9T70;
DR	PFam; PF00047; Ig-1.	DT	01-MAY-2000 (TrEMBLrel. 13, Created)
DR	PFam; PF00993; MHC_II_alpha; 1.	DT	01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
PROSITE	SM00407; IgG1; 1.	DT	05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DR	PROSITE; PS50835; Ig_LIKE; 1.	DE	DJ17K2.4.1 (Major histocompatibility complex, class II, DR alpha, isoform 1).
DR	PROSITE; PS00290; Ig_MHC; UNKNOWN 1.	DN	Name=HLA-DRA,
KW	Glycoprotein; MHC_II; Transmembrane.	OS	Homo sapiens (Human).
SEQUENCE	254 AA; 28289 MW; EF4799D00204440 CRC64;	OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Qy	1 MAISGVPVIGFFITAVLMSAQSWSA 25	OC	Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
Db	1 MAISGVPVIGFFITAVLMSAQSWSA 25	[1]	NCB_TaxID=9606;
Query Match	100.0%; Score 122; DB 2; Length 254;	RN	SEQUENCE FROM N.A.
Best Local Similarity	100.0%; Score 122; DB 2; Length 254;	RA	Williams S.; Submitted (SEP-2001) to the EMBL/GenBank/DBJ databases.
Matches	25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	RL	[2]
Qy	1 MAISGVPVIGFFITAVLMSAQSWSA 25	RN	SEQUENCE FROM N.A.
Db	1 MAISGVPVIGFFITAVLMSAQSWSA 25	RP	SEQUENCE FROM N.A.
RESULT	6	RC	TISSUE=Blood;
Q6EWL5	PRELIMINARY;	RX	MEDLINE:22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
ID	Q6EWL5;	RA	Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Klausner R.D., Collingwood F.S., Wagner L., Schuler G.D., Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F., Diachenko L., Marusina K., Farmer A.A., Rubin G.M., Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C., Raha S.S., Loquellano N., Peters G.J., Abramson R.D., Mullany S.J., Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Falvey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S., Krzywinski M.I., Skalska U., Smilus D.B., Schniech A., Schein J.E., Jones S.J., Marra M.A., "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences", Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RX	PubMed:15128802.	RA	[3]
RA	de Groot N., de Groot N.G., Otting N., Heijmans C., Rouweler A.J.M., Doxiadis G.G., Bontrop R.E.;	RN	SEQUENCE FROM N.A.
RT	"Genetic make-up of the DR region in rhesus macaques: gene content, transcripts and pseudogenes".	RP	SEQUENCE FROM N.A.
RT	J. Immunol. 172:6152-6157 (2004).	RC	TISSUE=Blood;
DR	EMBL; AJ566875; CAE22536..1; -.	RA	Strausberg R.; Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
DR	GO; GO:0016020; C:membrane; IEA.	RL	EMBL; BC032350; AAH32350..1; -.
DR	GO; GO:006555; P:immune response; IEA.	DR	DR; GO:0016020; C:membrane; IEA.
DR	InterPro; IPR007110; Ig-like.	DR	GO; GO:0006955; P:immune response; IEA.
DR	InterPro; IPR003597; Ig_C1.	DR	InterPro; IPR007110; Ig-like.
DR	InterPro; IPR003006; Ig_MHC.	DR	InterPro; IPR03597; Ig_C1.
DR	InterPro; IPR001003; MHC_II_alpha.	DR	InterPro; IPR003006; Ig_MHC.
DR	Pfam; PF07654; C1-set; 1.	DR	InterPro; IPR001003; MHC_II_alpha.
DR	Pfam; PF00993; MHC_II_alpha; 1.	DR	Pfam; PF07654; C1-set; 1.
DR	SMART; SM00407; IgG1; 1.	DR	SMART; SM00407; IgG1; 1.

DR	PROSITE; PS050835; IG_LIKE; 1.	OC	Cercopithecinae; Macaca.
DR	PROSITE; PS00290; IG_MHC; UNKNOWN 1.	OX	NCBI_TaxID=9544;
SQ	SEQUENCE 254 AA; 28621 MW; 3CDCDBA89D92350 CRC64;	RN	[1]_SEQUENCE FROM N.A.
		RP	RP MEDLINE=3605321; PubMed=7558932; DOI=10.1016/0198-8859(94)00155-J;
Query Match	Score 122; DB 2; Length 254;	RX	RA Lekutis C.; Letvin N.L.;
Best Local Similarity	100.0%; Pred. No. 9.4e-10;	RA	RT "Biochemical and molecular characterization of rhesus monkey major
Matches 25;	Conservative 0; Mismatches 0; Indels 0; Gaps 0;	RT	RT histocompatibility complex class II DR.";
Qy	1 MAISGVPLVGFFIILVLMQAESWA 25	RL	RL Hum. Immunol. 43:72-80(1995).
Db	1 MAISGVPLVGFFIILVLMQAESWA 25	CC	CC -1- SUBUNIT: Heterodimer of an alpha chain and a beta chain.
		CC	CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
RESULT 8		CC	CC This SWISS-PROT entry is copyright. It is produced through a collaboration
Q6EWK9	PRELIMINARY; PRT; 254 AA.	CC	CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
ID	Q6EWK9; PRELIMINARY; PRT; 254 AA.	CC	CC the European Bioinformatics Institute. There are no restrictions on its
AC	Q6EWK9; PRELIMINARY; PRT; 254 AA.	CC	CC use by non-profit institutions as long as its content is in no way
DT	25-OCT-2004 (TRIMBLrel. 28; Created)	CC	CC modified and this statement is not removed. Usage by and for commercial
DT	25-OCT-2004 (TRIMBLrel. 28; Last sequence update)	CC	CC entities requires a license agreement (See <a href="http://www.isb-sib.ch/announce/">http://www.isb-sib.ch/announce/</a> or send an email to license@isb-sib.ch).
DT	25-OCT-2004 (TRIMBLrel. 28; Last annotation update)	CC	CC
DB	MHC class II antigen.	DR	DR EMBL; L27739; AAB63305_1; -.
GN	Name=DRA;	DR	DR HSSP; P01903; MHC_II_alpha; 1.
OS	Macaca mulatta (Rhesus macaque)	DR	DR InterPro; IPR007110; Ig-like.
OC	de Groot N.; de Groot N.G.; Otting N.; Heijmans C.; Rouweler A.J.M.,	DR	DR InterPro; IPR003597; Ig_c1.
OC	Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	DR	DR InterPro; IPR003006; Ig_MHC.
OC	Mammalia; Butheria; Primates; Catarrhini; Cercopithecidae;	DR	DR InterPro; IPR001003; MHC_II_alpha.
OC	Cercopithecinae; Macaca.	DR	DR Pfam; PF00047; Ig; 1.
OX	NCBI_TaxID=9544;	DR	DR Pfam; PF00993; MHC_II_alpha; 1.
RN	[1]_SEQUENCE FROM N.A.	DR	DR SMART; SM00407; IgC1; 1.
RP	RP PubMed151288002;	DR	DR PROSITE; PS50835; Ig_LIKE; 1.
RX	RX PubMed151288002;	DR	DR PROSITE; PS00280; Ig_MHC; 1.
RA	RA Doxiadis G.G.; Bontrop R.E.;	DR	DR Glycoprotein; MHC_II_Signal; Transmembrane.
RA	RA "Genetic make-up of the DR region in rhesus macaques: gene content, transcripts and pseudogenes.";	FT	FT SIGNAL 1 25 By similarity.
RT	RT J. Immunol. 172:6152-6157(2004).	FT	FT CHAIN 26 254 HLA class II histocompatibility antigen, DR alpha chain.
RL	RL DR AJ586881; CAE5542; 1; -.	FT	FT DOMAIN 26 109 Extracellular alpha-1.
DR	DR GO; GO:001620; C:membrane; IEA.	FT	FT DOMAIN 110 203 Extracellular alpha-2.
GO	GO; GO:0006955; P:immune response; IEA.	FT	FT DOMAIN 204 216 Connecting peptide.
DR	DR InterPro; IPR007110; Ig-like.	FT	FT TRANSMEM 217 239 Cytoplasmic.
DR	DR InterPro; IPR003597; Ig_c1.	FT	FT DOMAIN 240 254 By similarity.
DR	DR InterPro; IPR003006; Ig_MHC.	FT	FT DISULFID 132 188 N-linked (GlcNAc. . .) (Potential).
DR	DR InterPro; IPR001003; MHC_II_alpha.	FT	FT CARBOHYD 103 103 Sequence 254 AA; 28405 MW; 8587C99EB2294443 CRC64;
DR	DR Pfam; PF07654; C1-set; 1.	FT	FT SEQUENCE 254 AA; 28405 MW; 8587C99EB2294443 CRC64;
DR	DR Pfam; PF00047; Ig; 1.	Query Match	Query Match 94.3%; Score 115; DB 1; Length 254;
DR	DR SMART; SM00407; IgC1; 1.	Best Local Similarity 96.0%; Pred. No. 1e-08; 0; Mismatches 0; Gaps 0;	
DR	DR PROSITE; PS050835; Ig_LIKE; 1.	Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
DR	DR PROSITE; PS00290; IG_MHC; UNKNOWN 1.	Qy 1 MAISGVPLVGFFIILVLMQAESWA 25	
RW	RW Glycoprotein; MHC_II_Signal; Transmembrane.	Db 1 MAISGVPLVGFFIILVLMQAESWA 25	
SEQUENCE	SEQUENCE 254 AA; 28361 MW; 9C47C29AB990433C CRC64;	DE	DE MHC class II antigen.
Qy	1 MAISGVPLVGFFIILVLMQAESWA 25	GN	GN Name=DRA;
Db	1 MAVSGVPLVGFFIILVLMQAESWA 25	OS	OS Macaca mulatta (Rhesus macaque).
RESULT 9		OC	OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi;
2DRA_MACTU	STANDARD; PRT; 254 AA.	AC	AC Mammalia; Primates; Catarrhini; Cercopithecidae;
Q30631;	(Rel. 42, Created)	DT	DT 25-OCT-2004 (TRIMBLrel. 28; Created)
DT	10-OCT-2003 (Rel. 42, Last sequence update)	DT	DT 25-OCT-2004 (TRIMBLrel. 28; Last sequence update)
DT	05-JUL-2004 (Rel. 44, Last annotation update)	DT	DT 25-OCT-2004 (TRIMBLrel. 28; Last annotation update)
DE	HLA class II histocompatibility antigen, DR alpha chain precursor (MHC	RN	RN [1]_SEQUENCE FROM N.A.
DB	class II antigen DRA.	RP	RP PubMed15128802;
GN	Name=H1A-DRA;	RA	RA de Groot N.; de Groot N.G.; Otting N.; Heijmans C.; Rouweler A.J.M.,
OS	Macaca mulatta (Rhesus macaque).	RA	RA Doxiadis G.G.; Bontrop R.R.;
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	RT	RT "Generic make-up of the DR region in rhesus macaques: gene content,
OC	Mammalia; Butheria; Primates; Catarrhini; Cercopithecidae;		

Db	1	MAISGGPVLPVLFPIIAILMSPQKSWA 26
RT	transcripts and pseudogenes.";	
RL	J. Immunol. 172:6152-6157 (2004).	
EMBL	AJ56683; ABE52544.1; -.	
EMBL	AJ56682; CAB32543.1; -.	
DR	GO: GO:0016020; C:membrane; IEA.	
DR	GO: GO:0006745; P:immune response; IEA.	
DR	InterPro; IPR007110; Ig-like.	
DR	InterPro; IPR003597; Ig_C1.	
DR	InterPro; IPR003006; Ig_MHC.	
DR	InterPro; IPR001003; MHC_II_alpha.	
PFam	PF07654; C1-set; 1.	
PFam	PF00047; Ig; 1.	
PFam	PF00993; MHC_II_alpha; 1.	
SMART	SM00407; IgCl; 1.	
DR	PROSITE; PS00835; Ig_LIKE; 1.	
DR	PROSITE; PS00280; Ig_MHC; UNKNOWN_1.	
KW	Glycoprotein; MHC_II; Transmembrane.	
SEQUENCE	254 AA; 28358 MW; 834 C99E2690447 CRC64;	
SQ	Query Match 94.3%; Score 115; DB 2; Length 254; Best Local Similarity 96.0%; Pred. No. 1e-08; Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
Qy	1 MAISGGPVLPVLFPIIAILMSPQKSWA 25	
Db	1 MAESGVLPVLFPIIAILMSPQKSWA 25	
RESULT 11		
Q30847	PRELIMINARY; PRT; 255 AA.	
ID		
AC		
DT	01-NOV-1996 (TREMBLrel. 01, Created)	
DT	01-NOV-1996 (TREMBLrel. 01, Last sequence update)	
DT	01-MAR-2004 (TREMBLrel. 26, Last annotation update)	
DB	Name-RLA-DR-alpha; Integral membrane protein precursor.	
OS	Oryctolagus cuniculus (Rabbit).	
OC	Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagidae.	
NCBI_TaxID	9986; NCBI_TaxID=9986;	
OX		
RN	SEQUENCE FROM N.A.	
RX	Medline=89339656; PubMed=2759665;	
RT	Lavriere A., Kullaa H., Kindt T.J., LeGuern C., Marche P.N.; "A rabbit class II MHC gene with strong similarities to HLA-DR-alpha."	
RT	Immunogenetics 30:137-140 (1989).	
DR	EMBL; M28161; AAA31394.1; -.	
DR	PIR; A45881; A45881.	
DR	HSRP; P01903; 1HQR.	
DR	GO: GO:0016020; C:membrane; IEA.	
DR	GO: GO:0006955; P:immune response; IEA.	
DR	InterPro; IPR007110; Ig-like.	
DR	InterPro; IPR003597; Ig_C1.	
DR	InterPro; IPR003006; Ig_MHC.	
DR	InterPro; IPR001003; MHC_II_alpha.	
PFam	PF07654; C1-set; 1.	
PFam	PF00993; MHC_II_alpha; 1.	
SMAR	SM00407; IgCl; 1.	
DR	PROSITE; PS00835; Ig_LIKE; 1.	
DR	PROSITE; PS00280; Ig_MHC; UNKNOWN_1.	
KW	Signal; 1 26 Potential.	
SIGFT	27 255 integral membrane protein.	
SEQUENCE	255 AA; 28622 MW; 5F89AA315F793E9 CRC64;	
SQ	Query Match 83.2%; Score 101.5; DB 2; Length 255; Best Local Similarity 84.6%; Pred. No. 1e-06; Matches 22; Conservative 2; Mismatches 1; Indels 1; Gaps 1;	
Qy	1 MAIS-GPVPVLPVLFPIIAILMSPQKSWA 25	

Mon Aug 22 13:02:30 2005

RP SEQUENCE FROM N.A.  
 RC TISSUE=Spleen;  
 RA Wetstein P.J.;  
 RL Submitted (AUG-1992) to the EMBL/GenBank/DDBJ databases.  
 [2]

RP SEQUENCE FROM N.A.  
 RC TISSUE=Spleen;  
 RA Wetstein P.J.; Jin L.; Chakraborty R.; States J.;  
 RL Submitted (AUG-1992) to the EMBL/GenBank/DDBJ databases.  
 [2]

RP SEQUENCE FROM N.A.  
 RC TISSUE=Spleen;  
 RA Wetstein P.J.;  
 RL Submitted (AUG-1992) to the EMBL/GenBank/DDBJ databases.  
 [2]

Query Match 68.0%; Score 83; DB 2; Length 251;  
 Best Local Similarity 72.0%; Pred. No. 0.00053;  
 Matches 18; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

Qy 1 MAISGVGVLGFFIAVLMQAQESWA 25  
 Db 1 MARSEVMVLGFFFMAVLMNPQESWA 25

RESULT 14  
 ID Q31297 PRELIMINARY; PRT; 254 AA.  
 AC 031297;  
 DT 01-NOV-1996 (TRIMBLrel. 01, Created)  
 DT 01-NOV-1996 (TRIMBLrel. 01, Last sequence update)  
 DT 01-MAR-2004 (TRIMBLrel. 26, Last annotation update)  
 DB MHC class II DR-alpha.  
 OS Sciurus aberti (Abert's squirrel).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Rodentia; Sciurognathii; Sciuridae; Sciurinae;  
 OC Sciurus.  
 OC NCBI\_TaxID=10007;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Spleen;  
 RA Wetstein P.J.;  
 RL Submitted (AUG-1992) to the EMBL/GenBank/DDBJ databases.  
 DR HSSP; P0103; 1HQR.  
 DR GO: GO:0006955; C:membrane; IEA.  
 DR InterPro; IPR003597; Ig\_C1.  
 DR InterPro; IPR001003; MHC\_I\_alpha.  
 DR InterPro; IPR007654; C1-set; 1.  
 DR Pfam; PF00993; MHC\_I\_alpha; 1.  
 DR SMART; SM00407; IgC1; 1.  
 DR PROSITE; PS50835; Ig\_LIKE; 1.  
 DR PROSITE; PS00290; Ig\_MHC; UNKNOWN 1.  
 SQ SEQUENCE 254 AA; F377EB107A0951800 CRC64;  
 DR HSSP; P01903; 2SEB.  
 DR GO; GO:0016020; C:membrane; IEA.  
 DR GO; GO:0006955; P:immune response; IEA.  
 DR InterPro; IPR007110; Ig\_Like.  
 DR InterPro; IPR003597; Ig\_C1.  
 DR InterPro; IPR001003; MHC\_I\_alpha.  
 DR InterPro; IPR007654; C1-set; 1.  
 DR Pfam; PF00993; MHC\_I\_alpha; 1.  
 DR SMART; SM00407; IgC1; 1.  
 DR PROSITE; PS50835; Ig\_LIKE; 1.  
 DR PROSITE; PS00290; Ig\_MHC; UNKNOWN 1.  
 SQ SEQUENCE 254 AA; 28731 MW; F377EB107A0951800 CRC64;

Query Match 68.0%; Score 83; DB 2; Length 254;  
 Best Local Similarity 72.0%; Pred. No. 0.00054;  
 Matches 18; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

Qy 1 MAISGVGVLGFFIAVLMQAQESWA 25  
 Db 1 MARSEVMVLGFFFMAVLMNPQESWA 25

RESULT 15  
 ID Q31626 PRELIMINARY; PRT; 254 AA.  
 AC 031626;  
 DT 01-NOV-1996 (TRIMBLrel. 01, Created)  
 DT 01-NOV-1996 (TRIMBLrel. 01, Last sequence update)  
 DT 05-JUL-2004 (TRIMBLrel. 27, Last annotation update)  
 DB MHC class II DR-alpha.  
 OS Sciurus aberti (Abert's squirrel).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Rodentia; Sciurognathii; Sciuridae; Sciurinae;  
 OC Sciurus.  
 OC NCBI\_TaxID=10007;  
 RN [1]

This Page Blank (uspto)

GenCore version 5.1.6  
 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 19, 2005, 23:29:59 ; Search time 30.8108 Seconds  
 (without alignments)  
 60.669 Million cell updates/sec

Title: US-10-603-062-16  
 Perfect score: 67  
 Sequence: 1 LMCTLGIVCPIC 12

Scoring table: BLOSUM62  
 Gapop 10.0 , Gapext 0.5

Searched: 718547 seqs, 155772573 residues

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0  
 Maximum DB seq length: 2000000000  
 Post-processing: Minimum Match 0%  
 Maximum Match 100%  
 Listing First 45 summaries

Database : Pending Patents AA New:  
 1: /cgn2\_6/ptodata/2/paa/\_PCT\_NEW\_COMB\_pep:  
 2: /cgn2\_6/ptodata/2/paa/\_US06\_NEW\_COMB\_pep:  
 3: /cgn2\_6/ptodata/2/paa/\_US07\_NEW\_COMB\_pep:  
 4: /cgn2\_6/ptodata/2/paa/\_US08\_NEW\_COMB\_pep:  
 5: /cgn2\_6/ptodata/2/paa/\_US09\_NEW\_COMB\_pep:  
 6: /cgn2\_6/ptodata/2/paa/\_US10\_NEW\_COMB\_pep:  
 7: /cgn2\_6/ptodata/2/paa/\_US11\_NEW\_COMB\_pep:  
 8: /cgn2\_6/ptodata/2/paa/\_US60\_NEW\_COMB\_pep:  
 \*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query	Match	Length	DB ID	Description
1	67	100.0	15	6	US-10-817-970-2091	Sequence 2091, Ap
2	67	100.0	98	1	PCT-US04-05292-6	Sequence 6, Appli
3	67	100.0	98	1	PCT-US04-13776-3	Sequence 3, Appli
4	67	100.0	98	1	PCT-US04-05292A-6	Sequence 6, Appli
5	67	100.0	98	6	US-10-520-253-14	Sequence 14, Appli
6	67	100.0	98	7	US-11-077-939-5	Sequence 5, Appli
7	67	100.0	98	7	US-11-179-478-4	Sequence 4, Appli
8	67	100.0	99	1	PCT-US04-05292-5	Sequence 5, Appli
9	67	100.0	99	1	PCT-US04-05292-65	Sequence 65, Appli
10	67	100.0	99	1	PCT-US04-13776-2	Sequence 2, Appli
11	67	100.0	99	1	PCT-US04-05292A-5	Sequence 5, Appli
12	67	100.0	99	1	PCT-US04-05292A-65	Sequence 65, Appli
13	67	100.0	127	1	PCT-US04-13776-7	Sequence 7, Appli
14	67	100.0	166	1	PCT-US04-05292-53	Sequence 53, Appli
15	67	100.0	166	1	PCT-US04-05292A-53	Sequence 53, Appli
16	67	100.0	185	7	US-11-072-288-2	Sequence 2, Appli
17	67	100.0	248	6	US-10-530-253-1	Sequence 1, Appli
18	67	100.0	248	6	US-10-530-253-3	Sequence 3, Appli
19	67	100.0	248	6	US-10-530-253-7	Sequence 7, Appli
20	67	100.0	248	6	US-10-530-253-9	Sequence 9, Appli
21	67	100.0	289	1	PCT-US04-05292A-63	Sequence 63, Appli
22	67	100.0	289	1	PCT-US04-05292A-63	Sequence 63, Appli
23	67	100.0	349	1	PCT-US04-05292-18	Sequence 18, Appli
24	67	100.0	349	1	PCT-US04-05292-21	Sequence 21, Appli
25	67	100.0	349	1	PCT-US04-05292A-18	Sequence 18, Appli

#### ALIGNMENTS

RESULT 1  
 US-10-817-970-2091 ; Sequence 2091, Application US/10817970  
 / GENERAL INFORMATION:  
 / APPLICANT: Grey, H.  
 / APPLICANT: Sette, A.  
 / APPLICANT: Sidney, J.  
 / APPLICANT: Southwood, S.  
 / APPLICANT: Kubo, R.  
 / APPLICANT: Celis, E.  
 / APPLICANT: Chehnut, R.  
 / APPLICANT: Kast, W.M.  
 / TITLE OF INVENTION: HLA Binding Motifs and Peptides and Their Uses  
 / FILE REFERENCE: 2060-0500000  
 / CURRENT APPLICATION NUMBER: US/10-817,970  
 / CURRENT FILING DATE: 2004-04-06  
 / PRIOR APPLICATION NUMBER: 08/821,739  
 / PRIOR FILING DATE: 1997-03-20  
 / PRIOR APPLICATION NUMBER: 60/013,833  
 / PRIOR FILING DATE: 1996-03-21  
 / PRIOR APPLICATION NUMBER: 08/589,107  
 / PRIOR FILING DATE: 1996-01-23  
 / PRIOR APPLICATION NUMBER: 08/451,913  
 / PRIOR FILING DATE: 1995-05-26  
 / PRIOR APPLICATION NUMBER: 08/186,266  
 / PRIOR FILING DATE: 1995-05-26  
 / PRIOR FILING DATE: 1993-11-29  
 / PRIOR APPLICATION NUMBER: 08/103,396  
 / PRIOR FILING DATE: 1993-08-06  
 / PRIOR APPLICATION NUMBER: 08/027,746  
 / PRIOR FILING DATE: 1993-03-05  
 / PRIOR APPLICATION NUMBER: 07/926,666  
 / PRIOR FILING DATE: 1992-08-07  
 / PRIOR APPLICATION NUMBER: 08/347,610  
 / PRIOR FILING DATE: 1994-12-01  
 / Remaining Prior Application data removed - See File Wrapper or PAM.  
 / NUMBER OF SEQ ID NO: 14635  
 / SOFTWARE: FastSEQ for Windows Version 4.0  
 / SEQ ID NO: 2091  
 / LENGTH: 15  
 / TYPE: PRT  
 / ORGANISM: Artificial Sequence  
 / FEATURE:  
 / OTHER INFORMATION: Synthetic Peptide  
 US-10-817-970-2091  
 Query Match 100.0% ; Score 67; DB 6; Length 15;

```

Best Local Similarity 100.0%; Pred. No. 0.00024; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Indels 0; Gaps 0;

; GENERAL INFORMATION:
; APPLICANT: Johns Hopkins University
; TITLE OF INVENTION: Molecular Vaccines Employing Nucleic Acid Encoding Anti-Apoptotic
; Proteins
; TITLE OF INVENTION: Proteins
; FILE REFERENCE: 26148-jhu16/pct
; CURRENT APPLICATION NUMBER: PCT/US04/05292A
; CURRENT FILING DATE: 2004-02-24
; PRIORITY NUMBER: US60/533,792
; PRIORITY APPLICATION NUMBER: US60/533,792
; PRIOR FILING DATE: 2003-12-31
; PRIOR FILING DATE: 2003-12-31
; PRIOR APPLICATION NUMBER: US60/488,527
; PRIOR FILING DATE: 2003-07-18
; CURRENT APPLICATION NUMBER: PCT/US04/05292
; CURRENT FILING DATE: 2004-02-24
; PRIOR APPLICATION NUMBER: US60/449,429
; PRIOR FILING DATE: 2003-02-24
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO: 6
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Human papillomavirus
PCT-US04-05292-6

RESULT 2
PCT-US04-05292-6
; Sequence 6, Application PC/TUUS0405292
; GENERAL INFORMATION:
; APPLICANT: Johns Hopkins University
; TITLE OF INVENTION: Molecular Vaccines Employing Nucleic Acid Encoding Anti-Apoptotic
; Proteins
; TITLE OF INVENTION: Proteins
; FILE REFERENCE: 26148-jhu16/pct
; CURRENT APPLICATION NUMBER: PCT/US04/05292
; CURRENT FILING DATE: 2004-02-24
; PRIOR APPLICATION NUMBER: US60/533,792
; PRIOR FILING DATE: 2003-12-31
; PRIOR FILING DATE: 2003-07-18
; CURRENT APPLICATION NUMBER: PCT/US04/05292
; CURRENT FILING DATE: 2004-02-24
; PRIOR APPLICATION NUMBER: US60/449,429
; PRIOR FILING DATE: 2003-02-24
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO: 6
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Human papillomavirus
PCT-US04-05292-6

Query Match 100.0%; Score 67; DB 1; Length 98;
Best Local Similarity 100.0%; Pred. No. 0.0016; Mismatches 0; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LMGTGIVCPIC 12
Db 3 LMGTGIVCPIC 14

; GENERAL INFORMATION:
; Sequence 6, Application PC/TUUS0405292
; GENERAL INFORMATION:
; APPLICANT: Johns Hopkins University
; TITLE OF INVENTION: Molecular Vaccines Employing Nucleic Acid Encoding Anti-Apoptotic
; Proteins
; TITLE OF INVENTION: Proteins
; FILE REFERENCE: 26148-jhu16/pct
; CURRENT APPLICATION NUMBER: PCT/US04/05292
; CURRENT FILING DATE: 2004-02-24
; PRIORITY NUMBER: US60/533,792
; PRIORITY APPLICATION NUMBER: US60/533,792
; PRIOR FILING DATE: 2003-12-31
; PRIOR FILING DATE: 2003-12-31
; PRIOR APPLICATION NUMBER: US60/488,527
; PRIOR FILING DATE: 2003-07-18
; CURRENT APPLICATION NUMBER: PCT/US04/05292
; CURRENT FILING DATE: 2004-02-24
; PRIOR APPLICATION NUMBER: PCT/US04/05292
; CURRENT FILING DATE: 2004-02-24
; PRIOR APPLICATION NUMBER: US60/449,429
; PRIOR FILING DATE: 2003-02-24
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO: 6
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Human papillomavirus
PCT-US04-05292-6

RESULT 5
US-10-530-253-14
; Sequence 14, Application US/10530253
; GENERAL INFORMATION:
; APPLICANT: Caselli, Maria C.
; TITLE OF INVENTION: HUMAN PAPILLOMAVIRUS POLYPEPTIDES AND IMMUNOGENIC COMPOSITIONS
; FILE REFERENCE: 00630/100M137-US2
; CURRENT APPLICATION NUMBER: US/10/530-253
; CURRENT FILING DATE: 2005-04-04
; PRIOR APPLICATION NUMBER: PCT/US2003/031726
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,929
; PRIOR FILING DATE: 2002-10-03
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO: 14
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Human papillomavirus type 16
US-10-530-253-14

Query Match 100.0%; Score 67; DB 6; Length 98;
Best Local Similarity 100.0%; Pred. No. 0.0016; Mismatches 0; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LMGTGIVCPIC 12
Db 83 LMGTGIVCPIC 94

; GENERAL INFORMATION:
; Sequence 5, Application US/11077939
; GENERAL INFORMATION:
; APPLICANT: Fraser, Ian Hector
; TITLE OF INVENTION: Gene Expression System Based on Codon Translation Efficiency
; FILE REFERENCE: 10338-11U1
; CURRENT APPLICATION NUMBER: US/11/077,939
; CURRENT FILING DATE: 2005-03-11
; PRIOR APPLICATION NUMBER: PCT/AU2003/001200
PCT-US04-05292-6

RESULT 4
PCT-US04-05292-6
; Sequence 6, Application PC/TUUS0405292A
; APPLICANT: 6, Application PC/TUUS0405292A

```

```

; PRIOR FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: US 60/410410
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO: 5
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Human papillomavirus type 16
US-11-077-939-5

RESULT 7
US-11-179-478-4
; Sequence 4, Application US/11179478
; GENERAL INFORMATION:
; APPLICANT: BURGER, Alexander
; APPLICANT: HALLEK, Michael
; TITLE OF INVENTION: PAPILLOMA VIRUS CAPSOMERE VACCINE
; FORMULATIONS AND METHODS OF USE
; NUMBER OF SEQUENCES: 28
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FOLEY & LARDNER
; STREET: 3000 K Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/11/179,478
; FILING DATE: 13-JULY-2005
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/654,129
; FILING DATE: 04-SEP-2003
; CLASSIFICATION DATA:
; REGISTRATION NUMBER: 31,298
; REFERENCE DOCKET NUMBER: 37067/102
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 672-5300
; TELEFAX: (202) 672-5399
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 98 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: Protein
US-11-179-478-4

Query Match 100.0%; Score 67; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 0.0016; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 0; Gaps 0;

Qy 1 LMGTGIVCPIC 12
Db 83 LMGTGIVCPIC 94

RESULT 8
PCT-US04-05292-5
; Sequence 5, Application PC/TUS0405292
; GENERAL INFORMATION:
; APPLICANT: Johns Hopkins University
; TITLE OF INVENTION: Molecular Vaccines Employing Nucleic Acid Encoding Anti-Apoptotic
; TITLE OF INVENTION: Proteins
; FILE REFERENCE: 26148.jhu16/pct
; CURRENT APPLICATION NUMBER: PCT-US04/05292
; CURRENT FILING DATE: 2002-02-24
; PRIOR APPLICATION NUMBER: US60/533,792
; PRIOR FILING DATE: 2003-12-31
; PRIOR APPLICATION NUMBER: US60/488,527
; PRIOR FILING DATE: 2003-07-18
; PRIOR APPLICATION NUMBER: US60/449,429
; PRIOR FILING DATE: 2003-02-24
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO: 5
; LENGTH: 99
; TYPE: PRT
; ORGANISM: Human papillomavirus
PCT-US04-05292-5

Query Match 100.0%; Score 67; DB 1; Length 99;
Best Local Similarity 100.0%; Pred. No. 0.0016; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 0; Gaps 0;

Qy 1 LMGTGIVCPIC 12
Db 83 LMGTGIVCPIC 94

RESULT 9
PCT-US04-05292-65
; Sequence 65, Application PC/TUS0405292
; GENERAL INFORMATION:
; APPLICANT: Johns Hopkins University
; TITLE OF INVENTION: Molecular Vaccines Employing Nucleic Acid Encoding Anti-Apoptotic
; TITLE OF INVENTION: Proteins
; FILE REFERENCE: 26148.jhu16/pct
; CURRENT APPLICATION NUMBER: PCT-US04/05292
; CURRENT FILING DATE: 2002-02-24
; PRIOR APPLICATION NUMBER: US60/533,792
; PRIOR FILING DATE: 2003-12-31
; PRIOR APPLICATION NUMBER: US60/488,527
; PRIOR FILING DATE: 2003-07-18
; PRIOR APPLICATION NUMBER: US60/449,429
; PRIOR FILING DATE: 2003-02-24
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO: 65
; LENGTH: 99
; TYPE: PRT
; ORGANISM: Human papillomavirus
PCT-US04-05292-65

Query Match 100.0%; Score 67; DB 1; Length 99;
Best Local Similarity 100.0%; Pred. No. 0.0016; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 0; Gaps 0;

Qy 1 LMGTGIVCPIC 12
Db 83 LMGTGIVCPIC 94

RESULT 10
PCT-US04-13756-2
; Sequence 2, Application PC/TUS0413756
; GENERAL INFORMATION:
; APPLICANT: JOHNS HOPKINS UNIVERSITY
; TITLE OF INVENTION: ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL
; TITLE OF INVENTION: SEQUENCE, MUTANT ONCOPROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN
; TITLE OF INVENTION: SEQUENCE, MUTANT ONCOPROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN

```

FILE REFERENCE: JHU-18/PCT  
 CURRENT APPLICATION NUMBER: PCT/US04/13756  
 PRIOR APPLICATION NUMBER: US 60/467,602  
 PRIOR FILING DATE: 2003-05-05  
 NUMBER OF SEQ ID NOS: 16  
 SOFTWARE: PatentIn version 3.2  
 SEQ ID NO: 2  
 TYPE: PRT  
 ORGANISM: Human papillomavirus  
 PCT-US04-13756-2

Query Match, 100.0%; Score 67; DB 1; Length 99;  
 Best Local Similarity 100.0%; Pred. No. 0.0016;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 RESULT 13  
 PCT-US04-13756-7  
 Sequence 7, Application PC/TUS0413756  
 GENERAL INFORMATION:  
 APPLICANT: JOHNS HOPKINS UNIVERSITY  
 TITLE OF INVENTION: ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL  
 MATCHES, MUTANT ONCOPROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN  
 CURRENT APPLICATION NUMBER: PCT/US04/13756  
 CURRENT FILING DATE: 2004-05-05  
 PRIORITY APPLICATION NUMBER: US 60/467,602  
 PRIOR FILING DATE: 2003-05-05  
 NUMBER OF SEQ ID NOS: 16  
 SOFTWARE: PatentIn version 3.2  
 SEQ ID NO: 7  
 LENGTH: 127  
 TYPE: PRT  
 ORGANISM: Human papillomavirus  
 PCT-US04-13756-7

Query Match, 100.0%; Score 67; DB 1; Length 127;  
 Best Local Similarity 100.0%; Pred. No. 0.002;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 RESULT 14  
 PCT-US04-13756-7  
 Sequence 7, Application PC/TUS0413756  
 GENERAL INFORMATION:  
 APPLICANT: JOHNS HOPKINS UNIVERSITY  
 TITLE OF INVENTION: ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL  
 MATCHES, MUTANT ONCOPROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN  
 CURRENT APPLICATION NUMBER: PCT/US04/13756  
 CURRENT FILING DATE: 2004-05-05  
 PRIORITY APPLICATION NUMBER: US 60/467,602  
 PRIOR FILING DATE: 2003-05-05  
 NUMBER OF SEQ ID NOS: 16  
 SOFTWARE: PatentIn version 3.2  
 SEQ ID NO: 5  
 LENGTH: 99  
 TYPE: PRT  
 ORGANISM: Human papillomavirus  
 PCT-US04-05292A-5

Query Match, 100.0%; Score 67; DB 1; Length 99;  
 Best Local Similarity 100.0%; Pred. No. 0.0016;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 RESULT 11  
 PCT-US04-05292A-5  
 Sequence 5, Application PC/TUS0405292A  
 GENERAL INFORMATION:  
 APPLICANT: Johns Hopkins University  
 TITLE OF INVENTION: Molecular Vaccines Employing Nucleic Acid Encoding Anti-Apoptotic  
 TITLE OF INVENTION: Proteins  
 FILE REFERENCE: 26148-jhu-16/pct  
 CURRENT APPLICATION NUMBER: PCT/US04/05292A  
 CURRENT FILING DATE: 2004-02-24  
 PRIORITY APPLICATION NUMBER: US60/533,792  
 PRIOR FILING DATE: 2003-12-31  
 PRIORITY APPLICATION NUMBER: US60/488,527  
 PRIOR FILING DATE: 2003-07-18  
 PRIORITY APPLICATION NUMBER: US60/449,429  
 PRIOR FILING DATE: 2003-02-24  
 NUMBER OF SEQ ID NOS: 91  
 SOFTWARE: PatentIn version 3.2  
 SEQ ID NO: 5  
 LENGTH: 99  
 TYPE: PRT  
 ORGANISM: Human papillomavirus  
 PCT-US04-05292A-5

Query Match, 100.0%; Score 67; DB 1; Length 99;  
 Best Local Similarity 100.0%; Pred. No. 0.0016;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 RESULT 12  
 PCT-US04-05292A-65  
 Sequence 65, Application PC/TUS04/05292A  
 GENERAL INFORMATION:  
 APPLICANT: Johns Hopkins University  
 TITLE OF INVENTION: Molecular Vaccines Employing Nucleic Acid Encoding Anti-Apoptotic  
 TITLE OF INVENTION: Proteins  
 FILE REFERENCE: 26148-jhu-16/pct  
 CURRENT APPLICATION NUMBER: PCT/US04/05292A  
 CURRENT FILING DATE: 2004-02-24  
 PRIORITY APPLICATION NUMBER: US60/533,792  
 PRIOR FILING DATE: 2003-12-31  
 PRIORITY APPLICATION NUMBER: US60/488,527  
 PRIOR FILING DATE: 2003-07-18  
 NUMBER OF SEQ ID NOS: 91  
 SOFTWARE: PatentIn version 3.2  
 SEQ ID NO: 53  
 LENGTH: 166  
 TYPE: PRT  
 ORGANISM: Artificial Sequence  
 FEATURE:  
 OTHER INFORMATION: Synthetic peptide  
 PCT-US04-05292-53

Query Match, 100.0%; Score 67; DB 1; Length 166;  
 Best Local Similarity 100.0%; Pred. No. 0.0027;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LMGTIGIVCPIC 12  
Db 113 LMGTIGIVCPIC 124

RESULT 15  
PCT-US04-05292A-53  
/ Sequence 53, Application PCT-US04-05292A  
/ GENERAL INFORMATION:  
/ APPLICANT: Johns Hopkins University  
/ TITLE OF INVENTION: Molecular Vaccines Employing Nucleic Acid Encoding Anti-Apoptotic  
/ TITLE OF INVENTION: Proteins  
/ FILE REFERENCE: 26148-jhu-16/pct  
/ CURRENT APPLICATION NUMBER: PCT-US04-05292A  
/ CURRENT FILING DATE: 2004-02-24  
/ PRIOR APPLICATION NUMBER: US60/533,792  
/ PRIOR FILING DATE: 2003-12-31  
/ PRIOR APPLICATION NUMBER: US60/488,527  
/ PRIOR FILING DATE: 2003-07-18  
/ PRIOR APPLICATION NUMBER: US60/449,429  
/ PRIOR FILING DATE: 2003-02-24  
/ NUMBER OF SEQ ID NOS: 91  
/ SOFTWARE: PatentIn version 3.2  
/ SEQ ID NO: 53  
/ LENGTH: 166  
/ TYPE: PRT  
/ ORGANISM: Artificial Sequence  
/ FEATURE:  
/ OTHER INFORMATION: Synthetic peptide  
PCT-US04-05292A-53

Query Match 100.0%; Score 67; DB 1; Length 166;  
Best Local Similarity 100.0%; Pred. No. 0.0027;  
Matches 12; Conservative 0; Mismatches 0; Indels 0;  
Gaps 0;

Qy 1 LMGTIGIVCPIC 12  
Db 113 LMGTIGIVCPIC 124

Search completed: August 19, 2005, 23:48:36  
Job time : 30.8108 secs

This Page Blank (uspto)

GenCore version 5.1.6  
 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 19, 2005, 23:24:59 ; Search time 25 Seconds  
 Perfect score: 122 (without alignments)  
 Sequence: 74.649 Million cell updates/sec

Title: US-10-603-062-18

Scoring table: BLOSUM62

Scoring table: Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum March 100%

Listing first 45 summaries

Database : Issued\_Patents\_AA:\*

1: /cgn2\_6/picodata/1/iaa/5A\_COMB.pep:\*

2: /cgn2\_6/picodata/1/iaa/5B\_COMB.pep:\*

3: /cgn2\_6/picodata/1/iaa/6A\_COMB.pep:\*

4: /cgn2\_6/picodata/1/iaa/6B\_COMB.pep:\*

5: /cgn2\_6/picodata/1/iaa/PCIT2\_COMB.pep:\*

6: /cgn2\_6/picodata/1/iaa/backfile1.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match	Length	DB ID	Description
1	122	100.0	25	2	US-08-450-190-155	Sequence 155, App
2	122	100.0	25	3	US-08-488-379-155	Sequence 155, App
3	122	100.0	25	3	US-08-948-378A-18	Sequence 18, App
4	122	100.0	25	3	US-09-169-422C-18	Sequence 18, App
5	122	100.0	25	3	US-09-302-322A-4	Sequence 4, App
6	122	100.0	25	4	US-09-440-344-1	Sequence 1, App
7	122	100.0	25	4	US-08-415-399A-155	Sequence 155, App
8	122	100.0	25	4	US-09-632-064-3	Sequence 3, App
9	122	100.0	25	4	US-09-552-80B-43	Sequence 43, App
10	122	100.0	25	4	US-09-759-960-18	Sequence 18, App
11	122	100.0	25	4	US-09-637-319-4	Sequence 4, App
12	122	100.0	25	4	US-08-077-255A-155	Sequence 155, App
13	122	100.0	25	4	US-09-451-291-6	Sequence 6, App
14	122	100.0	25	5	PCT-US93-07545-155	Sequence 155, App
15	122	100.0	38	3	US-08-948-378A-6	Sequence 6, App
16	122	100.0	38	3	US-09-169-422C-6	Sequence 6, App
17	122	100.0	38	4	US-09-759-960-6	Sequence 6, App
18	122	100.0	40	4	US-08-475-399A-275	Sequence 275, App
19	122	100.0	49	4	US-08-475-399A-276	Sequence 276, App
20	122	100.0	129	4	US-09-513-999C-783-5	Sequence 7835, App
21	122	100.0	145	4	US-09-513-999C-4264	Sequence 4264, App
22	122	100.0	248	1	US-08-644-664B-27	Sequence 27, App
23	122	100.0	248	2	US-08-761-277A-27	Sequence 27, App
24	122	100.0	253	2	US-08-488-905-109	Sequence 109, App
25	122	100.0	253	3	US-08-481-985B-109	Sequence 109, App
26	122	100.0	254	4	US-09-949-016-6946	Sequence 6946, App

## ALIGNMENTS

RESULT 1  
 US-08-480-190-155  
 ; Sequence 155, Application US/08480190  
 ; Patent No. 5827516

GENERAL INFORMATION:

APPLICANT: Robert G. Urban  
 APPLICANT: Roman M. Chicz  
 APPLICANT: Dario A. A. Vignali  
 APPLICANT: Mary L. Hedley  
 APPLICANT: Lawrence J. Stern  
 APPLICANT: Jack L. Strominger  
 TITLE OF INVENTION: IMMUNOMODULATORY PEPTIDES  
 NUMBER OF SEQUENCES: 274

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish & Richardson  
 STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: Massachusetts  
 COUNTRY: U.S.A.  
 ZIP: 02110-2804

COMPUTER READABLE FORM:

COMPUTER: IBM PS/2 Model 50Z or 55SX  
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
 OPERATING SYSTEM: MS-DOS (Version 5.0)  
 SOFTWARE: WordPerfect (Version 5.1)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/480,190  
 FILING DATE:

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/077,255  
 FILING DATE: June 15, 1993  
 APPLICATION NUMBER: 07/925,460  
 FILING DATE: August 11, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Clik, Paul T.  
 REGISTRATION NUMBER: 30,162  
 REFERENCE/DOCKET NUMBER: 00246/168001  
 TELECOMMUNICATION INFORMATION:

TELEPHONE: (617) 542-5070  
 TELEFAX: (617) 542-8905  
 TELEX: 200154

SEQUENCE CHARACTERISTICS:

LENGTH: 25  
 TYPE: amino acid  
 STRANDEDNESS:  
 TOPOLOGY: linear  
 US-08-480-190-155

Query Match 100.0%; Score 122; DB 2; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 6.5e-14;  
 Matches 25; Conservation 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPVLGFFIAVLMQAESWA 25

Db 1 MAISGVPVLGFFIAVLMQAESWA 25

RESULT 2

US-08-488-379-155

Sequence 155, Application US/08488379

Patent No. 5880103

GENERAL INFORMATION:

APPLICANT: Robert G. Urban

APPLICANT: Roman M. Chicz

APPLICANT: Dario A. A. Vignali

APPLICANT: Mary L. Hedley

APPLICANT: Lawrence J. Stern

APPLICANT: Jack L. Strominger

TITLE OF INVENTION: IMMUNOMODULATORY PEPTIDES

NUMBER OF SEQUENCES: 274

CURRENT APPLICATION DATA:

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish & Richardson

STREET: 225 Franklin Street

CITY: Boston

STATE: Massachusetts

COUNTRY: U.S.A.

ZIP: 02110-2804

COMPUTER READABLE FORM:

COMPUTER: IBM PS/2 Model 502 OR 55SX

OPERATING SYSTEM: MS-DOS (Version 5.0)

SOFTWARE: WordPerfect (Version 5.1)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/488,379

FILING DATE:

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/077,255

FILING DATE: June 15, 1993

APPLICATION NUMBER: 07/925,460

FILING DATE: August 11, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Clark, Paul T.

REGISTRATION NUMBER: 30,162

REFERENCE/DOCKET NUMBER: 00246/168001

TELECOMMUNICATION INFORMATION:

TELEPHONE: (617) 542-5070

TELEFAX: (617) 542-8906

TELEX: 200154

INFORMATION FOR SEQ ID NO: 155:

SEQUENCE CHARACTERISTICS:

LENGTH: 25

TYPE: amino acid

STRANDBNESS:

TOPOLOGY: linear

US-08-488-379-155

Query Match 100.0%; Score 122; DB 2; Length 25;

Best Local Similarity 100.0%; Pred. No. 6.5e-14;

Matches 25; Conservation 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPVLGFFIAVLMQAESWA 25

Db 1 MAISGVPVLGFFIAVLMQAESWA 25

RESULT 3

US-08-948-378A-18

Sequence 18, Application US/08488379A

Patent No. 6013258

GENERAL INFORMATION:

APPLICANT: Urban, Robert G.

APPLICANT: Chicz, Roman M.

APPLICANT: Collins, Edward J.

APPLICANT: Hedley, Mary Lynn

TITLE OF INVENTION: IMMUNOCENIC PEPTIDES FROM THE HPV E7 PROTEIN

NUMBER OF SEQUENCES: 19

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish & Richardson, P.C.

STREET: 225 Franklin Street

CITY: Boston

STATE: MA

COUNTRY: US

ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: Windows95

Query Match 100.0%; Score 122; DB 2; Length 25;

Best Local Similarity 100.0%; Pred. No. 6.5e-14;

Matches 25; Conservation 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAISGVPVLGFFIAVLMQAESWA 25

Db 1 MAISGVPVLGFFIAVLMQAESWA 25

RESULT 4

US-09-169-428C-18

Sequence 18, Application US/09169425C

Patent No. 6183746

GENERAL INFORMATION:

APPLICANT: Urban, Robert G.

APPLICANT: Chicz, Roman M.

APPLICANT: Collins, Edward J.

APPLICANT: Hedley, Mary Lynn

TITLE OF INVENTION: IMMUNOCENIC PEPTIDES FROM THE HPV E7

NUMBER OF SEQUENCES: 33

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish & Richardson, P.C.

STREET: 225 Franklin Street

CITY: Boston

STATE: MA

COUNTRY: US

ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: Windows95

```

; GENERAL INFORMATION:
; APPLICANT: Valiera, Daniel A.
; APPLICANT: Blazar, Bruce R.
; TITLE OF INVENTION: MULTIMERIC IMMUNOTOXINS
; FILE REFERENCE: 09531/013001
; CURRENT APPLICATION NUMBER: US/09/440,344
; CURRENT FILING DATE: 1999-11-15
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-440-344-1

Query Match 100.0%; Score 122; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 6.5e-14;
Matches 25; Conservative 0; Mismatches 0; Indels 0;
Gaps 0

QY 1 MAISGPVPLGFFIAVLMQAESWA 25
Db 1 MAISGPVPLGFFIAVLMQAESWA 25

; RESULT 7
; US-08-475-399A-155
; Sequence 155, Application US/08475399A
; Patent No. 6509033
; GENERAL INFORMATION:
; APPLICANT: Urban, Robert G.
; APPLICANT: Chicz, Roman M.
; APPLICANT: Vignal, Dario A.A.
; APPLICANT: Hedley, Mary L.
; APPLICANT: Stern, Lawrence J.
; APPLICANT: Strominger, Jack L.
; TITLE OF INVENTION: IMMUNOMODULATORY PEPTIDES
; NUMBER OF SEQUENCES: 276
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZPP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/475,399A
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/077,255
; FILING DATE: 15-JUN-1993
; APPLICATION NUMBER: 07/925,460
; FILING DATE: 11-AUG-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Fraser, Janis K.
; REGISTRATION NUMBER: 34,819
; REFERENCE/DOCKET NUMBER: 00246/168003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-507
; TELEFAX: 617/542-890
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 155:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; Query Match 100.0%; Score 122; DB 4; Length 25;
; Best Local Similarity 100.0%; Pred. No. 6.5e-14;
; Matches 25; Conservative 0; Mismatches 0; Indels 0;
; Gaps 0;

; RESULT 5
; US-09-302-329A-4
; Sequence 4, Application US/09302329A
; GENERAL INFORMATION:
; PATENT NO. 6387701
; APPLICANT: NAIR, SMITA K.
; APPLICANT: BOCZKOWSKI, DAVID J.
; APPLICANT: GILBOA, ELIJU
; TITLE OF INVENTION: RNA-LOADED ANTIGEN PRESENTING CELLS
; FILE REFERENCE: 1579-197
; CURRENT APPLICATION NUMBER: US/09/302,329A
; CURRENT FILING DATE: 1999-04-30
; PRIOR APPLICATION NUMBER: 09/073,819
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 08/640,444
; PRIOR FILING DATE: 1996-04-30
; PRIOR APPLICATION NUMBER: 09/171,916
; PRIOR FILING DATE: 1999-02-16
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Signal peptide of MHC Class I
; US-09-302-329A-4

Query Match 100.0%; Score 122; DB 3; Length 25;
Best Local Similarity 100.0%; Pred. No. 6.5e-14;
Matches 25; Conservative 0; Mismatches 0; Indels 0;
Gaps 0

QY 1 MAISGPVPLGFFIAVLMQAESWA 25
Db 1 MAISGPVPLGFFIAVLMQAESWA 25

; RESULT 6
; US-09-440-344-1
; Sequence 1, Application US/09440344
; PATENT NO. 5682199
; LENGTH: 25 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; Query Match 100.0%; Score 122; DB 4; Length 25;

```

Best Local Similarity 100.0%; Pred. No. 6.5e-14;  
Matches 25; Conservative 0; Nismatches 0; Indels 0; Gaps 0;

US-09-759-960-18  
; Sequence 18, Application US/09759960  
; Patent No. 6582704  
; GENERAL INFORMATION:  
; APPLICANT: Urban, Robert G.  
; APPLICANT: Chicz, Roman M.  
; APPLICANT: Collins, Edward J.  
; APPLICANT: Hedley, Mary Lynn  
; TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM THE HPV E7  
; TITLE OF INVENTION: PROTEIN  
; NUMBER OF SEQUENCES: 33  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson, P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: US  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: Windows95  
; SOFTWARE: FastSEQ for Windows Version 2.0  
; CURRENT APPLICATION NUMBER: US/09/692,064  
; CURRENT FILING DATE: 2000-10-19  
; PRIORITY NUMBER: US 60/160,429  
; PRIOR FILING DATE: 1999-10-19  
; NUMBER OF SEQ ID NOS: 9  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO: 3  
; LENGTH: 25  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; US-09-692-064-3

Query Match 100.0%; Score 122; DB 4; Length 25;  
Best Local Similarity 100.0%; Pred. No. 6.5e-14;  
Matches 25; Conservative 0; Nismatches 0; Indels 0; Gaps 0;

US-09-552-802B-43  
; Sequence 43, Application US/09552802B  
; Patent No. 6562943  
; GENERAL INFORMATION:  
; APPLICANT: Peakman, Mark  
; APPLICANT: Peakman, Mark  
; TITLE OF INVENTION: PEPTIDE EPITOPES RECOGNIZED BY DISEASE PROMOTING  
; FILE REFERENCE: 08191-009002  
; CURRENT APPLICATION NUMBER: US/09/552,802B  
; CURRENT FILING DATE: 2000-04-20  
; PRIOR APPLICATION NUMBER: US 09/295,868  
; PRIOR FILING DATE: 1999-04-21  
; PRIOR APPLICATION NUMBER: US 60/130,355  
; NUMBER OF SEQ ID NOS: 55  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO: 43  
; LENGTH: 25  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; US-09-552-802B-43

RESULT 9  
US-09-552-802B-43  
; Sequence 43, Application US/09552802B  
; Patent No. 6562943  
; GENERAL INFORMATION:  
; APPLICANT: Peakman, Mark  
; APPLICANT: Peakman, Mark  
; TITLE OF INVENTION: PEPTIDE EPITOPES RECOGNIZED BY DISEASE PROMOTING  
; FILE REFERENCE: 08191-009002  
; CURRENT APPLICATION NUMBER: US/09/552,802B  
; CURRENT FILING DATE: 2000-04-20  
; PRIOR APPLICATION NUMBER: US 09/295,868  
; PRIOR FILING DATE: 1999-04-21  
; PRIOR APPLICATION NUMBER: US 60/130,355  
; NUMBER OF SEQ ID NOS: 55  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO: 43  
; LENGTH: 25  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; US-09-552-802B-43

Query Match 100.0%; Score 122; DB 4; Length 25;  
Best Local Similarity 100.0%; Pred. No. 6.5e-14;  
Matches 25; Conservative 0; Nismatches 0; Indels 0; Gaps 0;

US-09-667-319-4  
; Sequence 4, Application US/09667319  
; Patent No. 6670186  
; GENERAL INFORMATION:  
; APPLICANT: NAIR, SMITA K.  
; APPLICANT: BOCKOWSKI, DAVID J.  
; APPLICANT: GILBOA, ELI  
; TITLE OF INVENTION: RNA-LOADED ANTIGEN PRESENTING CELLS  
; FILE REFERENCE: 1579-485  
; CURRENT APPLICATION NUMBER: US/09/667,319  
; CURRENT FILING DATE: 2000-09-22  
; PRIOR APPLICATION NUMBER: 09/302,329  
; PRIOR FILING DATE: 1999-04-30  
; PRIOR APPLICATION NUMBER: 09/073,819  
; PRIOR FILING DATE: 1998-05-06  
; PRIOR APPLICATION NUMBER: 08/640,444  
; PRIOR FILING DATE: 1996-04-30  
; PRIOR APPLICATION NUMBER: 09/171,916

RESULT 10  
Query Match 100.0%; Score 122; DB 4; Length 25;  
Best Local Similarity 100.0%; Pred. No. 6.5e-14;  
Matches 25; Conservative 0; Nismatches 0; Indels 0; Gaps 0;

US-09-667-319-4  
; Sequence 4, Application US/09667319  
; Patent No. 6670186  
; GENERAL INFORMATION:  
; APPLICANT: NAIR, SMITA K.  
; APPLICANT: BOCKOWSKI, DAVID J.  
; APPLICANT: GILBOA, ELI  
; TITLE OF INVENTION: RNA-LOADED ANTIGEN PRESENTING CELLS  
; FILE REFERENCE: 1579-485  
; CURRENT APPLICATION NUMBER: US/09/667,319  
; CURRENT FILING DATE: 2000-09-22  
; PRIOR APPLICATION NUMBER: 09/302,329  
; PRIOR FILING DATE: 1999-04-30  
; PRIOR APPLICATION NUMBER: 09/073,819  
; PRIOR FILING DATE: 1998-05-06  
; PRIOR APPLICATION NUMBER: 08/640,444  
; PRIOR FILING DATE: 1996-04-30  
; PRIOR APPLICATION NUMBER: 09/171,916

RESULT 11  
Query Match 100.0%; Score 122; DB 4; Length 25;  
Best Local Similarity 100.0%; Pred. No. 6.5e-14;  
Matches 25; Conservative 0; Nismatches 0; Indels 0; Gaps 0;

US-09-667-319-4  
; Sequence 4, Application US/09667319  
; Patent No. 6670186  
; GENERAL INFORMATION:  
; APPLICANT: NAIR, SMITA K.  
; APPLICANT: BOCKOWSKI, DAVID J.  
; APPLICANT: GILBOA, ELI  
; TITLE OF INVENTION: RNA-LOADED ANTIGEN PRESENTING CELLS  
; FILE REFERENCE: 1579-485  
; CURRENT APPLICATION NUMBER: US/09/667,319  
; CURRENT FILING DATE: 2000-09-22  
; PRIOR APPLICATION NUMBER: 09/302,329  
; PRIOR FILING DATE: 1999-04-30  
; PRIOR APPLICATION NUMBER: 09/073,819  
; PRIOR FILING DATE: 1998-05-06  
; PRIOR APPLICATION NUMBER: 08/640,444  
; PRIOR FILING DATE: 1996-04-30  
; PRIOR APPLICATION NUMBER: 09/171,916

PRIOR FILING DATE: 1999-02-16  
 NUMBER OF SEQ ID NOS: 7  
 SOFTWARE: Patentin Ver. 2.1  
 SEQ ID NO: 4  
 LENGTH: 25  
 TYPE: PRT  
 ORGANISM: Artificial Sequence  
 FEATURE: Artificial Sequence  
 OTHER INFORMATION: Description of Artificial Sequence: Signal peptide of MHC Class I  
 US-09-667-319-4

RESULT 12  
 US-08-077-255A-155  
 Sequence 155, Application US/08077255A  
 General Information:  
 Patent No. 6696061  
 APPLICANT: Robert G. Urban  
 APPLICANT: Roman M. Chicz  
 APPLICANT: Dario A. A. Vignali  
 APPLICANT: Mary L. Hedley  
 APPLICANT: Lawrence J. Stern  
 APPLICANT: Jack L. Strominger  
 TITLE OF INVENTION: IMMUNOMODULATORY PEPTIDES  
 NUMBER OF SEQUENCES: 274  
 CORRESPONDENCE ADDRESS:  
 ADDRESSER: Fish & Richardson  
 STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: Massachusetts  
 COUNTRY: U.S.A.  
 ZIP: 02110-2804  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
 COMPUTER: IBM PS/2 Model 50Z or 55SX  
 OPERATING SYSTEM: MS-DOS (Version 5.0)  
 SOFTWARE: WordPerfect (Version 5.1)  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/077,255A  
 FILING DATE: June 15, 1993  
 CLASSIFICATION: 424  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: 07/925,460  
 FILING DATE: August 11, 1992  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Clark, Paul T.  
 REGISTRATION NUMBER: 30,162  
 REFERENCE DOCKET NUMBER: 00246/168001  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (617) 542-5070  
 TELEFAX: (617) 542-8906  
 TELN: 200154  
 INFORMATION FOR SEQ ID NO: 155:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 25  
 TYPE: amino acid  
 STRANDEDNESS:  
 TOPOLOGY: linear  
 US-08-077-255A-155

Query Match 100.0%; Score 122; DB 4; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 6.5e-14;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0; Gaps 0;

Db 1 MAISGVPVLGFFIATVLMQAQESWA 25

RESULT 13  
 US-09-451-291-6  
 Sequence 6, Application US/09451291  
 General Information:  
 APPLICANT: Chen, Lieping  
 TITLE OF INVENTION: B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE  
 FILE REFERENCE: 07039/197001  
 CURRENT APPLICATION NUMBER: US/09/451,291  
 CURRENT FILING DATE: 1999-11-30  
 NUMBER OF SEQ ID NOS: 12  
 SEQ ID NO: 6  
 SOFTWARE: FastSEQ for Windows Version 4.0  
 LENGTH: 25  
 TYPE: PRT  
 ORGANISM: Homo sapiens  
 US-09-451-291-6

Query Match 100.0%; Score 122; DB 4; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 6.5e-14;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0; Gaps 0;

Qy 1 MAISGVPVLGFFIATVLMQAQESWA 25  
 Db 1 MAISGVPVLGFFIATVLMQAQESWA 25

RESULT 14  
 PCT-US93-07545-155  
 Sequence 155, Application PCT/US93/07545  
 General Information:  
 APPLICANT: Robert G. Urban  
 APPLICANT: Roman M. Chicz  
 APPLICANT: Dario A. A. Vignali  
 APPLICANT: Mary L. Hedley  
 APPLICANT: Lawrence J. Stern  
 APPLICANT: Jack L. Strominger  
 TITLE OF INVENTION: IMMUNOMODULATORY PEPTIDES  
 NUMBER OF SEQUENCES: 273  
 CORRESPONDENCE ADDRESS:  
 ADDRESSE: Fish & Richardson  
 STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: Massachusetts  
 COUNTRY: U.S.A.  
 ZIP: 02110-2804  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
 COMPUTER: IBM PS/2 Model 50Z or 55SX  
 OPERATING SYSTEM: MS-DOS (Version 5.0)  
 SOFTWARE: WordPerfect (Version 5.1)  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/077,255A  
 FILING DATE: June 15, 1993  
 CLASSIFICATION: 424  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: 07/925,460  
 FILING DATE: August 11, 1992  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Clark, Paul T.  
 REGISTRATION NUMBER: 30,162  
 REFERENCE DOCKET NUMBER: 00246/168001  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (617) 542-5070  
 TELEFAX: (617) 542-8906  
 TELN: 200154  
 INFORMATION FOR SEQ ID NO: 155:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 25  
 TYPE: amino acid  
 STRANDEDNESS:  
 TOPOLOGY: linear  
 US-08-077-255A-155

Query Match 100.0%; Score 122; DB 4; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 6.5e-14;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0; Gaps 0; Gaps 0;

Qy 1 MAISGVPVLGFFIATVLMQAQESWA 25

TYPE: amino acid  
 STRANDEDNESS:  
 TOPOLOGY: linear  
 PCT-US93-07545-155

Query Match      100.0%;    Score 122;    DB 5;    Length 25;  
 Best Local Similarity      100.0%;    Pred. No. 6.5e-14;  
 Matches      25;    Conservative 0;    Mismatches 0;    Indels 0;    Gaps 0;  
 Qy      1 MAISGVYPVLFGLFFIAVLMQAESWA 25  
 Db      1 MAISGVYPVLFGLFFIAVLMQAESWA 25

---

RESULT 15  
 US-08-948-378A-6  
 Sequence 6, Application US/08948378A  
 Patent No. 6013258

GENERAL INFORMATION:  
 APPLICANT: Urban, Robert G.  
 APPLICANT: Chicz, Roman M.  
 APPLICANT: Collins, Edward J.  
 APPLICANT: Healey, Mary Lynn  
 TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM  
 TITLE OF INVENTION: THE HPV E7 PROTEIN  
 NUMBER OF SEQUENCES: 19  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Fish & Richardson, P.C.  
 STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: MA  
 COUNTRY: US  
 ZIP: 02110-2804  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Diskette  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: Windows95  
 SOFTWARE: FastSEQ for Windows Version 2.0  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/948,378A  
 FILING DATE: 09-OCT-1997  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER:  
 FILING DATE:  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Fraser, Janis K.  
 REGISTRATION NUMBER: 34,819  
 REFERENCE/DOCKET NUMBER: 08191/004001  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 617-542-5070  
 TELEFAX: 617-543-8906  
 TELEX: 200154  
 INFORMATION FOR SEQ ID NO: 6:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 38 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: protein  
 FRAGMENT TYPE: internal  
 US-08-948-378A-6

Query Match      100.0%;    Score 122;    DB 3;    Length 38;  
 Best Local Similarity      100.0%;    Pred. No. 1.1e-13;  
 Matches      25;    Conservative 0;    Mismatches 0;    Indels 0;    Gaps 0;  
 Qy      1 MAISGVYPVLFGLFFIAVLMQAESWA 25  
 Db      1 MAISGVYPVLFGLFFIAVLMQAESWA 25

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

## OM protein - protein search, using sw model

Run on: August 19, 2005, 23:22:13 ; Search time 32.4324 Seconds  
(without alignments)  
74.167 Million cell updates/sec

Title: US-10-603-062-18  
Perfect score: 122  
Sequence: 1 MAISGVPLGFPFLIAVLMQAESWA 25

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing First 45 summaries

Database : PIR 79:\*

1: \_pir1:\*

2: \_pir2:\*

3: \_pir3:\*

4: \_pir4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	122	100.0	254	1 HIRUTA	MHC class II histo
2	101.5	83.2	255	2 A45881	MHC class II histo
3	78	63.9	255	1 HUMSEA	H-2 class II histo
4	77.5	63.5	253	2 S15684	MHC class II histo
5	72.5	59.4	253	2 JC2388	class II histocomp
6	7	55.7	255	2 S06316	class II histocomp
7	68	53.3	252	2 A46505	SLA-DRB (MHC Class II)
8	65	49.2	23	2 156228	MHC class II proto
9	60	49.2	23	2 E88252	hypothetical proto
10	49	40.2	477	2 C91210	ExoP-related proto
11	49	40.2	556	2 C75596	hypothetical proto
12	48	39.3	75	2 S75553	oligopeptide ABC t
13	48	39.3	321	2 B72367	probable membrane
14	48	39.3	487	2 AH0956	hypothetical proto
15	48	39.3	513	2 B83758	probable membrane
16	47	38.5	445	2 C91210	probable membrane
17	47	38.5	445	2 P86056	probable membrane
18	47	38.5	445	2 C65174	hypothetical 46.9
19	47	38.5	605	2 T11114	NADH2 dehydrogenas
20	46	37.7	178	2 B84650	hypothetical proto
21	46	37.7	180	2 T08836	probable H+ export
22	46	37.7	458	2 C82232	proto/Glutamate S
23	46	37.7	458	2 T01969	potassium transpor
24	46	37.7	489	2 T01046	potassium transpor
25	46	37.7	606	2 T10982	NADH2 dehydrogenas
26	46	37.7	652	2 D85044	hypothetical proto
27	46	37.7	1808	2 AB1847	serine/threonine k
28	45.5	37.3	645	2 A75390	NADH2 dehydrogenas
29	45	36.9	67	2 I54475	HLA-DNA-related sm

## ALIGNMENTS

## RESULT 1

HLR0DA

MHC class II histocompatibility antigen HLA-DR alpha chain precursor - human

C;Species: Homo Sapiens (man)

C;Date: 17-Dec-1982 #sequence revision 27-Nov-1985 #text change 09-Jul-2004

C;Accession: A93952; A20898; A21113; 158045; A9107; A90825; A93927; 152975; 180

R;Das, H.K.; Lawrence, S.K.; Weisman, S.M.

Proc. Natl. Acad. Sci. U.S.A. 80, 3543-3547, 1983

A;Title: Structure and nucleotide sequence of the heavy chain gene of HLA-DR.

A;Reference number: A93952; MUID:83221632; PMID:6304715

A;Accession: A93952

A;Molecule type: DNA

A;Residues: 1-254 &lt;DAS&gt;

A;Cross-references: UNIPROT: P01903; GB: J00203; GB: J00204; NID: 9188427; PMID: A0A36302.1;

A;Note: this allele is designated DRA0101

R;Schambach, A.; Korman, A.J.; Kamb, A.; Strominger, J.L.

Nucleic Acids Res. 11, 8663-8675, 1983

A;Title: Use of synthetic oligonucleotide probes complementary to genes for human HLA-DR

A;Reference number: A21113; MUID:83169718; PMID:6403940

A;Accession: A21113

A;Molecule type: mRNA

A;Residues: 1-39 &lt;DAS&gt;

A;Cross-references: GB: J00197

R;Lee, J.S.; Trowbridge, J.; Travers, P.J.; Carey, J.; Grossveld, F.; Jenkins, J.; Bodmer, J.

Nature 299, 750-752, 1982

A;Title: sequence of an hla-dr alpha-chain cdna clone and intron-exon organization of the

A;Reference number: 158045; MUID: 83013020; PMID: 6811954

A;Accession: 158045

A;Status: translated from GB/EMBL/DBJ

A;Molecule type: mRNA

A;Residues: 1-254 &lt;REBS&gt;

A;Cross-references: GB: J00194; NID: 9188231; PMID: AAA36275.1; PID: 9307264

R;Das, H.K.; Lawrence, S.K.; Weisman, S.M.

Proc. Natl. Acad. Sci. U.S.A. 80, 7024, 1983

A;Content: annotation; erratum

R;Yang, C.Y.; Kratzin, H.; Gotz, H.; Thinnies, F.P.; Kruse, T.; Egert, G.; Pauly, E.; Kol

Hoppe-Seyler's B Z. Physiol. Chem. 363, 671-676, 1982

A;Title: Primaerstruktur menschlicher Histonkompatibilitaetsantigene der Klasse II. 2. Mit

A;Reference number: A9107; MUID: 8263347; PMID: 6955253

A;Accession: A9107

A;Molecule type: protein

A;Residues: 26-148, D', 150-204 &lt;YAN&gt;

R;Larhammar, D.; Gustafsson, K.; Claesson, L.; Bill, P.; Wiman, K.; Scheffing, L.; Sunde

Cell 30, 153-161, 1982  
 A;Title: Alpha chain of HLA-DR transplantation antigens is a member of the same protein  
 A;Reference: MUID:8025; PMID:83025073

A;Accession: A50825  
 A;Molecule type: protein  
 A;Residues: 26-60 <LAR>  
 A;Note: 28-Ala, 29-Asp, 33-Thr, 33-Pro, 34-Tyr, 35-Pro, 48-Gln, and 54-Thr were also found in the HLA-DR alpha chain.  
 A;Accession: B90825  
 A;Molecule type: mRNA  
 A;Cross-references: GB:J00196  
 A;Note: this allele is designated DRA\*0101  
 R;Korman, A.J.; Auftray, C.; Schambenbeck, A.; Strominger, J.L.  
 Proc. Natl. Acad. Sci. U.S.A. 79, 6013-6017, 1982  
 A;Title: The amino acid sequence and gene organization of the heavy chain of the HLA-DR  
 A;Reference number: A93927; MUID:832999316; PMID:68212129  
 A;Accession: A91927  
 A;Molecule type: DNA  
 A;Residues: 29-254 <KOR>  
 A;Cross-references: GB:J00201  
 A;Note: Leu was also found  
 A;Note: this allele is designated DRA\*0102  
 R;Kajimura, Y.; Toyoda, H.; Sato, M.; Miyakoshi, S.; Kaplan, S.A.; Ike, Y.; Goyert, S.M.  
 DNA 2, 175-182, 1983  
 A;Title: Cloning the heavy chain of human HLA-DR antigen using synthetic oligodeoxyribonucleotides  
 A;Reference number: 152975; MUID:84057142; PMID:6416803  
 A;Accession: 152975  
 A;Status: translated from GB/EMBL/DBJ  
 A;Molecule type: mRNA  
 A;Cross-references: K; Wiman, K.; Larhammar, D.G.; Rask, L.; Peterson, P.A.  
 R;Gustafsson, K.; Wiman, K.; Larhammar, D.G.; Rask, L.; Peterson, P.A.  
 A;Title: Signal sequences distinguish class II histocompatibility antigen beta chains of  
 A;Reference number: 159457; MUID:84146572; PMID:6422542  
 A;Accession: 150355  
 A;Status: translated from GB/EMBL/DBJ  
 A;Molecule type: mRNA  
 A;Residues: 1-50 <RR2>  
 A;Cross-references: GB:W35979; NID:9188262; PIDN:AAA36283.1; PID:gi188263  
 R;Lee, J.S.; Trowdsdale, J.; Bodmer, W.F.  
 Proc. Natl. Acad. Sci. U.S.A. 79, 545-549, 1982  
 A;Title: cDNA clones coding for the heavy chain of human hla-dr antigen.  
 A;Reference number: 158984; MUID:82197331; PMID:6952207  
 A;Accession: 158984  
 A;Status: translated from GB/EMBL/DBJ  
 A;Molecule type: mRNA  
 A;Residues: 1-50 <RR2>  
 A;Cross-references: GB:J00193; NID:9188213; PIDN:AAA36272.1; PID:gi188214  
 R;Koppelman, B.; Cresswell, P.  
 J. Immunol. 145, 2720-2736, 1990  
 A;Title: Rapid nonlysosomal degradation of assembled HLA class II glycoproteins incorporated into the cDNA clones for the heavy chain of HLA-DR antigens obtained after immunopurification.  
 A;Accession: 156085  
 A;Status: preliminary; translated from GB/EMBL/DBJ  
 A;Molecule type: mRNA  
 A;Residues: 1-241-'L', 243-254 <RE6>  
 A;Cross-references: GB:W60334; NID:9188255; PIDN:AAA59783.1; PID:gi188256  
 R;Korman, A.J.; Knudsen, P.J.; Kaufman, J.F.; Strominger, J.L.  
 Proc. Natl. Acad. Sci. U.S.A. 79, 1844-1848, 1982  
 A;Title: cDNA clones for the heavy chain of HLA-DR antigens obtained after immunopurification.  
 A;Accession: 137530  
 A;Status: preliminary; translated from GB/EMBL/DBJ  
 A;Molecule type: mRNA  
 A;Residues: 224-241-'L', 243-254 <RE6>  
 A;Cross-references: EMBL:V00528; NID:932192; PIDN:CAA23787.1; PID:9825675  
 C;Genetics:  
 A;Gene: GBP:HLA-DR  
 A;Cross-references: GDB:120641; OMIM:142860  
 A;Map position: 6p21.3-6p21.3  
 A;Introns: 82/1; 176/1  
 C;Superfamily: class II histocompatibility antigen; immunoglobulin homology

C;Keywords: glycoprotein; heterodimer; transmembrane protein  
 P;1-25/Domain: signal sequence #status predicted  
 F;2-216/Domain: class II histocompatibility antigen HLA-DR alpha chain #status predicted  
 F;26-109/Domain: extracellular #status predicted  
 F;26-109/Domain: alpha-1 <EX1>  
 F;25-19/Domain: immunoglobulin homology <IMM>  
 F;217-239/Domain: transmembrane #status predicted <TM>  
 F;240-254/Domain: intracellular #status predicted  
 F;103,143/Binding site: carbohydrate (Ash) (covalent) #status experimental  
 F;132-188/Disulfide bonds: #status experimental  
 Query Match Score 100.0%; Score 122; DB 1; Length 254;  
 Best Local Similarity 100.0%; Pred. No. 3..1e-11;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 C;Species: Oryctolagus cuniculus (domestic rabbit)  
 C;Date: 03-Jun-1993 #sequence\_revision 03-Jun-1993 #text\_change 09-Jul-2004  
 C;Accession: A45881  
 R;Laverrerie, A.; Kulaga, H.; Kindt, T.J.; Legern, C.; Marche, P.N.  
 Immunogenetics 30, 137-140, 1989  
 A;Title: A rabbit class II MHC gene with strong similarities to HLA-DRA.  
 A;Reference number: A45881; MUID:89339606; PMID:2755665  
 A;Accession: A45881  
 A;Status: preliminary  
 A;Molecule type: DNA  
 A;Residues: 1-255 <LAV>  
 A;Cross-references: UNIPROT:Q30847; GB:M28161; NID:9341842; PIDN:AAA31394.1; PID:9529576  
 C;Superfamily: class II histocompatibility antigen; immunoglobulin homology  
 F;126-19/Domain: immunoglobulin homology <IMM>  
 Query Match Score 93.2%; Score 101.5; DB 2; Length 255;  
 Best Local Similarity 84.6%; Pred. No. 4..4e-08;  
 Matches 22; Conservative 2; Mismatches 1; Indels 1; Gaps 1;  
 C;Species: Mus musculus (house mouse)  
 C;Date: 04-Dec-1986 #sequence\_revision 04-Dec-1986 #text\_change 09-Jul-2004  
 C;Accession: A21938; A02208  
 R;Mathis, D.J.; Benoist, C.O.; Williams II, V.E.; Kanter, M.R.; McDevitt, H.O.  
 Cell 32, 745-754, 1983  
 A;Title: The murine E- $\kappa$  immune response gene.  
 A;Reference number: A21938; MUID:83155651; PMID:6403249  
 A;Accession: A21938  
 A;Molecule type: mRNA  
 A;Residues: 1-255 <SBEN>  
 C;Superfamily: class II histocompatibility antigen E- $\kappa$  alpha chain precursor - mouse  
 C;Species: Mus musculus (house mouse)  
 C;Date: 04-Dec-1986 #sequence\_revision 04-Dec-1986 #text\_change 09-Jul-2004  
 C;Accession: A21938; A02208  
 R;Mathis, D.J.; Benoist, C.O.; Williams II, V.E.; McDevitt, H.O.  
 A;Title: The murine Ia alpha chains, E- $\kappa$  alpha and A- $\kappa$  alpha, show a surprising degree of sequence similarity.  
 A;Reference number: A93967; MUID:8315693; PMID:6300851  
 A;Accession: A02208  
 A;Status: nucleic acid sequence not shown  
 A;Molecule type: mRNA  
 A;Residues: 1-255 <SBEN>  
 C;Superfamily: class II histocompatibility antigen; immunoglobulin homology  
 A;Keywords: heterodimer; transmembrane protein  
 F;1-25/Domain: signal sequence #status predicted <SIG>  
 F;26-255/Product: H-2 class II histocompatibility antigen E- $\kappa$  alpha chain #status predict



F;203-215/Domain: connecting #status predicted <CNE>  
 F;215-239/Domain: transmembrane #status predicted <TM>  
 F;240-253/Domain: intracellular #status predicted <INT>  
 F;102/Binding site: carbohydrate (Asn) (prevalent) #status predicted

Query Match 59.4%; Score 72.5%; DB 2; Length 253;  
 Best Local Similarity 64.0%; Pred. No. 0.0013; Mismatches 3; Indels 1; Gaps 1;

Matches 16; Conservative 3; Mismatches 5; Indels 1; Gaps 1;

Qy 1 MAISGVGVLFPIIAVLMQESWA 25  
 Db 1 MAITRVPGLP-ITVVLIGEESWA 24

RESULT 7  
 S06316 class II histocompatibility antigen RT1-D alpha (u) chain precursor - rat  
 C;Species: Rattus norvegicus (Norway rat)  
 C;Date: 31-Mar-1990 #sequence\_revision 31-Mar-1990 #text\_change 09-Jul-2004  
 C;Accession: S06316  
 R;Holowach, B.W.; Green, M.K.; Martin, D.R.  
 Nucleic Acids Res. 15, 10551-10567, 1987  
 A;Title: The complete sequence of the MHC class II chain RT1-D-alpha (u) of the diabetic mouse  
 A;Reference: S06316  
 A;Accession: S06316  
 A;Status: not compared with conceptual translation  
 A;Molecule type: mRNA  
 A;Residues: 1-255 <HOL>  
 A;Cross-references: UNIPROT:Q31281; GB:Y00480; NID:957163; PID:CAA68540; 1; PMID:3122183  
 C;Superfamily: Class II histocompatibility antigen; immunoglobulin homology  
 C;Keywords: transmembrane protein  
 F;25/Domain: signal sequence #status predicted <SIG>  
 F;26-255/Domain: class II histocompatibility antigen, RT1-D alpha (u) chain #status predicted  
 F;26-109/Domain: extracellular alpha-1 #status predicted <ACH1>  
 F;110-203/Domain: extracellular alpha-2 #status predicted <ACH2>  
 F;204-216/Domain: immunoglobulin homology <IMM>  
 F;217-239/Domain: transmembrane #status predicted <TM>  
 F;240-255/Domain: intracellular #status predicted <INT>  

Query Match 55.7%; Score 68; DB 2; Length 255;  
 Best Local Similarity 60.0%; Pred. No. 0.0063; Mismatches 3; Indels 0; Gaps 0;

Matches 15; Conservative 7; Mismatches 7; Indels 0; Gaps 0;

Qy 1 MAISGVGVLFPIIAVLMQESWA 25  
 Db 1 MATIGDLVIRFFEMAVLMSPKSWA 25

RESULT 8  
 A46505 SLA-DRD (MHC Class II) - pig  
 C;Species: Sus scrofa domestica (domestic pig)  
 C;Date: 18-Jun-1993 #sequence\_revision 18-Nov-1994 #text\_change 09-Jul-2004  
 C;Accession: A46505  
 R;Hirsch, F.; Germana, S.; Gustafsson, K.; Pratt, K.; Sachs, D.H.; Lequern, C.  
 J. Immunol. 149, 841-846, 1992  
 A;Title: Structure and expression of class II alpha genes in miniature swine.  
 A;Reference number: A46505; MUID:923340887; PMID:1634772  
 A;Status: preliminary  
 A;Molecule type: mRNA  
 A;Residues: 1-252 <HIR>  
 A;Cross-references: UNIPROT:Q31065; GB:M93038; NID:9164551; PID:AA31075; 1; PMID:9164552  
 A;Note: sequence extracted from NCBI backbone (NCBIN:109901, NCBIPI:109902)  
 C;Superfamily: Class II histocompatibility antigen; immunoglobulin homology  
 F;123-188/Domain: immunoglobulin homology <IMM>

Query Match 53.3%; Score 65; DB 2; Length 252;  
 Best Local Similarity 56.0%; Pred. No. 0.018; Mismatches 4; Indels 5; Gaps 1;

Matches 14; Conservative 4; Mismatches 5; Indels 2; Gaps 2; Gaps 1;

Qy 1 MAISGVGVLFPIIAVLMQESWA 25

M.; Shen, M.; Vamathevan, J.J.; Lam, P.; McDonald, L.; Utterback, T.; Zalewski, C.; Ma, S.; Smith, H.O.; Venter, J.C.; Fraser, C.M.  
 Science 286, 1571-1577, 1999  
 A;Title: Genome sequence of the radioresistant bacterium *Deinococcus radiodurans* R1.  
 A;Reference number: A75250; MUID:20036896; PMID:10567266  
 A;Accession: C75596  
 A;Status: preliminary  
 A;Molecule type: DNA  
 A;Residues: 1-556 <RPT>  
 A;Cross-references: UNIPROT:Q8RZC1; GB:AE001862; PMID:AAF1227  
 A;Experimental source: strain R1  
 C;Genetics:  
 A;Gene: DRA0033  
 A;Map position: 2  
 Query Match Score 49; DB 2; Length 556;  
 Best Local Similarity 40.9%; Pred. No. 11;  
 Matches 9; Conservative 8; Mismatches 5; Indels 0; Gaps 0;  
 Qy 4 SCGVPLGFFIAVLMQAESWA 25  
 Db 522 SGUPLGFLINKVASSRDSYS 543  
 RESULT 12  
 S75553 hypothetical protein S811520 - *Synechocystis* sp. (strain PCC 6803)  
 C;Species: *Synechocystis* sp.  
 A;Variety: PCC 6803  
 C;Accession: S75553  
 C;Date: 25-Apr-1997 #sequence\_revision 25-Apr-1997 #text\_change 09-Jul-2004  
 R.;Kaneko, T.; Sato, S.; Kotani, H.; Tanaka, A.; Asamizu, E.; Nakamura, Y.; Miyajima, N.; O., K.; Okamura, S.; Shimojo, S.; Takeuchi, C.; Wada, T.; Watanabe, A.; Yamada, M.; Yasuda DNA Res. 3, 109-136, 1996  
 A;Title: Sequence analysis of the genome of the unicellular cyanobacterium *Synechocystis* sp. B.;Reference number: S743222; MUID:97061201; PMID:8905231  
 A;Accession: S75553  
 A;Status: preliminary  
 A;Molecule type: DNA  
 A;Residues: 1-75 <RAN>  
 A;Cross-references: UNIPROT:P74039; EMBL:D90911; GB:AB001339; NID:91653083; PIDN:BA1811  
 A;Note: The nucleotide sequence was submitted to the EMBL Data Library, June 1996

RESULT 13  
 B83758 hypothetical protein BH0166 [imported] - *Bacillus halodurans* (strain C-125)  
 C;Species: *Bacillus halodurans*  
 C;Date: 01-Dec-2000 #sequence\_revision 01-Dec-2000 #text\_change 09-Jul-2004  
 C;Accession: B83758  
 C;Cross-references: UNIPROT:Q8KBI6; GB:AP001510; NID:910173440; PIDN:BA0045  
 R.;Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Sasaki, R.; Masui, N.; Fuji, F.; Hira Nucleic Acids Res. 28, 4317-4331, 2000  
 A;Title: Complete genome sequence of the alkaliiphilic bacterium *Bacillus halodurans* and A;Reference number: A83650; MUID:20512582; PMID:11058132  
 A;Accession: B83758  
 A;Status: preliminary  
 A;Molecule type: DNA  
 A;Residues: 1-513 <STO>  
 A;Experimental source: strain C-125  
 C;Genetics:  
 A;Gene: BH0866

Query Match Score 48; DB 2; Length 75;  
 Best Local Similarity 36.0%; Pred. No. 2.5;  
 Matches 9; Conservative 9; Mismatches 3; Indels 4; Gaps 1;  
 Qy 1 MAISGVPLGFF--FIAVLMQAQ 21  
 Db 11 LIVMGIPLGVLVCAPIAVMSE 35

RESULT 13  
 B72367 oligopeptide ABC transporter, permease protein - *Thermotoga maritima* (strain MSB8)  
 C;Species: *Thermotoga maritima*  
 C;Date: 11-Jun-1999 #sequence\_revision 11-Jun-1999 #text\_change 09-Jul-2004  
 C;Accession: B72367  
 R.;Nelson, K.E.; Clayron, R.A.; Gill, S.R.; Gwinn, M.L.; Dodson, R.J.; Haft, D.H.; Hickey, Garrett, M.M.; Stewart, A.M.; Cotton, M.D.; Pratt, M.S.; Phillips, C.A.; Richardson, D.; C.M.  
 Nature 399, 323-329, 1999  
 A;Title: Evidence for lateral gene transfer between Archaea and Bacteria from genome seq  
 A;Reference number: A72200; MUID:99287316; PMID:10360571  
 A;Accession: B72267  
 A;Status: preliminary  
 A;Molecule type: DNA  
 A;Residues: 1-321 <RPT>  
 A;Cross-references: UNIPROT:Q9W202; GB:AE001728; NID:94981027; PMID:AAD561  
 A;Experimental source: strain MSB8  
 C;Genetics:  
 A;Gene: TM0532



GenCore version 5.1.6  
 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 19, 2005, 23:18:33 ; Search time 76.8649 Seconds  
 (without alignment)  
 60.380 Million cell updates/sec

Title: US-10-603-062-16  
 Perfect score: 67  
 Sequence: 1 LMGTGLGIVCPIC 12

Scoring table: BLOSUM62  
 Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0  
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
 Maximum Match 100%  
 Listing first 45 summaries

Database :

A\_Geneseq\_16Dec04:\*

1: geneseqp1980s:\*

2: geneseqp1980s:\*

3: geneseqp2000s:\*

4: geneseqp2001s:\*

5: geneseqp2002s:\*

6: geneseqp2003as:\*

7: geneseqp2003bs:\*

8: geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	67	100.0	12	2 AAY09332	Aay09332 Human pap
2	67	100.0	12	4 AAGG4707	AAGG4707 HPV immunogen
3	67	100.0	12	4 AAB20196	Aab20196 Immunogen
4	67	100.0	13	2 AAY09333	Aay09333 Human pap
5	67	100.0	13	2 AAY09342	Aay09342 Human pap
6	67	100.0	13	3 AAY09334	Aay09334 Human pap
7	67	100.0	13	3 AAB33711	Ab33711 Antigenic
8	67	100.0	13	4 AAGG4709	AAGG4709 HPV immunogen
9	67	100.0	13	4 AAGG4708	AAGG4708 HPV immunogen
10	67	100.0	13	4 AAGG4715	AAGG4715 HPV type
11	67	100.0	13	4 AAB20198	Aab20198 HPV type
12	67	100.0	13	4 AAB20199	Aab20199 HPV type
13	67	100.0	13	4 AAB20206	Aab20206 HPV type
14	67	100.0	13	6 ABU96663	Abu96663 MHC class I
15	67	100.0	14	6 AAO16633	Aao16633 Human pap
16	67	100.0	15	2 AAY45453	Aay45453 Immunogen
17	67	100.0	15	8 ADN65115	Adn65115 HLA, bindin
18	67	100.0	15	8 ADQ29045	Adq29045 Human pap
19	67	100.0	15	8 ADR42342	Adr42342 HPV 16 E7
20	67	100.0	16	3 AAB33710	Ab33710 MHC class II
21	67	100.0	16	4 AAGG4710	AAGG4710 HPV immunogen
22	67	100.0	16	4 AAGG3806	Aag3806 Human pap
23	67	100.0	16	4 AAB20200	Aab20200 HPV type
24	67	100.0	16	6 ABU96662	Abu96662 MHC class II
25	67	100.0	17	2 AAY09335	Aay09335 Human pap

#### ALIGNMENTS

Result 1	ID	AAV09332 standard; peptide; 12 AA.
	XX	
	AC	AAV09332;
	XX	
	DT	08-JUL-1999 (first entry)
	XX	Human papillomavirus E7 protein immunogenic peptide #1.
	DE	
	XX	Human papillomavirus; HPV; E7 protein; immunogenic; immune response;
	KW	infection; exophytic coneyloma; cervical cancer; respiratory papilloma;
	KW	conjunctival papilloma; genital tract infection.
	XX	Human papillomavirus.
	OS	
	OS	Synthetic.
	XX	
	PN	WO9918995-A1.
	XX	
	PD	22-APR-1999.
	XX	
	XX	XX 09-OCT-1998; 98WO-US021456.
	XX	XX 09-OCT-1997; 97US-00948378.
	PR	(PANG-) PANGAEA PHARM INC.
	XX	XX Urban RG, Chicz RM, Collins EJ, Hedley ML;
	PI	XX WPI: 1999-277445/23.
	DR	XX New human papilloma virus peptides - used for preventing or treating e.g. exophytic coneyloma, cervical cancer, respiratory papilloma, conjunctival papilloma or genital tract infection.
	PT	XX Claim 1: Page 24: 40pp; English.
	PS	XX The present invention describes human papillomavirus peptides which are used for preventing or treating e.g. exophytic coneyloma, cervical cancer, respiratory papilloma, conjunctival papilloma or genital tract infection. The peptides correspond to human Papilloma virus (HPV) sequences. The peptides and DNA encoding them can be used for inducing an immune response to HPV in a mammal. They can be used for treating a human who suffers from or is at risk of conditions such as exophytic condyloma, flat condyloma, cervical cancer, respiratory papilloma, conjunctival papilloma, genital tract infection and cervical dysplasia. They can also be used for treating or preventing e.g. bowenoid papulosis, anal dysplasia, vulval cancer, or prostate cancer

XX Sequence 12 AA;  
 SQ Query Match 100.0%; Score 67; DB 2; Length 12;  
 Best Local Similarity 100.0%; Pred. No. 0.00041;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 LMGTIGIVCPIC 12  
 Db 1 LMGTIGIVCPIC 12

RESULT 2  
 AAG64707  
 ID AAG64707 Standard; peptide; 12 AA.  
 XX AC AAG64707;  
 XX DT 24-SEP-2001 (first entry)  
 XX DE HPV immunogenic peptide SEQ ID 16.  
 XX KW Immunogenic peptide; HPV; class I restricted T cell epitope; cytostatic;  
 XX antiviral; exophytic condyloma; flat condyloma; cervical cancer;  
 XX respiratory papilloma; conjunctival papilloma; genital-tract HPV;  
 XX cervical dysplasia.  
 XX OS Human papillomavirus.

XX PN US2001006639-A1.  
 XX PD 05-JUL-2001.  
 XX PP 12-JAN-2001; 2001US-00759960.  
 XX PR 09-OCT-1997; 97US-0061657P.  
 XX PR 09-OCT-1998; 98US-00169425.  
 XX PA (ZYCO-) ZYCOS INC.

XX PI Urban RG, Chiecz RM, Collins EJ, Hedley ML;  
 XX DR WPI; 2001-190939/19.  
 XX PN US2001006639-A1.  
 XX PD 05-JUL-2001.  
 XX PP 12-JAN-2001; 2001US-00759960.  
 XX PR 09-OCT-1997; 97US-0061657P.  
 XX PR 09-OCT-1998; 98US-00169425.  
 XX PA (ZYCO-) ZYCOS INC.

XX DR WPI; 2001-190939/19.

XX PR 09-OCT-1997; 97US-0061657P.  
 XX PR 09-OCT-1998; 98US-00169425.  
 XX PA (ZYCO-) ZYCOS INC.

XX PI Urban RG, Chiecz RM, Collins EJ, Hedley ML;  
 XX DR WPI; 2001-190939/19.  
 XX PR 09-OCT-1997; 97US-0061657P.  
 XX PR 09-OCT-1998; 98US-00169425.  
 XX PA (ZYCO-) ZYCOS INC.

XX DR WPI; 2001-190939/19.

XX PR 09-OCT-1997; 97US-0061657P.  
 XX PR 09-OCT-1998; 98US-00169425.  
 XX PA (ZYCO-) ZYCOS INC.

XX DR WPI; 2001-190939/19.  
 XX PR 09-OCT-1997; 97US-0061657P.  
 XX PR 09-OCT-1998; 98US-00169425.  
 XX PA (ZYCO-) ZYCOS INC.

XX DR WPI; 2001-190939/19.  
 XX PR 09-OCT-1997; 97US-0061657P.  
 XX PR 09-OCT-1998; 98US-00169425.  
 XX PA (ZYCO-) ZYCOS INC.

RESULT 3  
 AAB20196  
 ID AAB20196 standard; peptide; 12 AA.

XX AC AAB20196;  
 XX DT 14-MAY-2001 (first entry)

XX DB Immunogenic peptide from HPV type 16 E7 protein used in vaccine.  
 XX KW Immunogenic peptide; immunogen; HPV; E7 protein; vaccine; infection;  
 XX gene therapy; exophytic condyloma; flat condyloma; cervical cancer;  
 XX respiratory papilloma; conjunctival papilloma; cervical dysplasia.  
 XX OS Human papillomavirus type 16.  
 XX PN US6183746-B1.

XX PD 06-FEB-2001.  
 XX PP 09-OCT-1998; 98US-00169425.  
 XX PR 09-OCT-1997; 97US-0061657P.

XX PA (ZYCO-) ZYCOS INC.

XX PI Urban RG, Chiecz RM, Collins EJ, Hedley ML;  
 XX DR WPI; 2001-190939/19.

XX PN US6183746-B1.  
 XX PD 06-FEB-2001.  
 XX PP 09-OCT-1998; 98US-00169425.  
 XX PR 09-OCT-1997; 97US-0061657P.  
 XX PA (ZYCO-) ZYCOS INC.

XX PI Urban RG, Chiecz RM, Collins EJ, Hedley ML;  
 XX DR WPI; 2001-190939/19.

XX PN US6183746-B1.  
 XX PD 06-FEB-2001.  
 XX PP 09-OCT-1998; 98US-00169425.  
 XX PR 09-OCT-1997; 97US-0061657P.

XX PA (ZYCO-) ZYCOS INC.

XX PI Urban RG, Chiecz RM, Collins EJ, Hedley ML;  
 XX DR WPI; 2001-190939/19.

XX PN US6183746-B1.  
 XX PD 06-FEB-2001.  
 XX PP 09-OCT-1998; 98US-00169425.  
 XX PR 09-OCT-1997; 97US-0061657P.

XX PA (ZYCO-) ZYCOS INC.

KW Human papillomavirus; HPV; E7 protein; immunogenic; immune response;

RESULT 4

AAV09333

ID AAV09333 standard; peptide; 13 AA.

XX AC AAV09333;

XX DT 08-JUL-1999 (first entry)

XX DB Human papillomavirus E7 protein immunogenic peptide #2.

KW Human papillomavirus; HPV; E7 protein; immunogenic; immune response;

KW infection; exophytic coneyloma; cervical cancer; respiratory papilloma;  
 KW conjunctival papilloma; genital tract infection.  
 XX Human Papillomavirus.  
 OS Synthetic.  
 XX WO9918995-A1.  
 PN 22-APR-1999.  
 PD 09-OCT-1998; 98WO-US021456.  
 PR 09-OCT-1997; 97US-00948378.  
 XX (PANG-) PANGAEA PHARM INC.  
 PA Urban RG, Chiccz RM, Collins EJ, Hedley ML;  
 XX WPI; 1999-277445/23.  
 PR 1999-277445/23.  
 XX (PANG-) PANGAEA PHARM INC.  
 PA Urban RG, Chiccz RM, Collins EJ, Hedley ML;  
 XX WPI; 1999-277445/23.  
 PR 1999-277445/23.  
 XX New human papilloma virus peptides - used for preventing or treating e.g.  
 PR exophytic coneyloma, cervical cancer, respiratory papilloma, conjunctival  
 PT papilloma or genital tract infection.  
 XX Claim 15; Page 25-26; 40pp; English.  
 PS Claim 15; Page 25-26; 40pp; English.  
 XX The present invention describes human papillomavirus peptides which are  
 CC used for preventing or treating e.g. exophytic condyloma, cervical  
 CC cancer, respiratory papilloma, conjunctival papilloma or genital tract  
 CC infection. The peptides correspond to human papilloma virus (HPV) E7  
 CC sequences. The peptides and DNA encoding them can be used for inducing an  
 CC immune response to HPV in a mammal. They can be used for treating a human  
 CC who suffers from or is at risk of conditions such as exophytic condyloma,  
 CC flat condyloma, cervical cancer, respiratory papilloma, conjunctival  
 CC papilloma, genital tract HPV infection and cervical dysplasia. They can  
 CC also be used for treating or preventing e.g. Bowenoid papulosis, anal  
 CC dysplasia, vulval cancer, or prostate cancer  
 XX Sequence 13 AA;  
 SQ Query Match 100.0%; Score 67; DB 2; Length 13;  
 ID Best Local Similarity 100.0%; Pred. No. 0.00044;  
 AC Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 XX Qy 1 LMGTIGIVCPIC 12  
 AC 2 LMGTIGIVCPIC 13  
 ID Db 2 LMGTIGIVCPIC 13  
 AC XX Sequence 13 AA;  
 ID RESULT 6  
 AC AAY09334 standard; peptide; 13 AA.  
 AC XX Query Match 100.0%; Score 67; DB 2; Length 13;  
 AC ID Best Local Similarity 100.0%; Pred. No. 0.00044;  
 AC AC Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 AC XX Qy 1 LMGTIGIVCPIC 12  
 AC 2 LMGTIGIVCPIC 13  
 AC DB Human Papillomavirus E7 protein immunogenic peptide #3.  
 AC XX Human Papillomavirus; HPV; E7 protein; immunogenic; immune response;  
 AC KW infection; exophytic coneyloma; cervical cancer; respiratory papilloma;  
 AC KW conjunctival papilloma; genital tract infection.  
 AC XX OS Human Papillomavirus.  
 AC OS Synthetic.  
 AC XX RESULT 5  
 AC ID AAY09342 standard; peptide; 13 AA.  
 AC XX DB Human Papillomavirus E7 protein immunogenic Peptide #11.  
 AC XX AC AAY09342;  
 AC XX DT 08-JUL-1999 (first entry)  
 AC XX PR 09-OCT-1997; 97US-00948378.  
 AC XX FH Key Misc-difference 1  
 AC XX FT /label= Met, Ala, Ser, Arg, Lys, Gly, Gln, Asp, Glu  
 AC XX PT XX WO9918995-A1.  
 AC XX PN Human Papillomavirus; HPV; E7 protein; immunogenic; immune response;  
 AC XX KW infection; exophytic coneyloma; cervical cancer; respiratory papilloma;  
 AC KW conjunctival papilloma; genital tract infection.  
 AC XX OS Human Papillomavirus.  
 AC OS Synthetic.  
 AC XX PN WO9918995-A1.  
 AC XX PD 22-APR-1999.  
 AC XX PR 09-OCT-1998; 98WO-US021456.  
 AC XX PR 09-OCT-1997; 97US-00948378.  
 AC XX DR WPI; 1999-277445/23.  
 AC XX PT New human papilloma virus peptides - used for preventing or treating e.g.  
 AC PT exophytic coneyloma, cervical cancer, respiratory papilloma, conjunctival

PT papilloma or genital tract infection.  
 XX Claim 3; Page 24; 40pp; English.  
 XX The present invention describes human papillomavirus peptides which are used for preventing or treating e.g. exophytic condyloma, cervical cancer, respiratory papilloma, conjunctival papilloma or genital tract infection. The peptides correspond to human papilloma virus (HPV) E7 sequences. The peptides and DNA encoding them can be used for inducing an immune response to HPV in a mammal. They can be used for treating a human who suffers from or is at risk of conditions such as exophytic condyloma, flat condyloma, cervical cancer, respiratory papilloma, conjunctival papilloma, genital-tract HPV infection and cervical dysplasia. They can also be used for treating or preventing e.g. Bowenoid papulosis, anal dysplasia, vulval cancer, or prostate cancer.

XX Sequence 13 AA;

Query Match 100.0%; Score 67; DB 2; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00044;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LMGTGLGIVCPIC 12

Db 2 LMGTGLGIVCPIC 13

RESULT 7

AAB33711 standard; Peptide; 13 AA.

XX DT 26-JAN-2001 (first entry)

XX Antigenic MHC class I-binding peptide SEQ ID 110.

XX Unidentified.

OS WO200053161-A2.

XX PD 14-SEP-2000.

XX PF 10-MAR-2000; 2000WO-US006578.

XX PR 11-MAR-1999; 99US-00266463.

XX 27-MAY-1999; 99US-00321346.

XX PA (ZYCO-) ZYCOS INC.

XX Lunsford LB, Putnam D, Hedley ML;

XX DR WPI; 2000-638130/61.

PT Microparticles useful for administering a nucleic acid into the mucosal tissue preferably vaginal tissue of an animal, comprises a polymeric matrix, a lipid and a nucleic acid molecule. The microparticle is specifically not encapsulated in a liposome and does not comprise a cell. The nucleotide sequence encodes an expression product that binds to major histocompatibility complex (MHC) type I or II molecules. Peptides AAB3302-B13647 represent MHC class II associated immunogenic peptides, and AAB33648-B33710 represent MHC class I associated immunogenic peptides. The peptides are examples of the expression products of the nucleotide sequences which can be included in the microparticles of the invention. Sequences AAB3311-

PT B33716 represent alternative expression products and nuclear localisation signals also used in the invention. The microparticles are useful for administering a nucleic acid into the mucosal tissue preferably vaginal tissue of an animal.

XX Sequence 13 AA;

Query Match 100.0%; Score 67; DB 3; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00044;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LMGTGLGIVCPIC 12

Db 2 LMGTGLGIVCPIC 13

RESULT 8

AAC64709

XX ID AAC64709 standard; peptide; 13 AA.

XX AC AAC64709;

XX DT 24-SEP-2001 (first entry)

XX DB HPV immunogenic peptide SEQ ID 19.

XX Immunogenic peptide; HPV; class I restricted T cell epitope; cytosatic; antiviral; exophytic condyloma; flat condyloma; cervical papilloma; respiratory papilloma; conjunctival papilloma; genital-tract HPV; cervical dysplasia.

XX OS Human papillomavirus.

XX XX FH Key Location/Qualifiers  
 XX FT Misc-difference 1 /label= Met, Ala, Ser, Arg, Lys, Gln, Asp, Glu  
 XX XX PR 09-OCT-1997; 97US-0061657P.  
 XX XX PR 09-OCT-1998; 98US-00169425.  
 XX XX DR 2001-407585/43.

XX XX PA (ZYCO-) ZYCOS INC.  
 XX XX PI Urban RG, Chiez RM, Collins EJ, Hedley ML;  
 XX XX DR WPI; 2001-407585/43.  
 XX XX PS Claim 3; Page 7; 12pp; English.  
 CC This invention relates to immunogenic peptides from human papillomavirus (HPV) type 16 E7 protein. The peptides are overlapping Class I restricted T cell epitopes. The invention includes a therapeutic composition and vaccine containing the immunogenic peptides. Use of the composition results in cytosatic and/or antiviral activity. The peptides and nucleic acids encoding them can be used as vaccines to treat or prevent disease conditions such as exophytic condyloma, flat condyloma, cervical cancer, respiratory papilloma, conjunctival papilloma, genital-tract HPV infection, and cervical dysplasia. The present sequence represents a peptide of the invention

XX Sequence 13 AA;

Query Match 100.0%; Score 67; DB 4; Length 13;



PN	US6183746-B1.	PR	09-OCT-1997;	97US-0061657P.
XX	XX	XX	(ZICO-)	ZYCOS INC.
PD	06-FEB-2001.	PA	Urban RG, Chicz RM, Collins EJ, Hedley ML;	
XX	XX	PI		
PF	09-OCT-1998;	XX		
XX	98US-00169425.	XX		
PR	09-OCT-1997;	XX		
XX	97US-0061657P.	XX		
PA	(ZICO-)	XX	WPI;	2001-190939/19.
XX	ZYCOS INC.	XX		
Urban RG, Chicz RM, Collins EJ, Hedley ML;	XX	XX		
PI	XX	XX		
DR	XX	XX		
WPI;	2001-190939/19.	XX		
XX		XX		
PT	Inducing an immune response in a mammal for prophylaxis and treatment of	XX		
XX	human papilloma virus infections such as cervical cancer, comprises	XX		
PT	administering immunogenic peptides from the papilloma virus type 16 E7	XX		
PT	protein.	XX		
XX		XX		
PS	Claim 17; Col 32; 23pp; English.	PS	Claim 17; Col 32; 23pp; English.	
XX		XX		
CC	The present sequence is that of an immunogenic peptide derived from human	CC	The present sequence is that of an immunogenic peptide derived from human	
CC	papillomavirus (HPV) type 16 E7 protein. The peptide is based on an	CC	papillomavirus (HPV) type 16 E7 protein. The peptide is based on an	
CC	immunogenic peptide (see AAB20196), identified in HPV type 16 E7 protein,	CC	immunogenic peptide (see AAB20196), identified in HPV type 16 E7 protein,	
CC	which contains multiple overlapping class I HLA-binding T-cell epitopes.	CC	which contains multiple overlapping class I HLA-binding T-cell epitopes.	
CC	It can be used to elicit an immune response against HPV E7 protein.	CC	It can be used to elicit an immune response against HPV E7 protein.	
CC	Claimed methods for inducing an immune response in a mammal involve	CC	Claimed methods for inducing an immune response in a mammal involve	
CC	administering a nucleic acid coding for a peptide comprising the present	CC	administering a nucleic acid coding for a peptide comprising the present	
CC	sequence, or involve administering a nucleic acid or Plasmid encoding a	CC	sequence, or involve administering a nucleic acid or Plasmid encoding a	
CC	polypeptide comprising first peptide which controls intracellular	CC	polypeptide comprising first peptide which controls intracellular	
CC	trafficking linked to a second peptide comprising the present sequence.	CC	trafficking linked to a second peptide comprising the present sequence.	
CC	The immunogenic peptides and nucleic acids of the invention are used as	CC	The immunogenic peptides and nucleic acids of the invention are used as	
CC	vaccines prophylactically or therapeutically in subjects having,	CC	vaccines prophylactically or therapeutically in subjects having,	
CC	suspected of having, or at risk of exophytic condyloma, flat condyloma,	CC	suspected of having, or at risk of exophytic condyloma, flat condyloma,	
CC	cervical cancer, respiratory papilloma, conjunctival papilloma, genital-	CC	cervical cancer, respiratory papilloma, conjunctival papilloma, genital-	
CC	tract HPV infection and cervical dysplasia (claimed)	CC	tract HPV infection and cervical dysplasia (claimed)	
SQ	Sequence 13 AA;	SQ	Sequence 13 AA;	
Query	100.0% Score 67; DB 4; Length 13;	Query	100.0% Score 67; DB 4; Length 13;	
Best Local Similarity	100.0% Pred. No 0.00044;	Best Local Similarity	100.0% Pred. No 0.00044;	
Matches	0; Mismatches 0; Indels 0; Gaps 0;	Matches	0; Mismatches 0; Indels 0; Gaps 0;	
Db	1 LMGTIGIVCPIC 12	Db	1 LMGTIGIVCPIC 12	
	2 LMGTIGIVCPIC 13		2 LMGTIGIVCPIC 13	
RESULT 13		RESULT 13		
AAB20206		AAB20206		
ID	standard; peptide; 13 AA.	ID	standard; peptide; 13 AA.	
XX		XX		
AC	AAB20199	AC	AAB20206;	
AC	AAB20199 standard; peptide; 13 AA.	AC		
AC		XX		
AC	AAB20199;	AC		
XX		XX		
DT	14-MAY-2001 (first entry)	DT	14-MAY-2001 (first entry)	
XX		XX		
HPV	type 16 E7 protein immunogenic peptide used in vaccine.	HPV	type 16 E7 protein immunogenic peptide used in vaccine.	
XX		XX		
Immunogenic peptide; immunogen: HPV; E7 protein; vaccine; infection;	Immunogenic peptide; immunogen: HPV; E7 protein; vaccine; infection;			
KW	gene therapy; exophytic condyloma; flat condyloma; cervical cancer;	KW	gene therapy; exophytic condyloma; flat condyloma; cervical cancer;	
KW	respiratory papilloma; conjunctival papilloma; cervical dysplasia.	KW	respiratory papilloma; conjunctival papilloma; cervical dysplasia.	
XX		XX		
Human	papillomavirus type 16.	Human	papillomavirus type 16.	
OS		OS		
XX		XX		
FH	Key Location/Qualifiers	PF	09-OCT-1998;	98US-00169425.
FT	Misc-difference 1	XX		
FT	/label= Met, Ala, Ser, Arg, Lys, Gln, Asp, Glu	PR	09-OCT-1997;	97US-0061657P.
FT	/note= "Xaa is Ala or Met in peptide of Claim 18"	XX		
XX		PA		
PN	US6183746-B1.	PA	(ZICO-)	ZYCOS INC.
XX		PA		
PD	06-FEB-2001.	PI	Urban RG, Chicz RM, Collins EJ, Hedley ML;	
XX		XX		
PF	09-OCT-1998;	XX		
XX	98US-00169425.	XX		
XX		XX		
PT	Inducing an immune response in a mammal for prophylaxis and treatment of	PT		

PT human papilloma virus infections such as cervical cancer, comprises  
 PT administering immunogenic peptides from the papilloma virus type 16 E7  
 PT protein.  
 XX Claim 27; Col 32; 23pp; English.  
 PS The present sequence is that of an immunogenic peptide derived from human  
 CC papillomavirus (HPV) type 16 E7 protein. The peptide is based on an  
 CC immunogenic peptide (ssse AAB20196), identified in HPV type 16 E7 protein,  
 CC which contains multiple overlapping class I HLA-binding T-cell epitopes.  
 CC It can be used to elicit an immune response against HPV E7 protein.  
 CC Claimed methods for inducing an immune response in a mammal involve  
 CC administering a nucleic acid coding for a peptide comprising the present  
 CC sequence, or involve administering a nucleic acid or plasmid encoding a  
 CC polypeptide comprising a first peptide which controls intracellular  
 CC trafficking linked to a second peptide comprising the present sequence.  
 CC The immunogenic peptides and nucleic acids of the invention are used as  
 CC vaccines prophylactically or therapeutically in subjects having,  
 CC suspected of having, or at risk of exophytic condyloma, flat condyloma,  
 CC cervical cancer, respiratory papilloma, conjunctival papilloma, genital-  
 CC tract HPV infection and cervical dysplasia (claimed)  
 XX Sequence 13 AA;

Query Match 100.0%; Score 67; DB 4; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00044;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 LMGTGIVCPIC 12  
 Db 2 LMGTGIVCPIC 13

RESULT 14  
 ABU96663 ID ABU96663 standard; peptide; 13 AA.  
 XX AC ABU96663;  
 XX DT 12-AUG-2003 (first entry)  
 XX DE MHC class I overlapping peptide.

XX Microparticle; microsphere; polynucleotide delivery; phagocytic cell;  
 KW tumour; viral infection; bacterial infection; fungal infection;  
 KW protozoan infection; gene therapy; major histocompatibility complex;  
 KW MHC class I.  
 XX OS Synthetic.  
 XX PN US2002182258-A1.  
 XX PD 05-DEC-2002.  
 XX PP 18-JUL-2001; 2001US-00909460.  
 XX PR 22-JAN-1997; 97US-00359831P.  
 PR 06-JAN-1998; 98US-0003233.  
 PR 22-JAN-1998; 98WO-US001439.  
 PR 11-MAR-1999; 99US-00266463.  
 PR 27-MAY-1999; 99US-00321346.  
 XX PA (ZYCO) - ZYCO INC.  
 XX Lunsford LB, Putnam D, Hedley ML;  
 XX DR WPI; 2003-438782/41.

XX Microparticles, useful as vehicles for delivery of polynucleotides to  
 PT phagocytic cells, comprises polymeric matrix, lipid, and nucleic acid  
 PR molecule.  
 XX Disclosure; Page 6; 37pp; English.

XX The invention relates to a microparticle (microsphere) less than 20  
 CC microns in diameter that comprises: (1) a polymeric matrix; (2) a lipid;  
 CC and (3) a nucleic acid molecule. The microparticle is not encapsulated in  
 CC a cell. The nucleic acid molecule and the microparticle does not comprise a cell. The  
 CC microparticles are used as vehicles for the delivery of polynucleotides  
 CC into phagocytic cells. The microparticles can be used to express antigens  
 CC to treat tumour cells, bacterial, fungal or protozoan  
 CC infections. The microparticles can be made without adversely affecting  
 CC nucleic acid integrity. The present sequence represents the amino acid  
 CC sequence of a major histocompatibility complex, MHC, class I associated  
 CC peptide.  
 XX Sequence 13 AA;

Query Match 100.0%; Score 67; DB 6; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00044;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 LMGTGIVCPIC 12  
 Db 2 LMGTGIVCPIC 13

RESULT 15  
 AAO16633 ID AAO16633 standard; peptide; 14 AA.  
 XX AC AAO16633;  
 XX DT 15-MAY-2003 (first entry)  
 XX DB Human papillomavirus E7 antigen-related peptide #3.  
 XX KW Epitope; E7 antigen; CD4-positive T cell activation;  
 XX KW uterine cancer lesion.  
 XX OS Unidentified.  
 XX PN WO2002100889-A1.  
 XX PD 19-DEC-2002.  
 XX PP 10-JUN-2002; 2002WO-JP005747.  
 XX PR 08-JUN-2001; 2001JP-00173803.  
 XX PA (KIRI ) KIRIN BEER KK.  
 XX PI Maeda H, Okubo M;  
 XX DR WPI; 2003-156946/15.  
 XX PT Novel epitope of human papilloma virus' E7 antigen capable of activating  
 CC CD4-positive T cells specific to (pre-)uterine cancer lesion, applicable  
 PT in drug compositions for preventing and treating uterine cancer.  
 XX PS Example 4; Page 19; 40pp; Japanese.  
 XX PT The invention comprises an epitope of the human papillomavirus E7 antigen  
 CC that is capable of activating CD4-positive T cells that are specific to  
 CC uterine cancer lesions. The epitope of the invention is useful for  
 CC preventing and treating uterine cancer. The present amino acid sequence  
 CC represents a peptide that was used in an example of the invention  
 XX Sequence 14 AA;

Query Match 100.0%; Score 67; DB 6; Length 14;  
 Best Local Similarity 100.0%; Pred. No. 0.00047;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 LMGTGIVCPIC 12  
 Db 2 LMGTGIVCPIC 13

Db 2 LMGTGIVCPIC 13

Search completed: August 19, 2005, 23:29:44  
Job time : 78.8649 secs

---

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 19, 2005, 23:24:59 ; Search time 12 Seconds  
(without alignments)  
74.649 Million cell updates/sec

Title: US-10-603-062-16  
Perfect score: 67  
Sequence: 1 LMGTGIVCPIC 12

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen Parameters: 513545

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 1.0%  
Maximum Match 10.0%  
Listing first 45 summaries

Database : Issued Patents AA:  
1: /cgn2\_6/ptodata/1/iaas/5A\_COMB.pep:  
2: /cgn2\_6/ptodata/1/iaas/5B\_COMB.pep:  
3: /cgn2\_6/ptodata/1/iaas/6A\_COMB.pep:  
4: /cgn2\_6/ptodata/1/iaas/6B\_COMB.pep:  
5: /cgn2\_6/ptodata/1/iaas/PCRTUS\_COMB.pep:  
6: /cgn2\_6/ptodata/1/iaas/backfile1.pep:  
\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	67	100.0	12	3 US-08-948-378A-16	Sequence 16, Appl
2	67	100.0	12	3 US-09-168-425C-16	Sequence 16, Appl
3	67	100.0	12	4 US-09-759-960-16	Sequence 16, Appl
4	67	100.0	13	3 US-08-948-378A-3	Sequence 3, Appl
5	67	100.0	13	3 US-08-948-378A-4	Sequence 4, Appl
6	67	100.0	13	3 US-08-948-378A-19	Sequence 19, Appl
7	67	100.0	13	3 US-09-168-425C-3	Sequence 3, Appl
8	67	100.0	13	3 US-09-168-425C-4	Sequence 4, Appl
9	67	100.0	13	3 US-09-168-425C-19	Sequence 19, Appl
10	67	100.0	13	4 US-09-759-960-3	Sequence 3, Appl
11	67	100.0	13	4 US-09-759-960-4	Sequence 4, Appl
12	67	100.0	13	4 US-09-759-960-19	Sequence 19, Appl
13	67	100.0	15	3 US-08-339A-1168	Sequence 16.8, Appl
14	67	100.0	16	3 US-09-168-425C-25	Sequence 25, Appl
15	67	100.0	16	4 US-09-759-960-25	Sequence 25, Appl
16	67	100.0	19	4 US-09-988-523A-18	Sequence 18, Appl
17	67	100.0	20	3 US-08-075-541D-50	Sequence 50, Appl
18	67	100.0	21	2 US-08-934-915-50	Sequence 50, Appl
19	67	100.0	21	4 US-09-980-177A-76	Sequence 76, Appl
20	67	100.0	21	3 US-08-075-541D-40	Sequence 40, Appl
21	67	100.0	28	4 US-09-488-394-5	Sequence 5, Appl
22	67	100.0	30	3 US-08-938-915-54	Sequence 54, Appl
23	67	100.0	38	3 US-08-948-378A-6	Sequence 6, Appl
24	67	100.0	38	3 US-09-168-425C-6	Sequence 6, Appl
25	67	100.0	38	4 US-09-759-960-6	Sequence 6, Appl
26	67	100.0	98	1 US-08-406-248-6	Sequence 6, Appl
27	67	100.0	98	3 US-08-075-541D-42	Sequence 42, Appl

## ALIGNMENTS

RESULT 1  
US-08-948-378A-16  
; Sequence 16, Application US/08948378A  
; Patent No. 6013258

GENERAL INFORMATION:  
; APPLICANT: Urban, Robert G.  
; APPLICANT: Chicz, Roman M.  
; APPLICANT: Collins, Edward J.  
; APPLICANT: Hedley, Mary Lynn  
; TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM  
; TITLE OF INVENTION: THE HPV E7 PROTEIN  
; NUMBER OF SEQUENCES: 19  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson, P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: US  
; ZIP: 02110-2804

COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: Windows95  
; SOFTWARE: FASTSEQ for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/948,378A  
; FILING DATE: 09-OCT-1997  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Fraser, Janis K.  
; REGISTRATION NUMBER: 34,819  
; REFERENCE/DOCKET NUMBER: 08191/004001  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-543-5070  
; TELEFAX: 617-543-8906  
; TELEX: 200154  
; INFORMATION FOR SEQ ID NO: 16:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 12 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-948-378A-16

Query Match 100.0%; Score 67; DB 3; Length 12;  
Best Local Similarity 100.0%; Pred. No. 0.00014;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LMGTLGIVCPIC 12  
 1 ||||| |||||  
 Db 1 LMGTLGIVCPIC 12

RESULT 2  
 US-09-169-425C-16  
 ; Sequence 16, Application US/09169425C  
 ; GENERAL INFORMATION:  
 ; Patent No. 6183746  
 ; APPLICANT: Urban, Robert G.  
 ; APPLICANT: Chicz, Roman M.  
 ; APPLICANT: Collins, Edward J.  
 ; APPLICANT: Hedley, Mary Lynn  
 ; TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM THE HPV E7  
 ; NUMBER OF SEQUENCES: 33  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Fish & Richardson, P.C.  
 ; STREET: 225 Franklin Street  
 ; CITY: Boston  
 ; STATE: MA  
 ; ZIP: 02110-2804  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Diskette  
 ; COMPUTER: IBM Compatible  
 ; OPERATING SYSTEM: Windows95  
 ; SOFTWARE: FastSEQ for Windows Version 2.0  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/09/759,960  
 ; FILING DATE:  
 ; PRIORITY APPLICATION DATA:  
 ; APPLICATION NUMBER: 09/169,425  
 ; FILING DATE:  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Fraser, Janis K.  
 ; REGISTRATION NUMBER: 34,819  
 ; REFERENCE/DOCKET NUMBER: 08191/004002  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 617-542-5070  
 ; TELEFAX: 617-543-8906  
 ; TELEX: 200154  
 ; INFORMATION FOR SEQ ID NO: 16:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 12 amino acids  
 ; TYPE: amino acid  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: Peptide  
 ; US-09-759-960-16

Query Match Score 100.0%; DB 4; Length 12;  
 Best Local Similarity 100.0%; Pred. No. 0.00014;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LMGTLGIVCPIC 12  
 Db 1 LMGTLGIVCPIC 12

RESULT 4  
 US-08-948-378A-3  
 ; Sequence 3, Application US/08948378A  
 ; Patent No. 6013458  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Urban, Robert G.  
 ; APPLICANT: Chicz, Roman M.  
 ; APPLICANT: Collins, Edward J.  
 ; APPLICANT: Hedley, Mary Lynn  
 ; TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM  
 ; NUMBER OF SEQUENCES: 19  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Fish & Richardson, P.C.  
 ; STREET: 225 Franklin Street  
 ; CITY: Boston  
 ; STATE: MA  
 ; ZIP: 02110-2804  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Diskette  
 ; COMPUTER: IBM Compatible  
 ; OPERATING SYSTEM: Windows95  
 ; SOFTWARE: FastSEQ for Windows Version 2.0  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/948,378A  
 ; FILING DATE: 09-OCT-1997  
 ; PRIORITY APPLICATION DATA:  
 ; APPLICATION NUMBER:  
 ; FILING DATE:  
 ; ATTORNEY/AGENT INFORMATION:  
 ; CORRESPONDENCE ADDRESS:

Qy 1 LMGTLGIVCPIC 12  
 1 ||||| |||||  
 Db 1 LMGTLGIVCPIC 12

RESULT 3  
 US-09-759-960-16  
 ; Sequence 16, Application US/09759960  
 ; Patent No. 6582704  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Urban, Robert G.  
 ; APPLICANT: Chicz, Roman M.  
 ; APPLICANT: Collins, Edward J.  
 ; APPLICANT: Hedley, Mary Lynn  
 ; TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM THE HPV E7  
 ; NUMBER OF SEQUENCES: 33  
 ; CORRESPONDENCE ADDRESS:

NAME: Fraser, Janis K.  
 REGISTRATION NUMBER: 34,819  
 REFERENCE/DOCKET NUMBER: 08191/004001  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 617-542-5070  
 TELEX: 200154  
 INFORMATION FOR SEQ ID NO: 3:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 13 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: peptide  
 US-08-948-378A-3

Query Match 100.0%; Score 67; DB 3; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00015;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 LMGTGIVCPIC 12  
 Db 2 LMGTGIVCPIC 13

RESULT 5  
 US-08-948-378A-4

Query Match 100.0%; Score 67; DB 3; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00015;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 LMGTGIVCPIC 12  
 Db 2 LMGTGIVCPIC 13

RESULT 5  
 US-08-948-378A-4

Query Match 100.0%; Score 67; DB 3; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00015;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

NAME: Fraser, Janis K.  
 REGISTRATION NUMBER: 34,819  
 REFERENCE/DOCKET NUMBER: 08191/004001  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 617-542-5070  
 TELEX: 200154  
 INFORMATION FOR SEQ ID NO: 4:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 13 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: peptide  
 US-08-948-378A-3

Query Match 100.0%; Score 67; DB 3; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00015;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 6  
 US-08-948-378A-19

Query Match 100.0%; Score 67; DB 3; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00015;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LMGTGIVCPIC 12  
 Db 2 LMGTGIVCPIC 13

RESULT 7  
 US-09-169-425C-3

Query Match 100.0%; Score 67; DB 3; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00015;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LMGTGIVCPIC 12  
 Db 2 LMGTGIVCPIC 13

RESULT 7  
 US-09-169-425C-3

Query Match 100.0%; Score 67; DB 3; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00015;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

APPLICANT: Collins, Edward J.  
 APPLICANT: Hedley, Mary Lynn  
 TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM THE HPV E7  
 NUMBER OF SEQUENCES: 33  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEES: Fish & Richardson, P.C.  
 STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: MA  
 ZIP: 02110-2804  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Discrete  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: Windows95  
 SOFTWARE: FastSEQ for Windows Version 2.0  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/09/169,425C  
 FILING DATE: 09-OCT-1998  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: 60/061,657  
 FILING DATE: 09-OCT-1997  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Fraser, Janis K.  
 REGISTRATION NUMBER: 34,819  
 REFERENCE/DOCKET NUMBER: 08191/004002  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 617-542-5070  
 TELEX: 617-543-8906  
 TELEX: 200154  
 INFORMATION FOR SEQ ID NO: 3:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 13 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: peptide  
 US-09-169-425C-4

RESULT 8  
 US-09-169-425C-4  
 Sequence 4, Application US/09169425C  
 Patent No. 6183746  
 GENERAL INFORMATION:  
 ATTORNEY/AGENT INFORMATION:  
 APPLICANT: Urban, Robert G.  
 APPLICANT: Chicz, Roman M.  
 APPLICANT: Collins, Edward J.  
 APPLICANT: Hedley, Mary Lynn  
 TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM THE HPV E7  
 NUMBER OF SEQUENCES: 33  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEES: Fish & Richardson, P.C.  
 STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: MA  
 ZIP: 02110-2804  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Diskette  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: Windows95  
 SOFTWARE: FastSEQ for Windows Version 2.0  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/09/169,425C  
 FILING DATE: 09-OCT-1998  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Fraser, Janis K.  
 REGISTRATION NUMBER: 34,819  
 REFERENCE/DOCKET NUMBER: 08191/004002  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 617-542-5070  
 TELEX: 617-543-8906  
 INFORMATION FOR SEQ ID NO: 19:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 13 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear

MOLECULE TYPE: Peptide  
 FEATURE: Other  
 LOCATION: 1..1  
 OTHER INFORMATION: where Xaa at position 1 is Met, Ala, Ser, Arg, Lys, Glu, Asp, or Glu  
 OTHER INFORMATION: US-09-169-425-19

Query Match 100.0%; Score 67; DB 3; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00015;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 LMGTIGIVCPIC 12  
 Db 2 LMGTIGIVCPIC 13

US-09-759-960-4  
 Sequence 4, Application US/09759960  
 Patent No. 6582704

GENERAL INFORMATION:  
 APPLICANT: Urban, Robert G.  
 APPLICANT: Chicz, Roman M.  
 APPLICANT: Collins, Edward J.  
 APPLICANT: Hedley, Mary Lynn

TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM THE HPV E7  
 TITLE OF INVENTION: PROTEIN  
 NUMBER OF SEQUENCES: 33  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Fish & Richardson, P.C.  
 STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: MA  
 COUNTRY: US  
 ZIP: 02110-2804

COMPUTER READABLE FORM:  
 MEDIUM TYPE: Diskette  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: Windows95  
 SOFTWARE: Fasseq for Windows Version 2.0

CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/09/759,960  
 FILING DATE:  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: 09/169,425  
 FILING DATE:  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Fraser, Janis K.  
 REGISTRATION NUMBER: 34,819  
 REFERENCE/DOCKET NUMBER: 08191/004002

TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 617-542-5070  
 TELEFAX: 617-543-8906  
 TELEX: 200154

INFORMATION FOR SEQ ID NO: 4:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 13 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: peptide

US-09-759-960-4  
 Query Match 100.0%; Score 67; DB 4; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00015;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 12  
 US-09-759-960-19  
 Sequence 19, Application US/09759960  
 Patent No. 6582704

GENERAL INFORMATION:  
 APPLICANT: Urban, Robert G.  
 APPLICANT: Chicz, Roman M.  
 APPLICANT: Collins, Edward J.  
 APPLICANT: Hedley, Mary Lynn

TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM THE HPV E7  
 TITLE OF INVENTION: PROTEIN  
 NUMBER OF SEQUENCES: 33  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Fish & Richardson, P.C.  
 STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: MA  
 COUNTRY: US  
 ZIP: 02110-2804

1 LMGTIGIVCPIC 12  
 2 LMGTIGIVCPIC 13

RESULT 11  
 1 LMGTIGIVCPIC 12  
 2 LMGTIGIVCPIC 13

Qy Db

RESULT 11  
 1 LMGTIGIVCPIC 12  
 2 LMGTIGIVCPIC 13

Qy Db

RESULT 11

```

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Disquette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/759, 960
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/169, 425
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Fraser, Janis K.
; REGISTRATION NUMBER: 34, 819
; REFERENCE/DOCKET NUMBER: 09191/004002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-543-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; LOCATION: 1...1
; OTHER INFORMATION: where Xaa at position 1 is Met, Ala, Ser,
; NAME/KEY: Other
; OTHER INFORMATION: Arg, Lys, Gly, Gln, Asp, or Glu
US-09-759-960-19

; RESULT 13
; US-09-159-339A-1168
; Sequence 1168, Application US/08159339A
; Patent No. 6,037135
; GENERAL INFORMATION:
; APPLICANT: Kubo, Ralph T.
; APPLICANT: Grey, Howard M.
; APPLICANT: Sette, Alessandro
; APPLICANT: Celis, Esteban
; TITLE OF INVENTION: HLA Binding peptides and Their
; TITLE OF INVENTION: Uses
; NUMBER OF SEQUENCES: 1254
; CURRENT APPLICATION DATA:
; ADDRESS: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Disquette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/159, 339A
; FILING DATE: 29-NOV-1993
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/926, 666
; FILING DATE: 07-AUG-1992
; APPLICATION NUMBER: US 08/027, 746
; FILING DATE: 07-AUG-1992
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: Peptide
; FILING DATE: 07-AUG-1992
; APPLICATION NUMBER: US/09/759, 960
; FILING DATE: 07-AUG-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Weber, Ellen Lauver
; REGISTRATION NUMBER: 32, 762
; REFERENCE/DOCKET NUMBER: 018623-005030US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; TELEX:
; INFORMATION FOR SEQ ID NO: 1168:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-159-339A-1168

; RESULT 14
; US-09-169-445C-25
; Sequence 25, Application US/09169445C
; Patent No. 6,183746
; GENERAL INFORMATION:
; APPLICANT: Urban, Robert G.
; APPLICANT: Chicz, Roman M.
; APPLICANT: Collins, Edward J.
; APPLICANT: Hedley, Mary Lynn
; TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM THE HPV E7
; TITLE OF INVENTION: PROTEIN
; NUMBER OF SEQUENCES: 33
; CURRENT APPLICATION DATA:
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/169, 425C
; FILING DATE: 09-OCT-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 6,0/061, 657
; FILING DATE: 09-OCT-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Fraser, Janis K.
; REGISTRATION NUMBER: 34, 819
; REFERENCE/DOCKET NUMBER: 08191/004002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-543-8906
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: Peptide
; FILING DATE: 07-AUG-1992
; APPLICATION NUMBER: US/08/159, 339A
; FILING DATE: 07-AUG-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Weber, Ellen Lauver
; REGISTRATION NUMBER: 32, 762
; REFERENCE/DOCKET NUMBER: 018623-005030US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; TELEX:
; INFORMATION FOR SEQ ID NO: 1168:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-159-339A-1168

```

US-09-169-425C-25

Query Match 100.0%; Score 67; DB 3; Length 16;  
 Best Local Similarity 100.0%; Pred. No. 0.00018;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LMGTGIVCPIC 12

Db 2 LMGTGIVCPIC 13

RESULT 15

US-09-759-960-25

Sequence 25, Application US/09759960

Patent No. 6592704

GENERAL INFORMATION:

APPLICANT: Urban, Robert G.

APPLICANT: Chicz, Roman M.

APPLICANT: Collins, Edward J.

APPLICANT: Hedley, Mary Lynn

TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM THE HPV E7

TITLE OF INVENTION: PROTEIN

NUMBER OF SEQUENCES: 33

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish &amp; Richardson, P.C.

STREET: 225 Franklin Street

CITY: Boston

STATE: MA

COUNTRY: US

ZIP: 02110-2604

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: Windows95

SOFTWARE: FastSEQ for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/759,960

FILING DATE:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 09/169,425

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Fraser, Janis K.

REGISTRATION NUMBER: 34,819

REFERENCE/DOCID: 08191/004002

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617-542-5070

TELEFAX: 617-543-8906

TELEX: 200154

INFORMATION FOR SEQ ID NO: 25:

SEQUENCE CHARACTERISTICS:

LENGTH: 16 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-09-759-960-25

Query Match 100.0%; Score 67; DB 4; Length 16;  
 Best Local Similarity 100.0%; Pred. No. 0.00018;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LMGTGIVCPIC 12

Db 2 LMGTGIVCPIC 13

Search completed: August 19, 2005, 23:35:15  
 Job time: 13 secs

This Page Blank (uspto)

Copyright (c) 1993 - 2005 Compugen Ltd.

GenCore version 5.1.6

4 protein - protein search, using sw model

Run on: August 19, 2005, 23:22:13 ; Search time 15:56:76 Seconds  
(without alignments)  
74.167 Million cell updates/sec

Title: US-10-603-062-16

Sequence: 1 LMGTGIVCPIC 12

Sequence: 2 DRCMTCVCPIC 12

Sequence: 3 DRCMTCVCPIC 12

Sequence: 4 DRCMTCVCPIC 12

Sequence: 5 DRCMTCVCPIC 12

Sequence: 6 DRCMTCVCPIC 12

Sequence: 7 DRCMTCVCPIC 12

Sequence: 8 DRCMTCVCPIC 12

Sequence: 9 DRCMTCVCPIC 12

Sequence: 10 DRCMTCVCPIC 12

Sequence: 11 DRCMTCVCPIC 12

Sequence: 12 DRCMTCVCPIC 12

Sequence: 13 DRCMTCVCPIC 12

Sequence: 14 DRCMTCVCPIC 12

Sequence: 15 DRCMTCVCPIC 12

Sequence: 16 DRCMTCVCPIC 12

Sequence: 17 DRCMTCVCPIC 12

Sequence: 18 DRCMTCVCPIC 12

Sequence: 19 DRCMTCVCPIC 12

Sequence: 20 DRCMTCVCPIC 12

Sequence: 21 DRCMTCVCPIC 12

Sequence: 22 DRCMTCVCPIC 12

Sequence: 23 DRCMTCVCPIC 12

Sequence: 24 DRCMTCVCPIC 12

Sequence: 25 DRCMTCVCPIC 12

Sequence: 26 DRCMTCVCPIC 12

Sequence: 27 DRCMTCVCPIC 12

Sequence: 28 DRCMTCVCPIC 12

Sequence: 29 DRCMTCVCPIC 12

Sequence: 30 DRCMTCVCPIC 12

Sequence: 31 DRCMTCVCPIC 12

Sequence: 32 DRCMTCVCPIC 12

Sequence: 33 DRCMTCVCPIC 12

Sequence: 34 DRCMTCVCPIC 12

Sequence: 35 DRCMTCVCPIC 12

Sequence: 36 DRCMTCVCPIC 12

Sequence: 37 DRCMTCVCPIC 12

Sequence: 38 DRCMTCVCPIC 12

Sequence: 39 DRCMTCVCPIC 12

Sequence: 40 DRCMTCVCPIC 12

Sequence: 41 DRCMTCVCPIC 12

Sequence: 42 DRCMTCVCPIC 12

Sequence: 43 DRCMTCVCPIC 12

Sequence: 44 DRCMTCVCPIC 12

Sequence: 45 DRCMTCVCPIC 12

R;Dartmann, K.; Schwarz, E.; Giessmann, L.; zur Hausen, H.  
 Virology 151, 124-130, 1986  
 A;Title: The nucleotide sequence and genome organization of human papilloma virus type 1  
 A;Reference number: A94338; MUID:86181601; PMID:3008427

A;Molecule type: DNA  
 A;Accession: A03690  
 A;Residues: 1-98 <DAR>  
 A;Cross-references: UNIPROT:P04020; GB:MI4119; PID:9330326; PID:AAA46928.1; PID:9496194  
 C;Superfamily: papillomavirus E7 protein; zinc finger  
 C;Keywords: DNA binding; early protein; transcription regulation; zinc finger  
 F;58-94/Region: zinc finger CCCC motif

Query Match Score 86.6%; DB 1; Length 98;  
 Best Local Similarity 83.3%; Pred. No. 0.029;  
 Matches 10; Conservative 1; N mismatches 1; Indels 0; Gaps 0;

Qy 1 LMGTIGIVCPIC 12  
 Db 83 LLGTINIVCPIC 94

RESULT 3  
 W7N16  
 E7 protein - human papillomavirus type 6b  
 C;Species: human papillomavirus type 6b  
 C;Accession: D20558  
 C;Cross-references: D20558  
 R;Schwarz, E.; Dürst, M.; Demankowski, C.; Lattermann, O.; Zech, R.; Wolfsperger, E.; Su  
 EMBL J. 23:1-23:8. 1983  
 A;Title: DNA sequence and genome organization of genital human papillomavirus type 6b.  
 A;Reference number: A90975; MUID:84131949; PMID:6321162

A;Accession: D20558  
 A;Molecule type: DNA  
 A;Residues: 1-98 <SCH>  
 A;Cross-references: UNIPROT:P06464; GB:X00203; NID:960955; PID:CAA25019.1; PID:960957  
 C;Superfamily: papillomavirus E7 protein  
 C;Keywords: DNA binding; early protein; transcription regulation; zinc finger  
 F;58-94/Region: zinc finger CCCC motif

Query Match Score 86.6%; DB 1; Length 98;  
 Best Local Similarity 83.3%; Pred. No. 0.029;  
 Matches 10; Conservative 1; N mismatches 1; Indels 0; Gaps 0;

Qy 1 LMGTIGIVCPIC 12  
 Db 83 LLGTINIVCPIC 94

RESULT 4  
 W7N13  
 E7 protein - human papillomavirus type 13  
 C;Species: human papillomavirus type 13  
 C;Accession: B42955  
 C;Cross-references: EMBL:X74477; NID:9396997; PID:CAA52562.1; PID:939699  
 R;van Ranst, M.; Fiten, P.; Beuken, E.; Pfister, H.; Burk, R.D.; Opdenakker, G  
 Virology 190, 587-596, 1992  
 A;Title: Human papillomavirus type 13 and pygmy chimpanzee papillomavirus type 1: Comparison  
 A;Reference number: A42955; MUID:1325597  
 A;Accession: B42955  
 A;Molecule type: DNA  
 A;Residues: 1-101 <VAN>  
 A;Cross-references: UNIPROT:Q02271; EMBL:X62843; NID:960295; PID:CAA44648.1; PID:960297  
 C;Superfamily: papillomavirus E7 protein  
 C;Keywords: DNA binding; early protein; transcription regulation; zinc finger  
 F;61-97/Region: zinc finger CCCC motif

Query Match Score 83.6%; DB 1; Length 101;  
 Best Local Similarity 75.0%; Pred. No. 0.061;  
 Matches 9; Conservative 2; N mismatches 1; Indels 0; Gaps 0;

Qy 1 LMGTIGIVCPIC 12

C;Species: human papillomavirus type 32  
C;Date: 20-Feb-1995 #sequence\_revision 20-Feb-1995 #text\_change 09-Jul-2004  
C;Accession: S36510  
R;Delius, H.; Hofmann, B.  
Submitted to the EMBL Data Library, August 1993  
A;Description: Primer-directed sequencing of human papillomavirus types.  
A;Reference number: S36469  
A;Accession: S36510  
A;Molecule type: DNA  
A;Residues: 1-104 <DBL>  
A;Cross-references: UNIPROT:P36827; EMBL:X74475; PIDN:CAA52550.1; PID:93969  
C;Superfamily: Papillomavirus E7 protein  
C;Keywords: DNA binding; early protein; transcription regulation

Query Match 82.1%; Score 55; DB 2; Length 104;  
Best Local Similarity 75.0%; Pred. No. 0.09;  
Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
Db 99 LMGTGIVCPIC 12  
Db 99 LMGTGIVCPIC 100

## RESULT 8

S36585 E7 protein - human papillomavirus type 7  
C;Species: human papillomavirus type 7  
C;Date: 20-Feb-1995 #sequence\_revision 20-Feb-1995 #text\_change 09-Jul-2004  
R;Delius, H.; Hofmann, B.  
Submitted to the EMBL Data Library, August 1993  
A;Description: Primer-directed sequencing of human papillomavirus types.  
A;Reference number: S36469  
A;Accession: S36585  
A;Molecule type: DNA  
A;Residues: 1-111 <DBL>  
A;Cross-references: UNIPROT:P36816; EMBL:X74463; PID:9397060; PIDN:CAA52477.1; PID:93970  
C;Superfamily: Papillomavirus E7 protein  
C;Keywords: DNA binding; early protein; transcription regulation

Query Match 80.4%; Score 54; DB 2; Length 111;  
Best Local Similarity 83.3%; Pred. No. 0.14;  
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Db 96 LMGTGIVCPIC 12  
Db 96 LMGTGIVCPNC 107

## RESULT 9

W7WLR1 E7 protein - rhesus papillomavirus (type 1)  
C;Species: rhesus Papillomavirus  
C;Date: 31-Dec-1991 #sequence\_revision 31-Dec-1991 #text\_change 09-Jul-2004  
C;Accession: B38503  
R;Ostrow, R. S.; LaBresh, K. V.; Paras, A. J.  
Virology 181, 424-429, 1991  
A;Title: Characterization of the complete RhoPV 1 genomic sequence and an integration loc  
A;Reference number: A38503; PMID:91135018; PMID:1847267  
A;Accession: B38503  
A;Status: translation not shown  
A;Molecule type: DNA  
A;Residues: 1-113 <OST>  
A;Cross-references: UNIPROT:P22161; EMBL:M37717  
C;Superfamily: Papillomavirus E7 protein  
C;Keywords: DNA binding; early protein; transcription regulation

Query Match 80.6%; Score 54; DB 1; Length 113;  
Best Local Similarity 83.3%; Pred. No. 0.14;  
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Db 1 LMGTGIVCPIC 12  
Db 1 LMGTGIVCPIC 94

RESULT 10  
S19907 E7 protein - human papillomavirus type 33  
C;Species: human papillomavirus type 33  
C;Date: 30-Jun-1992 #sequence\_revision 30-Jun-1992 #text\_change 09-Jul-2004  
C;Accession: S19907  
R;Snijders, P.J.F.; van den Brule, A.J.C.; Schrijnemakers, H.F.J.; Raaphorst, P.M.C.; Me  
submitted to the EMBL Data Library, January 1992  
A;Description: HPV type 33 in a tonsillar carcinoma generates its putative E7 mRNA via t  
A;Reference number: S19907  
A;Accession: S19907  
A;Molecule type: mRNA  
A;Residues: 1-55 <SN>  
A;Cross-references: UNIPROT:Q81886; EMBL:X64086;  
C;Superfamily: Papillomavirus E7 protein  
C;Keywords: early protein

Query Match 79.1%; Score 53; DB 2; Length 55;  
Best Local Similarity 75.0%; Pred. No. 0.11;  
Matches 9; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
Db 1 LMGTGIVCPIC 12  
Db 41 LMGTGIVCPIC 52

RESULT 11  
W7WLR1 E7 protein - human papillomavirus type 33  
C;Species: human papillomavirus type 33  
C;Date: 30-Jun-1987 #sequence\_revision 30-Jun-1987 #text\_change 09-Jul-2004  
C;Accession: A03682; S23827  
R;Cole, S.T.; Streeck, R.E.  
J. Virol. 58, 991-995, 1986  
A;Title: Genome organization and nucleotide sequence of human papillomavirus type 33, wh  
A;Reference number: A93020; PMID:6200464; PMID:3009902  
A;Accession: A03682  
A;Molecule type: DNA  
A;Residues: 1-97 <COL>  
A;Cross-references: UNIPROT:B06429; GB:M12732; PID:9333049; PID:AAA6959.1; PID:9463178  
C;Superfamily: Papillomavirus E7 protein  
C;Keywords: DNA binding; early protein; transcription regulation; zinc finger  
F;58-94/Region: zinc finger CCCC motif  
A;Description: HPV type 33 in a tonsillar carcinoma generates its putative E7 mRNA via t  
A;Reference number: S19906  
A;Accession: S23831  
A;Status: preliminary  
A;Molecule type: mRNA  
A;Residues: 1-97 <SN>  
A;Cross-references: EMBL:X64085; PID:90278; PIDN:CAA45434.1; PID:EMBL:X64084; N  
C;Superfamily: Papillomavirus E7 protein  
C;Keywords: DNA binding; early protein; transcription regulation; zinc finger  
F;58-94/Region: zinc finger CCCC motif

Query Match 79.1%; Score 53; DB 1; Length 97;  
Best Local Similarity 75.0%; Pred. No. 0.18;  
Matches 9; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
Db 1 LMGTGIVCPIC 12  
Db 83 LMGTGIVCPIC 94

RESULT 12  
W7WLC1 E7 protein - pygmy chimpanzee papillomavirus (type 1)  
C;Species: pygmy chimpanzee papillomavirus  
C;Date: 30-Jun-1993 #sequence\_revision 30-Jun-1993 #text\_change 16-Jul-1999  
C;Accession: B36818  
R;van Ranst, M.; Fueb, A.; Fiten, P.; Beuken, E.; Pfister, H.; Burk, R.D.; Opdenakker, C  
Virology 190, 587-596, 1992

A;Title: Human papillomavirus type 13 and pygmy chimpanzee papillomavirus type 1: Comparison  
 A;Reference number: A42935; MUID:32391075; PMID:1325897

A;Accession: B36818  
 A;Molecule type: DNA  
 A;Residues: 1-98 <GOL>  
 A;Cross-references: EMBL:X62844; NID:961010; PIDN:CAA44656.1; PID:961012  
 C;Species: human papillomavirus type 53  
 C;Comment: This protein may be involved in the oncogenic potential of this virus.  
 C;Superfamily: papillomavirus E7 protein  
 C;Keywords: DNA binding; early protein; transcription regulation; transforming protein;  
 P;Region: zinc finger CCCC motif

Query Match 77.6%; Score 52; DB 1; Length 98;  
 Best Local Similarity 66.7%; Pred. No. 0.25;  
 Matches 8; Conservative 3; Mismatches 1; Indels 0; Gaps 0;  
 Qy 1 LMGTGIVCPIC 12  
 :||:|||:|||:  
 Db 83 LMGSNIVCPIC 94

RESULT 13  
 W7WNL31  
 E7 protein - human papillomavirus type 31  
 C;Species: human papillomavirus type 31  
 A;Note: host Homo sapiens (man)  
 C;Date: 31-Mar-1990 #sequence\_revision 31-Mar-1990 #text\_change 09-Jul-2004  
 C;Accession: B32444  
 R;Goldsbrough, M.D.; Disilvestre, D.; Temple, G.R.; Lorincz, A.T.  
 Virology 171, 306-311, 1989  
 A;Title: Nucleotide sequence of human papillomavirus type 31: a cervical neoplasia-associated virus  
 A;Reference number: A94398; MUID:892993478; PMID:254536  
 A;Accession: B32444  
 A;Status: translation not shown  
 A;Molecule type: DNA  
 A;Residues: 1-98 <GOL>  
 A;Cross-references: UNIPROT:PI7387; GB:J04453; NID:933048; PIDN:AAA46951.1; PID:9459917  
 C;Comment: This protein may be involved in the oncogenic potential of this virus.  
 C;Superfamily: papillomavirus E7 protein  
 C;Keywords: DNA binding; early protein; transcription regulation; zinc finger  
 P;Region: zinc finger CCCC motif

Query Match 77.6%; Score 52; DB 1; Length 98;  
 Best Local Similarity 75.0%; Pred. No. 0.25;  
 Matches 9; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
 Qy 1 LMGTGIVCPIC 12  
 :||:|||:|||:  
 Db 83 LMGSNIVCPIC 94

RESULT 14  
 S36528  
 E7 protein - human papillomavirus type 53  
 C;Species: human papillomavirus type 53  
 C;Date: 20-Feb-1995 #sequence\_revision 20-Feb-1995 #text\_change 09-Jul-2004  
 C;Accession: S36528  
 A;Accession: S36528  
 A;Molecule type: DNA  
 A;Residues: 1-105 <DEL>  
 A;Cross-references: UNIPROT:P36832; EMBL:X74482; NID:9397046; PIDN:CAA52592.1; PID:93970  
 C;Superfamily: papillomavirus E7 protein  
 C;Keywords: DNA binding; early protein; transcription regulation

Query Match 77.6%; Score 52; DB 2; Length 105;  
 Best Local Similarity 66.7%; Pred. No. 0.27;  
 Matches 8; Conservative 3; Mismatches 1; Indels 0; Gaps 0;  
 Qy 1 LMGTGIVCPIC 12  
 :||:|||:|||:  
 Db 90 LMGTGIVCPIC 101

Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 19, 2005, 23:33:49 ; Search time 69.4054 Seconds  
(without alignment) 67.704 Million cell updates/sec

Title: US-10-603-062-16  
Perfect score: 67  
Sequence: 1 LMCTLGIVCPIC 12

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1759131 seqs, 391586102 residues

Total number of hits satisfying chosen parameters: 1759131

Minimum DB Seq length: 0

Maximum DB Seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%  
Listing first 45 summaries

Published Applications AA:\*

1: /cgn2\_6/\_picodata/2/\_pubpaas/US07\_PUBCOMB.pep:\*

2: /cgn2\_6/\_picodata/2/\_pubpaas/US06\_NEW\_PUB.pep:\*

3: /cgn2\_6/\_picodata/2/\_pubpaas/US06\_NEW\_PUB.pep:\*

4: /cgn2\_6/\_picodata/2/\_pubpaas/US06\_PUBCOMB.pep:\*

5: /cgn2\_6/\_picodata/2/\_pubpaas/\_PCTUS\_PUBCOMB.pep:\*

6: /cgn2\_6/\_picodata/2/\_pubpaas/\_NEW\_PUB.pep:\*

7: /cgn2\_6/\_picodata/2/\_pubpaas/\_NEW\_PUB.pep:\*

8: /cgn2\_6/\_picodata/2/\_pubpaas/\_NEW\_PUBCOMB.pep:\*

9: /cgn2\_6/\_picodata/2/\_pubpaas/\_US09A\_PUBCOMB.pep:\*

10: /cgn2\_6/\_picodata/2/\_pubpaas/\_US09C\_PUBCOMB.pep:\*

11: /cgn2\_6/\_picodata/2/\_pubpaas/\_US09C\_PUBCOMB.pep:\*

12: /cgn2\_6/\_picodata/2/\_pubpaas/\_US10\_NEW\_PUB.pep:\*

13: /cgn2\_6/\_picodata/2/\_pubpaas/\_US10A\_PUBCOMB.pep:\*

14: /cgn2\_6/\_picodata/2/\_pubpaas/\_US10C\_PUBCOMB.pep:\*

15: /cgn2\_6/\_picodata/2/\_pubpaas/\_US10C\_PUBCOMB.pep:\*

16: /cgn2\_6/\_picodata/2/\_pubpaas/\_US10D\_PUBCOMB.pep:\*

17: /cgn2\_6/\_picodata/2/\_pubpaas/\_US10E\_PUBCOMB.pep:\*

18: /cgn2\_6/\_picodata/2/\_pubpaas/\_US10\_NEW\_PUB.pep:\*

19: /cgn2\_6/\_picodata/2/\_pubpaas/\_US11A\_PUBCOMB.pep:\*

20: /cgn2\_6/\_picodata/2/\_pubpaas/\_US11A\_NEW\_PUB.pep:\*

21: /cgn2\_6/\_picodata/2/\_pubpaas/\_US60\_NEW\_PUB.pep:\*

22: /cgn2\_6/\_picodata/2/\_pubpaas/\_US60\_PUBCOMB.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	67	100.0	12	9 US-09-753-960-16	Sequence 16, Appl
2	67	100.0	12	16 US-10-603-062-16	Sequence 3, Appl
3	67	100.0	13	9 US-09-753-960-3	Sequence 4, Appl
4	67	100.0	13	9 US-09-753-960-4	Sequence 19, Appl
5	67	100.0	13	9 US-09-753-960-19	Sequence 110, Appl
6	67	100.0	13	9 US-09-900-460-110	Sequence 110, Appl
7	67	100.0	13	11 US-09-826-856-110	Sequence 3, Appl
8	67	100.0	13	16 US-10-603-062-3	Sequence 4, Appl
9	67	100.0	13	16 US-10-603-062-4	Sequence 19, Appl
10	67	100.0	13	16 US-10-603-062-19	Sequence 84, Appl
11	67	100.0	15	16 US-10-366-541-84	

ALIGNMENTS

RESULT 1  
US-09-759-960-16  
; Sequence 16, Application US/09759960  
; Patent No. US20010006639A1  
; GENERAL INFORMATION:  
; APPLICANT: Urban, Robert G.  
; APPLICANT: Chicz, Roman M.  
; APPLICANT: Collins, Edward J.  
; APPLICANT: Heiley, Mary Lynn  
; TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM THE HPV E7  
; TITLE OF INVENTION:  
; NUMBER OF SEQUENCES: 33  
; CORRESPONDENCE ADDRESS:  
; ADDRESS: Fish & Richardson, P. C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: US  
ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: Windows 95  
; SOFTWARE: FASTSEQ for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/759,960  
; FILING DATE:  
; PRIORITY APPLICATION DATA:  
; APPLICATION NUMBER: 09/169,425  
; FILING DATE:

ATTORNEY/AGENT INFORMATION:  
NAME: Faser, Janis K.  
REGISTRATION NUMBER: 34,819  
REFERENCE/DOCKET NUMBER: 08191/004002

TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 617-542-5070  
 TELEX: 200154  
 INFORMATION FOR SEQ ID NO: 16:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 12 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: peptide  
 US-09-759-960-16

RESULT 2  
 US-10-603-062-16  
 Query Match Score 67; DB 9; Length 12;  
 Best Local Similarity 100.0%; Pred. No. 0.00051;  
 Mismatches 0; Indels 0; Gaps 0;  
 Matches 12; Conservative 0; Mismatches 0;  
 Indels 0; Gaps 0;

Qy 1 LMGTGIVCPIC 12  
 Db 1 LMGTGIVCPIC 12

STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: MA  
 COUNTRY: US  
 ZIP: 02110-2804  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Diskette  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: Windows95  
 SOFTWARE: FastSEQ for Windows Version 2.0  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/09/759,960  
 PRIORITY NUMBER: 09/169,425  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: 09/169,425  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Fraser, Janis K.  
 REGISTRATION NUMBER: 34,819  
 REFERENCE DOCKET NUMBER: 08191/004002  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 617-542-5070  
 TELEFAX: 617-543-8906  
 TELEX: 200154  
 INFORMATION FOR SEQ ID NO: 3:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 13 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: peptide  
 US-09-759-960-3

Query Match Similarity 100.0%; Score 67; DB 9; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00055; Mismatches 0; Indels 0;

Qy 1 LMGTGIVCPIC 12  
 Db 2 LMGTGIVCPIC 13

RESULT 3  
 US-09-759-960-3  
 Sequence 3, Application US/09759960  
 Patent No. US2010006639A1  
 GENERAL INFORMATION:  
 APPLICANT: Urban, Robert G.  
 APPLICANT: Chicz, Roman M.  
 APPLICANT: Collins, Edward J.  
 APPLICANT: Hedley, Mary Lynn  
 TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM THE HPV E7  
 TITLE OF INVENTION: PROTEIN  
 NUMBER OF SEQUENCES: 33  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Fish & Richardson, P.C.  
 STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: MA  
 COUNTRY: US  
 ZIP: 02110-2804  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Diskette  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: Windows95  
 SOFTWARE: FastSEQ for Windows Version 2.0  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/10/603, 062  
 PRIORITY NUMBER: US/09/169, 425C  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: US/09/169, 425C  
 PRIORITY DATE: 24-Jun-2003  
 PRIORITY NUMBER: 09-OCT-1998  
 PRIORITY APPLICATION NUMBER: 09/169, 425C  
 PRIORITY DATE: 09-OCT-1997  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Fraser, Janis K.  
 REGISTRATION NUMBER: 34,819  
 REFERENCE DOCKET NUMBER: 08191/004002  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 617-542-5070  
 TELEFAX: 617-543-8906  
 TELEX: 200154  
 INFORMATION FOR SEQ ID NO: 16:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 12 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: peptide  
 SEQUENCE DESCRIPTION: SEQ ID NO: 16:  
 US-10-603-062-16

Query Match Similarity 100.0%; Score 67; DB 16; Length 12;  
 Best Local Similarity 100.0%; Pred. No. 0.00051; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LMGTGIVCPIC 12  
 Db 1 LMGTGIVCPIC 12

RESULT 4  
 US-09-759-960-4  
 Sequence 4, Application US/09759960  
 Patent No. US2010006639A1  
 GENERAL INFORMATION:  
 APPLICANT: Urban, Robert G.  
 APPLICANT: Chicz, Roman M.  
 APPLICANT: Collins, Edward J.  
 APPLICANT: Hedley, Mary Lynn  
 TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM THE HPV E7  
 TITLE OF INVENTION: PROTEIN  
 NUMBER OF SEQUENCES: 33  
 TITLE OF INVENTION: PROTEIN  
 NUMBER OF SEQUENCES: 33

CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Fish & Richardson, P.C.  
 STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: MA  
 COUNTRY: US  
 ZIP: 02110-2804  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Diskette  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: Windows 95  
 SOFTWARE: FastSEQ for Windows Version 2.0  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/09/759, 960  
 FILING DATE:  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: 09/169, 425  
 FILING DATE:  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Fraser, Janis K.  
 REGISTRATION NUMBER: 34, 819  
 REFERENCE/DOCKET NUMBER: 08191/004002  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 617-542-5070  
 TELEFAX: 617-543-8906  
 TELEX: 200154  
 INFORMATION FOR SEQ ID NO: 4:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 13 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: peptide  
 us-09-759-960-4

Query Match 100.0%; Score 67; DB 9; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00055;  
 Matches 12; Conservative 0; Mismatches 0;  
 Indels 0; Gaps 0;

Qy 1 LMGTGIVCPIC 12  
 Db 2 LMGTGIVCPIC 13

RESULT 5  
 us-09-759-960-19  
 Sequence 19, Application US/09759960  
 Patent No. US2001006632A1  
 GENERAL INFORMATION:  
 APPLICANT: Urban, Robert G.  
 APPLICANT: Chic, Roman M.  
 APPLICANT: Collins, Edward J.  
 APPLICANT: Hedley, Mary Lynn  
 TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM THE HPV B7  
 NUMBER OF SEQUENCES: 33  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Fish & Richardson, P.C.  
 STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: MA  
 COUNTRY: US  
 ZIP: 02110-2804  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Diskette  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: Windows 95  
 SOFTWARE: FastSEQ for Windows Version 2.0  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/09/759, 960  
 FILING DATE:  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: 09/169, 425  
 FILING DATE:

ATTORNEY/AGENT INFORMATION:  
 NAME: Fraser, Janis K.  
 REGISTRATION NUMBER: 34, 819  
 REFERENCE/DOCKET NUMBER: 08191/004002  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 617-542-5070  
 TELEFAX: 617-543-8906  
 TELEX: 200154  
 INFORMATION FOR SEQ ID NO: 19:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 13 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: peptide  
 FEATURE:  
 NAME/KEY: Other  
 LOCATION: 1...1  
 OTHER INFORMATION: where Xaa at position 1 is Met, Ala, Ser,  
 US-09-759-960-19

Query Match 100.0%; Score 67; DB 9; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00055;  
 Matches 12; Conservative 0; Mismatches 0;  
 Indels 0; Gaps 0;

Qy 1 LMGTGIVCPIC 12  
 Db 2 LMGTGIVCPIC 13

RESULT 6  
 US-09-909-460-110  
 Sequence 110, Application US/09909460  
 Publication No. US20020182258A1  
 GENERAL INFORMATION:  
 APPLICANT: Lunstford, Lynn B.  
 APPLICANT: Putnam, David  
 APPLICANT: Hedley, Mary Lynn  
 TITLE OF INVENTION: MICROPARTICLES FOR DELIVERY OF NUCLEIC  
 ACID  
 FILE REFERENCE: 08191/014001  
 CURRENT APPLICATION NUMBER: US/09/909, 460  
 PRIORITY APPLICATION NUMBER: 1999-05-27  
 SEQ ID NO 110  
 NUMBER OF SEQ ID NOS: 114  
 CURRENT FILING DATE: 2001-07-18  
 PRIORITY FILING DATE: 1999-05-27  
 SOFTWARE: FastSEQ for Windows Version 3.0  
 LENGTH: 13  
 TYPE: PRT  
 ORGANISM: Human papilloma virus  
 us-09-909-460-110

Query Match 100.0%; Score 67; DB 9; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00055;  
 Matches 12; Conservative 0; Mismatches 0;  
 Indels 0; Gaps 0;

Qy 1 LMGTGIVCPIC 12  
 Db 2 LMGTGIVCPIC 13

RESULT 7  
 US-09-872-836-110  
 Sequence 110, Application US/09872836  
 Publication No. US20040142475A1  
 GENERAL INFORMATION:  
 APPLICANT: Barmann, Shikha P.  
 APPLICANT: McKeever, Una  
 APPLICANT: Hedley, Mary Lynn  
 TITLE OF INVENTION: DELIVERY SYSTEMS FOR BIOACTIVE AGENTS  
 FILE REFERENCE: 08191-018001  
 CURRENT APPLICATION NUMBER: US/09/872, 836

CURRENT FILING DATE: 2001-06-01  
 PRIOR APPLICATION NUMBER: US 60/208,830  
 PRIOR FILING DATE: 2000-06-02  
 NUMBER OF SEQ ID NOS: 120  
 SOFTWARE: FastSEQ for Windows Version 4.0  
 SEQ ID NO: 110  
 LENGTH: 13  
 TYPE: PRT  
 ORGANISM: Homo sapiens  
 US-09-872-836-110

Query Match 100.0%; Score 67; DB 11; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00055;  
 Matches 12; Conservative 0; N mismatches 0; Indels 0; Gaps 0;  
 Qy 1 LMGTIGIVCPIC 12  
 Db 2 LMGTIGIVCPIC 13

RESULT 8  
 US-10-603-062-3  
 Sequence 3, Application US/10603062  
 Publication No. US20040229809A1  
 GENERAL INFORMATION:  
 APPLICANT: Urban, Robert G.  
 Chicz, Roman M.  
 Collins, Edward J.  
 Hedley, Mary Lynn  
 TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM THE HPV E7  
 NUMBER OF SEQUENCES: 33  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Fish & Richardson, P.C.  
 STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: MA  
 ZIP: 02110-2804  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Diskette  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: Windows95  
 SOFTWARE: FastSEQ for Windows Version 2.0  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/10/603,062  
 FILING DATE: 24-Jun-2003  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: US/09/169,425C  
 FILING DATE: 09-OCT-1998  
 APPLICATION NUMBER: 60/061,657  
 FILING DATE: 09-OCT-1997  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Fraser, Janis K.  
 REGISTRATION NUMBER: 34,819  
 REFERENCE/DOCKET NUMBER: 08191/004002  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 617-542-5070  
 TELEX: 617-543-8906  
 FAX: 200154

INFORMATION FOR SEQ ID NO: 4:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 13 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: peptide  
 SEQUENCE DESCRIPTION: SEQ ID NO: 4:  
 US-10-603-062-4  
 Query Match 100.0%; Score 67; DB 16; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00055;  
 Matches 12; Conservative 0; N mismatches 0; Indels 0; Gaps 0;  
 Qy 1 LMGTIGIVCPIC 12  
 Db 2 LMGTIGIVCPIC 13

RESULT 10  
 US-10-603-062-19  
 Sequence 19, Application US/10603062  
 Publication No. US20040229809A1  
 GENERAL INFORMATION:  
 APPLICANT: Urban, Robert G.  
 Chicz, Roman M.  
 Collins, Edward J.  
 Hedley, Mary Lynn  
 TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM THE HPV E7

Qy 1 LMGTIGIVCPIC 12  
 Db 2 LMGTIGIVCPIC 13  
 RESULT 9  
 US-10-603-062-4  
 Sequence 4, Application US/10603062  
 Publication No. US20040229809A1  
 GENERAL INFORMATION:  
 APPLICANT: Urban, Robert G.  
 Chicz, Roman M.  
 Collins, Edward J.  
 Hedley, Mary Lynn  
 TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM THE HPV E7  
 NUMBER OF SEQUENCES: 33  
 CORRESPONDENCE ADDRESS:  
 STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: MA  
 COUNTRY: US  
 ZIP: 02110-2804  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Diskette  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: Windows95  
 SOFTWARE: FastSEQ for Windows Version 2.0  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/10/603,062  
 FILING DATE: 24-Jun-2003  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: US/09/169,425C  
 FILING DATE: 09-OCT-1998  
 APPLICATION NUMBER: 60/061,657  
 FILING DATE: 09-OCT-1997  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Fraser, Janis K.  
 REGISTRATION NUMBER: 34,819  
 REFERENCE/DOCKET NUMBER: 08191/004002  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 617-542-5070  
 TELEX: 617-543-8906  
 FAX: 200154  
 IN INFORMATION FOR SEQ ID NO: 4:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 13 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: peptide  
 SEQUENCE DESCRIPTION: SEQ ID NO: 4:  
 US-10-603-062-4  
 Query Match 100.0%; Score 67; DB 16; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00055;  
 Matches 12; Conservative 0; N mismatches 0; Indels 0; Gaps 0;  
 Qy 1 LMGTIGIVCPIC 12  
 Db 2 LMGTIGIVCPIC 13  
 RESULT 10  
 US-10-603-062-19  
 Sequence 19, Application US/10603062  
 Publication No. US20040229809A1  
 GENERAL INFORMATION:  
 APPLICANT: Urban, Robert G.  
 Chicz, Roman M.  
 Collins, Edward J.  
 Hedley, Mary Lynn  
 TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM THE HPV E7

PROTBIN  
 NUMBER OF SEQUENCES: 33  
 CORRESPONDENCE ADDRESS: Fish & Richardson, P.C.  
 ADDRESS: 225 Franklin Street  
 STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: MA  
 COUNTRY: US  
 ZIP: 02110-2804

COMPUTER READABLE FORM:

PROTBIN  
 MEDIUM TYPE: Diskette  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: Windows95  
 SOFTWARE: FASTSEQ for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/10/603,062  
 FILING DATE: 24-Jun-2003

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/09/169,425C  
 FILING DATE: 09-OCT-1998  
 ATTORNEY/AGENT INFORMATION:

NAME: Fraser, Janis K.  
 REGISTRATION NUMBER: 34,819

REFERENCE/DOCKET NUMBER: 08191/004002

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617-542-5070  
 TELEX: 200154  
 FAX: 617-543-8906

INFORMATION FOR SEQ ID NO: 19:

SEQUENCE CHARACTERISTICS:

LENGTH: 13 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: peptide

FEATURE:

NAME/KEY: Other  
 LOCATION: 1..1  
 OTHER INFORMATION: where Xaa at position 1 is Met, Ala, Ser, Arg, Lys, Gln, Asp, or Glu

SEQUENCE DESCRIPTION: SEQ ID NO: 19:  
 US-10-603-062-19

Query Match 100.0%; Score 67; DB 16; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00055;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LMGTGIVCPIC 12  
 Db 2 LMGTGIVCPIC 13

RESULT 11  
 US-10-306-541-84  
 / Sequence 84, Application US/10306541  
 / Publication No. US2004017108A1  
 / GENERAL INFORMATION:  
 / APPLICANT: Mittelman, Abraham  
 / APPLICANT: Kanduc, Daria  
 / TITLE OF INVENTION: Improved Antigens  
 / FILE REFERENCE: 12354/4  
 / CURRENT APPLICATION NUMBER: US/10/306,541  
 / CURRENT FILING DATE: 2003-08-25  
 / PRIORITY APPLICATION NUMBER: 10/306,541  
 / PRIORITY FILING DATE: 11-25-2002  
 / PRIORITY APPLICATION NUMBER: 60/333,249  
 / PRIORITY FILING DATE: 11-23-2001  
 / NUMBER OF SEQ ID NOS: 108  
 / SOFTWARE: WordPerfect 8.0 for Windows  
 / SEQ ID NO: 84  
 / LENGTH: 15  
 / TYPE: PRT  
 / ORGANISM: human papillomavirus  
 / US-10-306-541-84

Query Match 100.0%; Score 67; DB 18; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 0.00063;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LMGTGIVCPIC 12  
 Db 4 LMGTGIVCPIC 15

RESULT 12  
 US-10-648-547-84  
 / Sequence 84, Application US/10648547  
 / Publication No. US20040147044A1  
 / GENERAL INFORMATION:  
 / APPLICANT: Mittelman, Abraham  
 / APPLICANT: Kanduc, Daria  
 / TITLE OF INVENTION: Improved Antigens  
 / FILE REFERENCE: 12354/9  
 / CURRENT APPLICATION NUMBER: US/10/648,547  
 / CURRENT FILING DATE: 2003-08-25  
 / PRIORITY APPLICATION NUMBER: 10/306,541  
 / PRIORITY FILING DATE: 11-25-2002  
 / PRIORITY APPLICATION NUMBER: 60/333,249  
 / PRIORITY FILING DATE: 11-23-2001  
 / NUMBER OF SEQ ID NOS: 108  
 / SOFTWARE: WordPerfect 8.0 for Windows  
 / SEQ ID NO: 84  
 / LENGTH: 15  
 / TYPE: PRT  
 / ORGANISM: human papillomavirus  
 / US-10-648-547-84

Query Match 100.0%; Score 67; DB 18; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 0.00063;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LMGTGIVCPIC 12  
 Db 4 LMGTGIVCPIC 15

RESULT 13  
 US-09-759-960-25  
 / Sequence 25, Application US/09759960  
 / Patent No. US20010006639A1  
 / GENERAL INFORMATION:  
 / APPLICANT: Urban, Robert G.  
 / APPLICANT: Chicz, Roman M.  
 / APPLICANT: Collins, Edward J.  
 / APPLICANT: Hadley, Mary Lynn  
 / TITLE OF INVENTION: IMMUNOGENIC PEPTIDES FROM THE HPV E7  
 / NUMBER OF SEQUENCES: 33  
 / CORRESPONDENCE ADDRESS:  
 / ADDRESSEE: Fish & Richardson, P.C.  
 / STREET: 225 Franklin Street  
 / CITY: Boston  
 / STATE: MA  
 / COUNTRY: US  
 / ZIP: 02110-2804  
 / COMPUTER: IBM Compatible  
 / OPERATING SYSTEM: Windows95  
 / SOFTWARE: FASTSEQ for Windows Version 2.0  
 / CURRENT APPLICATION DATA:  
 / APPLICATION NUMBER: US/09/759,960  
 / FILING DATE:  
 / PRIORITY APPLICATION DATA:  
 / APPLICATION NUMBER: 09/169,425  
 / FILING DATE:  
 / ATTORNEY/AGENT INFORMATION:  
 / US-10-306-541-84  
 / LENGTH: 15  
 / TYPE: PRT  
 / ORGANISM: human papillomavirus  
 / US-10-306-541-84

```

; NAME: Fraser, Janis K. ; LENGTH: 16 ;
; REGISTRATION NUMBER: 34,819 ; TYPE: PRT ;
; TELECOMMUNICATION INFORMATION: ; ORGANISM: Homo sapiens
; TELEPHONE: 617-342-5070 ; US-09-872-836-109
; TELEX: 200154 ; Query Match 100.0%; Score 67; DB 11; Length 16;
; INFORMATION FOR SEQ ID NO: 25: Best Local Similarity 100.0%; Pred. No. 0.00067;
; SEQUENCE CHARACTERISTICS: Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
; LENGTH: 16 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-09-759-960-25

Query Match 100.0%; Score 67; DB 9; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.00067;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 LMGTGIVCPIC 12
Db 2 LMGTGIVCPIC 13

Search completed: August 19, 2005, 23:52:17
Job time : 70.4054 secs

RESULT 14
US-09-460-109
Sequence 109, Application US/0909460
Publication No. US20020182258A1
GENERAL INFORMATION:
APPLICANT: Lunsford, Lynn B.
APPLICANT: Putnam, David
APPLICANT: Hedley, Mary Lynn
TITLE OF INVENTION: MICROPARTICLES FOR DELIVERY OF NUCLEIC
ACID
FILE REFERENCE: 08191/014001
CURRENT APPLICATION NUMBER: US/09/909,460
CURRENT FILING DATE: 2001-07-18
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US/09/321,346
PRIOR FILING DATE: EARLIER FILING DATE: 1999-05-27
NUMBER OF SEQ ID NOS: 114
SOFTWARE: FastSEQ for Windows Version 3.0
SEQ ID NO: 109
LENGTH: 16
TYPE: PRT
ORGANISM: Human papilloma virus
US-09-909-460-109

Query Match 100.0%; Score 67; DB 9; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.00067;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 LMGTGIVCPIC 12
Db 2 LMGTGIVCPIC 13

RESULT 15
US-09-872-836-109
Sequence 109, Application US/09872836
Publication No. US20040142475A1
GENERAL INFORMATION:
APPLICANT: Barman, Shikha P.
APPLICANT: McKeever, Una
APPLICANT: Hedley, Mary Lynne
TITLE OF INVENTION: DELIVERY SYSTEMS FOR BIOACTIVE AGENTS
FILE REFERENCE: 08191-018001
CURRENT APPLICATION NUMBER: US/09/872,836
CURRENT FILING DATE: 2001-06-01
PRIOR APPLICATION NUMBER: US/09/208,830
PRIOR FILING DATE: 2000-06-02
NUMBER OF SEQ ID NOS: 120
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO: 109

```